# Path to Peptides - Full Compound Corpus
# Source: https://www.pathtopeptides.com/llms-full.txt
# Generated: 2026-04-20
# Purpose: Single-file research corpus optimized for LLM crawler ingestion
# Scope: 150 compound protocol pages and hub articles
# License: Research and educational use. Cite as "Path to Peptides" with the per-compound URL.

This document is a concatenated research summary of every peptide, SARM, GLP-1 analog, and related research compound covered on pathtopeptides.com. Each section is self-contained with a short answer, protocol overview, dosing, reconstitution, and FAQ so that any single chunk can stand alone as a citation source.

---

## 5-Amino-1MQ Protocol Guide — Dosing, Reconstitution & Administration
**URL:** https://www.pathtopeptides.com/5-amino-1mq-protocol
**Last reviewed:** 2026-04-10

**Summary:** 5-Amino-1MQ is a small molecule inhibitor of nicotinamide N-methyltransferase (NNMT), an enzyme involved in cellular energy metabolism and fat cell metabolism research.

**Protocol Overview:**
- **Compound:** 5-Amino-1MQ (Small Molecule NNMT Inhibitor)
- **Category:** Research Compound
- **Form:** 50mg capsule
- **Reconstitution:** None required (oral capsule)
- **Route:** Oral
- **Frequency:** Daily (50mg 1-2x/day)

**Dosing (sample):**
```
Starting | 50mg (1 cap) | Once daily | Morning with food
Standard | 50mg (1 cap) | Twice daily | Morning + evening with food
Research | 100mg (2 caps) | Twice daily | Morning + evening with food
```

**FAQs:**
- **Q: What is the standard 5-Amino-1MQ dosing protocol?**
  - A: The standard 5-Amino-1MQ research protocol uses 50mg taken orally twice daily (100mg total daily). Starting dose is 50mg once daily with food. Research protocols may go up to 100mg twice daily (200mg/day).
- **Q: How is 5-Amino-1MQ administered?**
  - A: 5-Amino-1MQ is taken orally as a capsule with water. No injection or reconstitution is required. Take with food.
- **Q: What are the storage requirements for 5-Amino-1MQ?**
  - A: Sealed container: Room temperature, protect from light and moisture. Opened container: Room temperature, keep sealed, use within 90 days.

---

## AC-262,536 Protocol Guide — Dosing, Reconstitution & Administration
**URL:** https://www.pathtopeptides.com/ac-262536-protocol
**Last reviewed:** 2026-04-10

**Summary:** AC-262,536 is a non-steroidal SARM with a mild anabolic profile and interest in cognitive research applications. Preclinical studies suggest approximately 66% of the anabolic effect of testosterone with only 27% of its androgenic potency. Research also explores its potential neuroprotective properties, particularly in models relevant to Alzheimer's disease via androgen receptor-mediated pathways. Capsule Content 10mg per capsule (10,000mcg per capsule) Route of Administration Oral (capsule)

**Protocol Overview:**
- **Compound:** AC-262,536 (Oral Research Compound - Mild Anabolic / Cognitive Research)
- **Category:** Selective Androgen Receptor Modulator
- **Vial Size:** Capsules
- **Reconstitution:** N/A (oral capsule)
- **Route:** Oral
- **Frequency:** 7 days/week

**Dosing (sample):**
```
Monday | 1 cap | 10mg | Morning
Tuesday | 1 cap | 10mg | Morning
Wednesday | 1 cap | 10mg | Morning
Thursday | 1 cap | 10mg | Morning
Friday | 1 cap | 10mg | Morning
Saturday | 1 cap | 10mg | Morning
Sunday | 1 cap | 10mg | Morning
```

**FAQs:**
- **Q: What is the standard AC-262,536 dosing protocol?**
  - A: The standard AC-262,536 research protocol uses 10mg administered morning on protocol days. Weekly Total: 7 capsules (70mg) • Cycle Duration: 8 weeks on, 4 weeks off
- **Q: Does AC-262,536 require reconstitution?**
  - A: No. AC-262,536 is supplied as an oral capsule (10mg per capsule) and does not require reconstitution with bacteriostatic water. Take one capsule by mouth with water in the morning as described in the dosing schedule.
- **Q: What are the storage requirements for AC-262,536?**
  - A: Store sealed capsules at room temperature in a cool, dry place, protected from light and moisture. Keep the bottle tightly closed between doses and away from direct sunlight and heat.

---

## Adamax Protocol Guide — Dosing, Reconstitution & Administration
**URL:** https://www.pathtopeptides.com/adamax-protocol
**Last reviewed:** 2026-04-10

**Summary:** Adamax is a modified Semax analog studied for neuroplasticity enhancement and cognitive function. Research suggests it may support synaptic plasticity, memory consolidation, and neuroprotective pathways with a distinct activity profile from standard Semax.

**Protocol Overview:**
- **Compound:** Adamax (Modified Semax Analog for Neuroplasticity)
- **Category:** Neuroplasticity Research Peptide
- **Vial Size:** 10mg (10,000mcg)
- **Reconstitution:** 2mL bacteriostatic water (5mg/mL)
- **Route:** Subcutaneous injection
- **Frequency:** 5 days/week

**Dosing (sample):**
```
Monday | 6 | 300mcg | Morning
Tuesday | 6 | 300mcg | Morning
Wednesday | 6 | 300mcg | Morning
Thursday | 6 | 300mcg | Morning
Friday | 6 | 300mcg | Morning
```

**FAQs:**
- **Q: What is the standard Adamax dosing protocol?**
  - A: The standard Adamax research protocol uses 300mcg administered morning on protocol days. Weekly Total: 30 units (1,500mcg) • Vial Duration: ~33 days
- **Q: How do you reconstitute Adamax?**
  - A: Using 2mL of bacteriostatic water results in a concentration of 5mg/mL (5000mcg/mL). Always use sterile techniques.
- **Q: What are the storage requirements for Adamax?**
  - A: Lyophilized (powder): Room temperature or refrigerated, protect from light. Reconstituted: Refrigerated 36-46F (2-8C), use within 28 days.

---

## Adipotide Protocol Guide — Dosing, Reconstitution & Administration
**URL:** https://www.pathtopeptides.com/adipotide-protocol
**Last reviewed:** 2026-04-10

**Summary:** Adipotide (also known as FTPP) is an experimental peptidomimetic that targets prohibitin on the vasculature of white adipose tissue. It induces apoptosis in fat cells by disrupting their blood supply. VERY limited research use - this compound has significant safety considerations and is NOT approved for clinical use.

**Protocol Overview:**
- **Compound:** Adipotide (Prohibitin-Targeting Peptidomimetic - VERY LIMITED USE)
- **Category:** Experimental Targeted Fat Cell Apoptosis Peptide
- **Vial Size:** 1mg (1,000mcg)
- **Reconstitution:** 1mL bacteriostatic water (1mg/mL)
- **Route:** Subcutaneous injection
- **Frequency:** 3 days/week

**Dosing (sample):**
```
Monday | 10 | 0.1mg | Morning
Wednesday | 10 | 0.1mg | Morning
Friday | 10 | 0.1mg | Morning
```

**FAQs:**
- **Q: What is the standard Adipotide dosing protocol?**
  - A: The standard Adipotide research protocol uses 0.1mg administered morning on protocol days. Weekly Total: 30 units (0.3mg) • Vial Duration: ~10 doses
- **Q: How do you reconstitute Adipotide?**
  - A: Using 1mL of bacteriostatic water results in a concentration of 1mg/mL. EXPERIMENTAL compound - very limited research use only. Always use sterile techniques.
- **Q: What are the storage requirements for Adipotide?**
  - A: Lyophilized (powder): Room temperature or refrigerated, protect from light. Reconstituted: Refrigerated 36-46F (2-8C), use within 28 days.

---

## AHK-Cu Protocol Guide — Dosing, Reconstitution & Administration
**URL:** https://www.pathtopeptides.com/ahk-cu-protocol
**Last reviewed:** 2026-04-10

**Summary:** AHK-Cu is a copper-binding tripeptide studied for hair follicle stimulation and dermal papilla cell proliferation. Research suggests it may promote hair growth by increasing follicle size, stimulating blood flow to follicles, and reducing follicular miniaturization.

**Protocol Overview:**
- **Compound:** AHK-Cu (Alanine-Histidine-Lysine Copper Peptide)
- **Category:** Hair Follicle Stimulation Peptide
- **Vial Size:** 5mg (5,000mcg)
- **Reconstitution:** 2mL bacteriostatic water (2.5mg/mL)
- **Route:** Subcutaneous injection
- **Frequency:** 7 days/week

**Dosing (sample):**
```
Monday | 8 | 200mcg | Morning
Tuesday | 8 | 200mcg | Morning
Wednesday | 8 | 200mcg | Morning
Thursday | 8 | 200mcg | Morning
Friday | 8 | 200mcg | Morning
Saturday | 8 | 200mcg | Morning
Sunday | 8 | 200mcg | Morning
```

**FAQs:**
- **Q: What is the standard AHK-Cu dosing protocol?**
  - A: The standard AHK-Cu research protocol uses 200mcg administered morning on protocol days. Weekly Total: 56 units (1,400mcg) • Vial Duration: ~18 days
- **Q: How do you reconstitute AHK-Cu?**
  - A: Using 2mL of bacteriostatic water results in a concentration of 2.5mg/mL. Can be used topically or subcutaneously. Always use sterile techniques.
- **Q: What are the storage requirements for AHK-Cu?**
  - A: Lyophilized (powder): Room temperature or refrigerated, protect from light. Reconstituted: Refrigerated 36-46F (2-8C), use within 28 days.

---

## AOD-9604 + BPC-157 Stack Protocol — Dosing
**URL:** https://www.pathtopeptides.com/aod-9604-bpc-157-stack-protocol
**Last reviewed:** 2026-04-07

**Summary:** The AOD-9604 + BPC-157 stack combines two of the most well-researched peptides for complementary body recomposition and healing benefits. AOD-9604 (hGH fragment 176-191) stimulates lipolysis and inhibits lipogenesis without affecting blood glucose or IGF-1 levels, while BPC-157 (Body Protection Compound-15) promotes systemic tissue repair, accelerates wound healing, reduces inflammation, and supports gut health through multiple pathways including VEGF upregulation and NO system modulation. Together they provide targeted fat loss with enhanced recovery, making this stack particularly popular for subjects seeking body recomposition with concurrent injury rehabilitation.

**Protocol Overview:**
- **Compounds:** AOD-9604 (hGH fragment 176-191) + BPC-157
- **Category:** Fat Loss / Tissue Repair Stack
- **Mechanism:** AOD-9604: lipolysis via beta-3 adrenergic pathway | BPC-157: tissue repair via VEGF, NO, FAK-paxillin pathway modulation
- **Route:** Subcutaneous (can combine in one syringe)
- **Frequency:** 1-2x daily
- **Cycle Length:** 8-12 weeks on, 4 weeks off

**Dosing (sample):**
```
Standard | 300 mcg | 250 mcg | 1x daily (AM fasted) | 8-12 weeks
Enhanced Repair | 300 mcg (AM) | 250 mcg 2x (AM + PM) | 2x daily BPC | 8-12 weeks
Advanced | 300 mcg 2x (AM + PM) | 250 mcg 2x (AM + PM) | 2x daily both | 8-12 weeks
```

**FAQs:**
- **Q: Why stack AOD-9604 with BPC-157?**
  - A: AOD-9604 and BPC-157 address complementary goals: AOD-9604 targets fat loss through lipolysis stimulation without affecting blood sugar or growth, while BPC-157 promotes tissue repair, reduces inflammation, and supports gut health. Together they provide body recomposition with enhanced recovery, making this one of the most popular peptide stacks for fat loss with healing support.
- **Q: What is the standard AOD-9604 + BPC-157 stack dosing?**
  - A: The standard protocol uses AOD-9604 at 300mcg and BPC-157 at 250-500mcg, both administered subcutaneously once daily. AOD-9604 is best taken fasted in the morning, while BPC-157 can be taken at any time. Both can be drawn into the same syringe for convenience.
- **Q: Can AOD-9604 and BPC-157 be mixed in the same syringe?**
  - A: Yes. AOD-9604 and BPC-157 are compatible and can be drawn into the same syringe for a single injection. Draw BPC-157 first, then AOD-9604. Both are stable peptides that do not interact negatively. Store reconstituted vials separately in the refrigerator.

---

## AOD-9604 Protocol Guide — Dosing, Reconstitution & Fat Loss Research
**URL:** https://www.pathtopeptides.com/aod-9604-protocol
**Last reviewed:** 2026-04-07

**Summary:** AOD-9604 (Advanced Obesity Drug 9604) is a modified fragment of human growth hormone corresponding to amino acids 176-191 of the hGH polypeptide. It is researched for its ability to stimulate lipolysis (fat breakdown) and inhibit lipogenesis (fat formation) without the growth-promoting or diabetogenic effects of full-length hGH. This protocol covers reconstitution from a 5mg vial, subcutaneous dosing at 300mcg daily on an empty stomach, fat metabolism timelines, and stacking recommendations.

**Protocol Overview:**
- **Compound:** AOD-9604 (hGH Fragment 176-191)
- **Category:** Fat Loss / Metabolic Peptide
- **Mechanism:** Mimics the lipolytic region of hGH, stimulating beta-3 adrenergic receptor-mediated fat breakdown and inhibiting de novo lipogenesis without affecting IGF-1 or insulin
- **Sequence:** 16 amino acids (hGH fragment 176-191 with C-terminal tyrosine)
- **Half-Life:** ~30-60 minutes
- **Vial Size:** 5mg lyophilized powder
- **Route:** Subcutaneous injection
- **Frequency:** Once daily (morning, fasted)
- **Cycle Length:** 8-12 weeks

**Dosing (sample):**
```
Standard Fat Loss | 300 mcg | 1x daily (AM, fasted) | Subcutaneous | 8-12 weeks
Moderate Protocol | 250 mcg | 1x daily (AM, fasted) | Subcutaneous | 8-12 weeks
Aggressive Protocol | 500 mcg | 1x daily (AM, fasted) | Subcutaneous | 8-12 weeks
```

**FAQs:**
- **Q: What is the standard AOD-9604 dosing protocol?**
  - A: The standard AOD-9604 research protocol uses 300mcg administered subcutaneously once daily in the morning on an empty stomach. The protocol is typically run 5 days per week (Monday-Friday) for 8-12 weeks, with a weekly total of approximately 1,500mcg.
- **Q: How do you reconstitute a 5mg vial of AOD-9604?**
  - A: Add 2mL of bacteriostatic water to a 5mg vial for a concentration of 2.5mg/mL (2500mcg/mL). Each 12 units on an insulin syringe equals 300mcg. Reconstituted AOD-9604 should be refrigerated at 2-8 degrees Celsius and used within 28 days.
- **Q: Does AOD-9604 affect blood sugar or growth hormone levels?**
  - A: AOD-9604 is specifically the fat-metabolizing fragment of hGH (amino acids 176-191) and does not produce the growth-promoting or blood sugar effects of full-length growth hormone. It works by mimicking the lipolytic region of hGH without affecting IGF-1 or insulin sensitivity.

---

## AOD-9604: Protocol, Dosage & Research Guide
**URL:** https://www.pathtopeptides.com/aod-9604
**Last reviewed:** 2026-04-07

**Summary:** AOD-9604 is the C-terminal fragment (residues 176–191) of human growth hormone, specifically the region responsible for GH's lipolytic (fat-burning) activity. It stimulates fat breakdown and inhibits fat synthesis through beta-3 adrenergic receptor activation in adipose tissue, without raising IGF-1 or producing GH's mitogenic effects — offering a targeted fat metabolism approach with a favorable safety profile. Grade B.

**FAQs:**
- **Q: What is AOD-9604 and how does it promote fat loss?**
  - A: AOD-9604 is the C-terminal fragment (residues 176-191) of human growth hormone, containing the region responsible for GH's lipolytic activity. It activates beta-3 adrenergic receptors in adipose tissue to stimulate lipolysis (fat breakdown) and inhibits lipogenesis (fat synthesis) without raising IGF-1 or producing the anabolic/proliferative effects of full GH.
- **Q: What dose of AOD-9604 is used in research?**
  - A: Standard research doses are 300 mcg/day subcutaneous, typically administered in the morning in a fasted state. Some protocols use 200–500 mcg/day. Phase III trials used oral formulations at 1 mg/day.
- **Q: Does AOD-9604 raise IGF-1 levels?**
  - A: No — this is AOD-9604's key clinical differentiator. Unlike full GH, AOD-9604 does not stimulate IGF-1 production and does not produce GH's mitogenic, proliferative, or insulin-desensitizing effects, making it significantly safer for chronic use.

---

## AOD9604 Protocol Guide — Dosing, Reconstitution & Administration
**URL:** https://www.pathtopeptides.com/aod9604-protocol
**Last reviewed:** 2026-04-10

**Summary:** AOD9604 is a modified fragment (amino acids 176-191) of human growth hormone studied for fat metabolism research without growth-promoting effects.

**Protocol Overview:**
- **Compound:** AOD9604 (hGH Fragment 176-191)
- **Category:** Research Peptide
- **Vial Size:** 5mg (5,000mcg)
- **Reconstitution:** 2mL bacteriostatic water (2.5mg/mL)
- **Route:** Subcutaneous injection
- **Frequency:** 5 days/week

**Dosing (sample):**
```
Monday | 12 | 300mcg | Morning
Tuesday | 12 | 300mcg | Morning
Wednesday | 12 | 300mcg | Morning
Thursday | 12 | 300mcg | Morning
Friday | 12 | 300mcg | Morning
```

**FAQs:**
- **Q: What is the standard AOD9604 dosing protocol?**
  - A: The standard AOD9604 research protocol uses 300mcg administered morning on protocol days. Weekly Total: 60 units (1,500mcg) • Vial Duration: ~17 days
- **Q: How do you reconstitute AOD9604?**
  - A: Using 2mL of bacteriostatic water results in a concentration of 2.5mg/mL. Always use sterile techniques.
- **Q: What are the storage requirements for AOD9604?**
  - A: Lyophilized (powder): Room temperature or refrigerated, protect from light. Reconstituted: Refrigerated 36-46F (2-8C), use within 28 days.

---

## Ara 290 Protocol Guide — Dosing, Reconstitution & Administration
**URL:** https://www.pathtopeptides.com/ara-290-protocol
**Last reviewed:** 2026-04-10

**Summary:** ARA 290 (Cibinetide) is an 11-amino acid peptide that selectively activates the innate repair receptor (IRR), a heterodimer of EPO and beta common receptors. It is studied for nerve regeneration, neuropathic pain reduction, and tissue repair without the erythropoietic (blood cell production) effects of EPO.

**Protocol Overview:**
- **Compound:** Ara 290 (Innate Repair Receptor (IRR) Agonist)
- **Category:** Nerve Regeneration Peptide
- **Vial Size:** 5mg (5,000mcg)
- **Reconstitution:** 2mL bacteriostatic water (2.5mg/mL)
- **Route:** Subcutaneous injection
- **Frequency:** 3 days/week

**Dosing (sample):**
```
Monday | 80 | 2mg | Morning
Wednesday | 80 | 2mg | Morning
Friday | 80 | 2mg | Morning
```

**FAQs:**
- **Q: What is the standard Ara 290 dosing protocol?**
  - A: The standard Ara 290 research protocol uses 2mg administered morning on protocol days. Weekly Total: 240 units (6mg) • Vial Duration: ~2.5 weeks
- **Q: How do you reconstitute Ara 290?**
  - A: Using 2mL of bacteriostatic water results in a concentration of 2.5mg/mL. Always use sterile techniques.
- **Q: What are the storage requirements for Ara 290?**
  - A: Lyophilized (powder): Room temperature or refrigerated, protect from light. Reconstituted: Refrigerated 36-46F (2-8C), use within 28 days.

---

## Argireline Protocol Guide — Dosing, Reconstitution & Administration
**URL:** https://www.pathtopeptides.com/argireline-protocol
**Last reviewed:** 2026-04-10

**Summary:** Argireline (Acetyl Hexapeptide-8) is a peptide that inhibits SNARE complex formation, reducing neurotransmitter release at the neuromuscular junction. This results in decreased muscle contraction intensity, making it a popular research compound for topical wrinkle reduction studies.

**Protocol Overview:**
- **Compound:** Argireline (Acetyl Hexapeptide-8 (Wrinkle Reduction))
- **Category:** Topical Anti-Wrinkle Peptide
- **Vial Size:** 500mg (500,000mcg)
- **Reconstitution:** N/A (topical solution)
- **Route:** Topical (serum/cream)
- **Frequency:** 7 days/week

**Dosing (sample):**
```
Monday | Topical | Apply 2x/day | AM and PM
Tuesday | Topical | Apply 2x/day | AM and PM
Wednesday | Topical | Apply 2x/day | AM and PM
Thursday | Topical | Apply 2x/day | AM and PM
Friday | Topical | Apply 2x/day | AM and PM
Saturday | Topical | Apply 2x/day | AM and PM
Sunday | Topical | Apply 2x/day | AM and PM
```

**FAQs:**
- **Q: What is the standard Argireline dosing protocol?**
  - A: The standard Argireline research protocol uses Apply 2x/day administered am and pm on protocol days. Weekly Total: 14 applications/week • Vial Duration: Varies by application area
- **Q: How do you reconstitute Argireline?**
  - A: Argireline is supplied as a ready-to-use topical solution. No reconstitution with bacteriostatic water is required. Apply directly to clean, dry skin.
- **Q: What are the storage requirements for Argireline?**
  - A: Lyophilized (powder): Room temperature or refrigerated, protect from light. Reconstituted: Refrigerated 36-46F (2-8C), use within 28 days.

---

## BPC-157 Arginate Protocol Guide — Dosing, Reconstitution & Administration
**URL:** https://www.pathtopeptides.com/bpc-157-arginate-protocol
**Last reviewed:** 2026-04-10

**Summary:** BPC-157 Arginate is the L-arginine salt form of Body Protection Compound-157, offering enhanced stability compared to the acetate salt. It is studied for gastric and tissue protection, wound healing acceleration, and tendon/ligament repair. The arginate form may also be taken orally for gut-related research applications with improved bioavailability.

**Protocol Overview:**
- **Compound:** BPC-157 Arginate (BPC-157 L-Arginine Salt Form)
- **Category:** Enhanced Stability Body Protection Compound
- **Vial Size:** 10mg (10,000mcg)
- **Reconstitution:** 2mL bacteriostatic water (5mg/mL)
- **Route:** Subcutaneous injection
- **Frequency:** 7 days/week

**Dosing (sample):**
```
Monday | 5 | 250mcg | Morning
Tuesday | 5 | 250mcg | Morning
Wednesday | 5 | 250mcg | Morning
Thursday | 5 | 250mcg | Morning
Friday | 5 | 250mcg | Morning
Saturday | 5 | 250mcg | Morning
Sunday | 5 | 250mcg | Morning
```

**FAQs:**
- **Q: What is the standard BPC-157 Arginate dosing protocol?**
  - A: The standard BPC-157 Arginate research protocol uses 250mcg administered morning on protocol days. Weekly Total: 35 units (1,750mcg) • Vial Duration: ~29 days
- **Q: How do you reconstitute BPC-157 Arginate?**
  - A: Using 2mL of bacteriostatic water results in a concentration of 5mg/mL. The arginate salt form provides enhanced stability. Always use sterile techniques.
- **Q: What are the storage requirements for BPC-157 Arginate?**
  - A: Lyophilized (powder): Room temperature or refrigerated, protect from light. Reconstituted: Refrigerated 36-46F (2-8C), use within 28 days.

---

## BPC-157 + GHK-Cu Stack Protocol Guide — Dosing, Synergy & Research Protocol
**URL:** https://www.pathtopeptides.com/bpc-157-ghk-cu-stack-protocol
**Last reviewed:** 2026-04-08

**Summary:** The BPC-157 + GHK-Cu stack combines two of the most researched regenerative peptides for comprehensive tissue repair and skin rejuvenation. BPC-157 promotes angiogenesis, upregulates growth factors (VEGF, EGF, FGF), and accelerates wound healing from the inside out. GHK-Cu (Glycyl-L-Histidyl-L-Lysine Copper Complex) is a naturally occurring tripeptide that stimulates collagen synthesis, glycosaminoglycan production, and tissue remodeling while providing potent antioxidant protection. Together, BPC-157 drives new blood vessel formation while GHK-Cu rebuilds the extracellular matrix and enhances skin quality.

**Protocol Overview:**
- **Compounds:** BPC-157 + GHK-Cu
- **Category:** Tissue Repair / Skin Regeneration
- **Mechanism:** BPC-157: angiogenesis, growth factor upregulation, nitric oxide modulation. GHK-Cu: collagen/elastin synthesis, metalloproteinase regulation, stem cell attraction
- **Half-Life:** BPC-157: ~4 hrs | GHK-Cu: ~2-4 hrs
- **Route:** BPC-157: SubQ | GHK-Cu: SubQ or topical
- **Frequency:** BPC-157: 1x daily | GHK-Cu: 1-2x daily
- **Cycle Length:** 6-12 weeks

**Dosing (sample):**
```
Standard | BPC-157 250mcg/day SubQ | GHK-Cu 200mcg/day SubQ | AM | 6-8 weeks
Enhanced | BPC-157 500mcg/day SubQ | GHK-Cu 400mcg/day SubQ | AM + PM split | 8-12 weeks
Topical Combo | BPC-157 250mcg/day SubQ | GHK-Cu cream 2x/day topical | AM + PM | 8 weeks
```

**FAQs:**
- **Q: What are the benefits of stacking BPC-157 with GHK-Cu?**
  - A: BPC-157 creates new blood vessels and upregulates growth factors at injury sites, while GHK-Cu stimulates collagen and elastin synthesis for structural repair. Together they provide both vascular support and building materials for complete tissue regeneration and skin rejuvenation.
- **Q: Can BPC-157 and GHK-Cu be injected together?**
  - A: They should be administered as separate injections near the target area. Do not mix in the same syringe as copper from GHK-Cu may interact with BPC-157 peptide bonds. Inject sequentially at slightly different sites.
- **Q: Is GHK-Cu better used topically or injected when stacked with BPC-157?**
  - A: Injectable GHK-Cu provides systemic and deep tissue effects, while topical targets skin surface. For tissue healing, SubQ near the target is preferred. For anti-aging skin, combining SubQ BPC-157 with topical GHK-Cu cream works well.

---

## BPC-157 Oral Protocol — Dosing & GI Repair
**URL:** https://www.pathtopeptides.com/bpc-157-oral-protocol
**Last reviewed:** 2026-04-07

**Summary:** BPC-157 (Body Protection Compound-157) is a pentadecapeptide derived from human gastric juice that demonstrates remarkable stability in the GI tract. While injectable BPC-157 is commonly used for systemic musculoskeletal repair, oral administration specifically targets gastrointestinal healing including gastric ulcer repair, gut lining integrity, and inflammatory bowel support. The arginine salt form (BPC-157 Arginate) offers enhanced stability in gastric acid. This protocol covers oral capsule dosing at 250-500mcg twice daily, form selection, GI healing timelines, and stacking with gut-supportive compounds.

**Protocol Overview:**
- **Compound:** BPC-157 Oral (Body Protection Compound-157)
- **Category:** GI Repair / Tissue Healing Peptide
- **Mechanism:** Upregulates growth factor expression (EGF, VEGF), promotes angiogenesis in GI mucosa, modulates NO system, protects endothelium, accelerates mucosal healing
- **Sequence:** 15 amino acids (Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val)
- **Preferred Form:** Arginine salt (Arginate) for acid stability
- **Route:** Oral (capsule)
- **Frequency:** 2x daily on empty stomach
- **Cycle Length:** 4-8 weeks

**Dosing (sample):**
```
Standard GI Repair | 250 mcg | 2x daily (AM + PM, fasted) | Oral | 4-8 weeks
Intensive GI Protocol | 500 mcg | 2x daily (AM + PM, fasted) | Oral | 4-8 weeks
Maintenance | 250 mcg | 1x daily (AM, fasted) | Oral | Ongoing
```

**FAQs:**
- **Q: How does oral BPC-157 differ from injectable?**
  - A: Oral BPC-157 primarily targets the gastrointestinal tract, making it ideal for gut healing, gastric ulcer repair, and inflammatory bowel support. Injectable BPC-157 provides more systemic effects for musculoskeletal injuries, tendon repair, and wound healing. Many researchers use both routes simultaneously for comprehensive coverage.
- **Q: What is the recommended oral BPC-157 dose?**
  - A: The standard oral BPC-157 research protocol uses 250-500mcg taken twice daily on an empty stomach. The arginine salt form (BPC-157 Arginate) is preferred for oral use due to enhanced stability in gastric acid. Total daily dose typically ranges from 500mcg to 1mg.
- **Q: Does BPC-157 survive stomach acid?**
  - A: BPC-157 demonstrates remarkable stability in gastric juice, which is consistent with its origin as a gastric peptide. The arginine salt form further enhances acid stability. Studies show oral BPC-157 retains biological activity through the GI tract, though systemic bioavailability is lower than injectable administration.

---

## BPC-157 Pentadecapeptide Stack Protocol Guide — Dosing, Synergy & Research Protocol
**URL:** https://www.pathtopeptides.com/bpc-157-pentadecapeptide-stack-protocol
**Last reviewed:** 2026-04-08

**Summary:** The BPC-157 Pentadecapeptide Stack uses BPC-157 via two routes -- oral and injectable -- for comprehensive healing coverage. Oral BPC-157 (typically as arginine salt, BPC-157-Arginate) provides systemic gut healing, protects the GI mucosa, and offers whole-body anti-inflammatory effects via the gut-brain axis. Injectable BPC-157 targets specific injury sites through localized subcutaneous administration. By combining both routes, this protocol addresses gastrointestinal healing and musculoskeletal repair simultaneously, making it ideal for subjects with gut issues alongside physical injuries.

**Protocol Overview:**
- **Compounds:** BPC-157 Oral (Arginate) + BPC-157 Injectable
- **Category:** Dual-Route Healing / Gut + Tissue Repair
- **Mechanism:** Oral: GI mucosal protection, gut-brain axis modulation, systemic anti-inflammatory. Injectable: localized angiogenesis, VEGF/EGF upregulation
- **Half-Life:** ~4 hours (both forms)
- **Route:** Oral capsule + Subcutaneous injection
- **Frequency:** Oral: 2x daily | Injectable: 1x daily
- **Cycle Length:** 6-8 weeks

**Dosing (sample):**
```
Standard | BPC-157 oral 500mcg 2x/day | BPC-157 SubQ 250mcg 1x/day | AM oral+SubQ, PM oral | 6-8 weeks
Gut-Focus | BPC-157 oral 500mcg 2x/day | BPC-157 SubQ 250mcg EOD | AM/PM oral, AM SubQ | 6 weeks
Injury-Focus | BPC-157 oral 250mcg 1x/day | BPC-157 SubQ 500mcg 1x/day | AM oral, AM SubQ | 4-6 weeks
```

**FAQs:**
- **Q: Why use both oral and injectable BPC-157?**
  - A: Oral BPC-157 primarily targets the GI tract with direct mucosal contact, while injectable targets specific injury sites with localized angiogenesis. Using both simultaneously addresses gut health and musculoskeletal healing at the same time.
- **Q: Is oral BPC-157 as effective as injectable?**
  - A: For gut conditions (IBS, leaky gut, gastric ulcers), oral may be more effective due to direct mucosal contact. For musculoskeletal injuries, injectable near the injury site is superior. The combination leverages strengths of each route.
- **Q: Can you take oral and injectable BPC-157 on the same day?**
  - A: Yes, they are designed to be used together. They target different systems and the dual-route approach enhances overall healing. Take oral fasted and inject SubQ near injury site.

---

## BPC-157 Protocol Guide — Dosing, Reconstitution & Administration
**URL:** https://www.pathtopeptides.com/bpc-157-protocol
**Last reviewed:** 2026-04-10

**Summary:** BPC-157 is a synthetic peptide derived from a protective protein found in human gastric juice. It consists of 15 amino acids and is widely studied for tissue repair and regeneration research.

**Protocol Overview:**
- **Compound:** BPC-157 (Body Protection Compound-157)
- **Category:** Research Peptide
- **Vial Size:** 10mg (10,000mcg)
- **Reconstitution:** 2mL bacteriostatic water (5mg/mL)
- **Route:** Subcutaneous injection
- **Frequency:** 5 days/week

**Dosing (sample):**
```
Monday | 5 | 250mcg | Morning
Tuesday | 5 | 250mcg | Morning
Wednesday | 5 | 250mcg | Morning
Thursday | 5 | 250mcg | Morning
Friday | 5 | 250mcg | Morning
```

**FAQs:**
- **Q: What is the standard BPC-157 dosing protocol?**
  - A: The standard BPC-157 research protocol uses 250mcg administered morning on protocol days. Weekly Total: 25 units (1,250mcg) • Vial Duration: ~8 weeks (56 days)
- **Q: How do you reconstitute BPC-157?**
  - A: Using 2mL of bacteriostatic water results in a concentration of 5mg/mL (5,000mcg/mL). Always use sterile techniques.
- **Q: What are the storage requirements for BPC-157?**
  - A: Lyophilized (powder): Room temperature or refrigerated, protect from light. Reconstituted: Refrigerated 36-46F (2-8C), use within 28 days.

---

## BPC-157 / TB-500 Protocol Guide — Dosing, Reconstitution & Administration
**URL:** https://www.pathtopeptides.com/bpc-157-tb-500-protocol
**Last reviewed:** 2026-04-10

**Summary:** BPC-157 combined with TB-500 provides a synergistic blend studied for tissue repair, recovery, and inflammation modulation research.

**Protocol Overview:**
- **Compound:** BPC-157 / TB-500 (BPC-157 5mg + TB-500 5mg)
- **Category:** Recovery Blend
- **Vial Size:** 10mg total (10,000mcg)
- **Reconstitution:** 2mL bacteriostatic water (5mg/mL)
- **Route:** Subcutaneous injection
- **Frequency:** 5 days/week

**Dosing (sample):**
```
Monday | 5 | 250mcg | Morning
Tuesday | 5 | 250mcg | Morning
Wednesday | 5 | 250mcg | Morning
Thursday | 5 | 250mcg | Morning
Friday | 5 | 250mcg | Morning
```

**FAQs:**
- **Q: What is the standard BPC-157 / TB-500 dosing protocol?**
  - A: The standard BPC-157 / TB-500 research protocol uses 250mcg administered morning on protocol days. Weekly Total: 25 units (1,250mcg) • Vial Duration: ~40 days
- **Q: How do you reconstitute BPC-157 / TB-500?**
  - A: Using 2mL of bacteriostatic water results in a concentration of 5mg/mL total blend. Always use sterile techniques.
- **Q: What are the storage requirements for BPC-157 / TB-500?**
  - A: Lyophilized (powder): Room temperature or refrigerated, protect from light. Reconstituted: Refrigerated 36-46F (2-8C), use within 28 days.

---

## BPC-157 + TB-500 Stack Protocol Guide — Dosing, Reconstitution & Recovery Research
**URL:** https://www.pathtopeptides.com/bpc-157-tb-500-stack-protocol
**Last reviewed:** 2026-04-07

**Summary:** The BPC-157 + TB-500 combo stack is the most popular recovery peptide blend in research, combining two complementary healing peptides in a single vial. BPC-157 (Body Protection Compound) excels at localized tissue repair through angiogenesis and growth factor upregulation, while TB-500 (Thymosin Beta-4 fragment) provides systemic anti-inflammatory effects and promotes cellular migration to injury sites. Together they create synergistic healing that addresses both local tissue damage and systemic recovery. This protocol covers reconstitution from a 20mg total blend vial (10mg BPC-157 + 10mg TB-500), subcutaneous dosing at 250mcg daily, and advanced stacking for accelerated recovery.

**Protocol Overview:**
- **Compound:** BPC-157 + TB-500 (Recovery Blend)
- **Category:** Tissue Repair / Recovery Stack
- **Mechanism:** BPC-157: angiogenesis, VEGF/EGF upregulation, nitric oxide modulation. TB-500: actin sequestration, cellular migration, systemic anti-inflammatory, stem cell differentiation
- **Blend Ratio:** 1:1 (10mg BPC-157 + 10mg TB-500)
- **Half-Life:** BPC-157: ~4hrs | TB-500: ~6-8hrs
- **Vial Size:** 20mg total lyophilized blend
- **Route:** Subcutaneous injection
- **Frequency:** Once daily (AM)
- **Cycle Length:** 4-8 weeks

**Dosing (sample):**
```
Standard Recovery | 250 mcg | 1x daily (AM) | Subcutaneous near injury | 4-6 weeks
Aggressive Healing | 500 mcg | 1x daily (AM) | Subcutaneous near injury | 4-8 weeks
Maintenance | 250 mcg | Every other day | Subcutaneous | 2-4 weeks
```

**FAQs:**
- **Q: What is the standard BPC-157 + TB-500 stack dosing protocol?**
  - A: The standard BPC-157 + TB-500 blend protocol uses 250mcg of the combined blend administered subcutaneously once daily in the morning, 5 days per week. The pre-blended vial contains equal parts BPC-157 and TB-500 (10mg each, 20mg total), reconstituted with 2mL bacteriostatic water for a concentration of 10mg/mL.
- **Q: Why stack BPC-157 with TB-500 instead of using them separately?**
  - A: BPC-157 and TB-500 work through complementary mechanisms. BPC-157 excels at localized healing through angiogenesis and growth factor upregulation, while TB-500 provides systemic anti-inflammatory effects and promotes cellular migration to injury sites. Together they create a synergistic healing response that addresses both local tissue repair and systemic recovery.
- **Q: How do you reconstitute a BPC-157 + TB-500 blend vial?**
  - A: Add 2mL of bacteriostatic water to the 20mg total blend vial for a concentration of 10mg/mL (10,000mcg/mL). Each 2.5 units on an insulin syringe delivers 250mcg of the blend. Reconstituted solution should be refrigerated and used within 28 days.

---

## BPC-157 + TB-500 Stack: Protocol, Dosage & Research Guide
**URL:** https://www.pathtopeptides.com/bpc-157-tb-500
**Last reviewed:** 2026-04-07

**Summary:** The BPC-157 + TB-500 combination is the most extensively studied peptide healing stack, combining two complementary tissue-repair mechanisms: BPC-157's growth factor upregulation and NO-mediated angiogenesis with TB-500's actin-mediated cell migration and vascular remodeling. Together, they address more steps in the healing cascade than either compound alone, earning a combined evidence grade of A- for musculoskeletal injury recovery research.

**FAQs:**
- **Q: Why stack BPC-157 with TB-500?**
  - A: BPC-157 and TB-500 address complementary healing mechanisms: BPC-157 upregulates GH receptors, VEGF, and growth factors in injured tissue while modulating the NO system and GI tract. TB-500 promotes actin-mediated cell migration, blood vessel formation, and tissue remodeling. Together, they address more steps in the healing cascade than either compound alone.
- **Q: How are BPC-157 and TB-500 combined in a protocol?**
  - A: A typical stack combines BPC-157 250–500 mcg/day SubQ (daily injection) with TB-500 2.5–5 mg twice weekly (loading phase for 4–6 weeks), then TB-500 2.5 mg twice monthly (maintenance). The compounds are usually injected separately due to different dosing schedules.
- **Q: Can BPC-157 and TB-500 be mixed in the same syringe?**
  - A: Yes — many researchers combine both peptides in one syringe for convenience when doses coincide. Both are stable in bacteriostatic water and are compatible for co-administration. However, separate injections allow better dose control if you wish to adjust one compound independently.

---

## BPC-157: Complete Research Guide | PtP Wiki
**URL:** https://www.pathtopeptides.com/bpc-157
**Last reviewed:** 2026-04-07

**Summary:** BPC-157 is a synthetic pentadecapeptide consisting of 15 amino acids, derived from a naturally occurring protective protein found in human gastric juice. It is one of the most extensively studied research peptides, with over 100 preclinical studies documenting its capacity to accelerate healing across tendon, ligament, bone, muscle, gut mucosal, and neurological tissue models. Its unique stability in gastric acid distinguishes it from most peptides, enabling both injectable and oral routes of administration.

**FAQs:**
- **Q: What is the difference between BPC-157 and BPC-157 arginate?**
  - A: BPC-157 arginate (also called BPC-157 stable) is a salt form that pairs the BPC-157 peptide with arginine. This formulation is reported to have improved stability and solubility compared to the acetate salt form. Both forms share the same 15-amino-acid active sequence and the same proposed mechanisms of action. The arginate form may offer practical advantages for reconstitution and storage.
- **Q: How long does BPC-157 take to show effects in research models?**
  - A: In animal models, measurable tissue repair effects are typically observed within 24-72 hours of initial administration, with significant healing acceleration documented by day 7-14 of continuous dosing. Gut mucosal repair models show faster onset (24-48 hours) compared to tendon or ligament models (7-14 days). The timeline varies by tissue type, severity of injury, and dosing protocol.
- **Q: Is BPC-157 naturally found in the human body?**
  - A: BPC-157 is a synthetic peptide, but it is derived from a naturally occurring protein called BPC (Body Protection Compound) that is found in human gastric juice. The full parent protein has not been fully characterized, but the 15-amino-acid sequence of BPC-157 represents a biologically active fragment. It is considered a partial sequence of this endogenous gastric protein.

---

## Bremelanotide (PT-141) Protocol — Dosing Guide
**URL:** https://www.pathtopeptides.com/bremelanotide-protocol
**Last reviewed:** 2026-04-07

**Summary:** Bremelanotide (PT-141, brand name Vyleesi) is an FDA-approved melanocortin receptor agonist that activates MC3R and MC4R receptors in the central nervous system to enhance sexual desire and arousal. Unlike PDE5 inhibitors (sildenafil, tadalafil) which act peripherally on blood flow, bremelanotide works centrally in the brain by modulating dopaminergic and oxytocinergic pathways involved in sexual motivation. Approved for hypoactive sexual desire disorder (HSDD) in premenopausal women at 1.75mg subcutaneously as-needed, it has also been researched in men with erectile dysfunction refractory to PDE5 inhibitors. This protocol covers as-needed and research dosing, timing optimization, blood pressure monitoring, and nausea management strategies.

**Protocol Overview:**
- **Compound:** Bremelanotide (PT-141 / Vyleesi)
- **Category:** Sexual Function / Melanocortin Agonist
- **Mechanism:** MC3R/MC4R agonist; centrally acting to enhance sexual desire via dopaminergic and oxytocinergic modulation
- **Molecular Weight:** 1,025.2 g/mol
- **Half-Life:** ~2.7 hours
- **Form:** Auto-injector (1.75mg) or lyophilized powder
- **Route:** Subcutaneous
- **Frequency:** As needed (max 1x per 24h, max 8x per month)
- **FDA Status:** Approved (2019) for HSDD in premenopausal women

**Dosing (sample):**
```
FDA-Approved (Women) | 1.75 mg | As needed | SubQ | 45+ min before activity
Low-Dose Research | 0.5 mg | As needed | SubQ | Reduced nausea risk
Standard Research | 1.0 mg | As needed | SubQ | Common research dose
Male Research | 1.0-2.0 mg | As needed | SubQ | Phase 2 trial range
```

**FAQs:**
- **Q: What is Bremelanotide (PT-141) and how does it work?**
  - A: Bremelanotide (PT-141, brand name Vyleesi) is an FDA-approved melanocortin receptor agonist that activates MC3R and MC4R receptors in the central nervous system. Unlike PDE5 inhibitors that act peripherally on blood flow, bremelanotide works centrally in the brain to enhance sexual desire and arousal by modulating dopaminergic and oxytocinergic pathways involved in sexual motivation.
- **Q: What is the FDA-approved Bremelanotide dose?**
  - A: The FDA-approved dose is 1.75mg administered subcutaneously at least 45 minutes before anticipated sexual activity. It should not be used more than once in 24 hours or more than 8 doses per month. In research protocols, doses of 0.5-2mg have been studied for both men and women.
- **Q: Does Bremelanotide work for men?**
  - A: While FDA approval is specifically for premenopausal women with HSDD, research has investigated bremelanotide in men with erectile dysfunction, particularly those who do not respond to PDE5 inhibitors. Phase 2 trials showed pro-erectile effects in men via central nervous system mechanisms rather than peripheral vasodilation, working through a fundamentally different pathway than Viagra or Cialis.

---

## Cagrilintide Protocol Guide — Dosing, Reconstitution & Administration
**URL:** https://www.pathtopeptides.com/cagrilintide-protocol
**Last reviewed:** 2026-04-10

**Summary:** Cagrilintide is a long-acting acylated amylin analog studied for weight management. It works by activating amylin receptors to reduce appetite, slow gastric emptying, and promote satiety. Often studied in combination with semaglutide (CagriSema).

**Protocol Overview:**
- **Compound:** Cagrilintide (Weight Loss Research Peptide)
- **Category:** Long-Acting Amylin Analog
- **Vial Size:** 5mg (5,000mcg)
- **Reconstitution:** 2mL bacteriostatic water (2.5mg/mL)
- **Route:** Subcutaneous injection
- **Frequency:** Once weekly

**Dosing (sample):**
```
Monday | 10 | 0.25mg | Morning
```

**FAQs:**
- **Q: What is the standard Cagrilintide dosing protocol?**
  - A: The standard Cagrilintide research protocol uses 0.25mg administered morning on protocol days. Weekly Total: 10 units (0.25mg) • Vial Duration: ~20 weeks at starting dose
- **Q: How do you reconstitute Cagrilintide?**
  - A: Using 2mL of bacteriostatic water results in a concentration of 2.5mg/mL. Start at lowest dose and titrate. Always use sterile techniques.
- **Q: What are the storage requirements for Cagrilintide?**
  - A: Lyophilized (powder): Room temperature or refrigerated, protect from light. Reconstituted: Refrigerated 36-46F (2-8C), use within 28 days.

---

## Cartalax Protocol Guide — Dosing, Reconstitution & Administration
**URL:** https://www.pathtopeptides.com/cartalax-protocol
**Last reviewed:** 2026-04-10

**Summary:** Cartalax is a short bioregulatory peptide (Ala-Glu-Asp) studied for cartilage and joint tissue support. It belongs to the Khavinson peptide bioregulator family and is researched for its ability to normalize gene expression in cartilage cells, potentially supporting chondrocyte function and extracellular matrix maintenance.

**Protocol Overview:**
- **Compound:** Cartalax (Ala-Glu-Asp Tripeptide Bioregulator)
- **Category:** Cartilage / Joint Bioregulator
- **Vial Size:** 10mg (10,000mcg)
- **Reconstitution:** 2mL bacteriostatic water (5mg/mL)
- **Route:** Subcutaneous injection
- **Frequency:** Per protocol

**FAQs:**
- **Q: What is the standard Cartalax dosing protocol?**
  - A: Refer to the dosing table for the standard Cartalax protocol.
- **Q: How do you reconstitute Cartalax?**
  - A: Using 2mL of bacteriostatic water results in a concentration of 5mg/mL. Typically used in 10-day cycles. Always use sterile techniques.
- **Q: What are the storage requirements for Cartalax?**
  - A: Lyophilized (powder): Room temperature or refrigerated, protect from light. Reconstituted: Refrigerated 36-46F (2-8C), use within 28 days.

---

## Cerebrolysin 10mL Protocol Guide — Dosing, Reconstitution & Administration
**URL:** https://www.pathtopeptides.com/cerebrolysin-10ml-protocol
**Last reviewed:** 2026-04-10

**Summary:** Cerebrolysin is a brain-derived peptide preparation containing low-molecular-weight neuropeptides and free amino acids. It is studied for neurotrophic and neuroprotective effects, with research applications in neurodegeneration, traumatic brain injury, and cognitive enhancement. Administered in 10-20 day cycles.

**Protocol Overview:**
- **Compound:** Cerebrolysin 10mL (Porcine Brain-Derived Peptide Preparation)
- **Category:** Brain-Derived Neurotrophic Peptide Mix
- **Vial Size:** 10mL (Pre-mixed solution)
- **Reconstitution:** None required (pre-mixed liquid ampule)
- **Route:** Intramuscular (IM) injection
- **Frequency:** Daily for 10-20 day cycles

**Dosing (sample):**
```
Monday | 5mL | 5mL | Morning
Tuesday | 5mL | 5mL | Morning
Wednesday | 5mL | 5mL | Morning
Thursday | 5mL | 5mL | Morning
Friday | 5mL | 5mL | Morning
```

**FAQs:**
- **Q: What is the standard Cerebrolysin 10mL dosing protocol?**
  - A: The standard Cerebrolysin 10mL protocol uses 5mL administered via intramuscular (IM) injection daily for 10-20 day cycles. Intensive protocols use up to 10mL daily. Cycle 10-20 days on, 2-3 months off.
- **Q: Does Cerebrolysin 10mL require reconstitution?**
  - A: No. Cerebrolysin 10mL comes pre-mixed in ampules. Draw directly from the ampule — no reconstitution is needed. Use opened ampules immediately.
- **Q: What are the storage requirements for Cerebrolysin 10mL?**
  - A: Sealed ampules: Store at room temperature, protect from light. Opened ampules: Use immediately — do not store partially used ampules.

---

## Cerebrolysin Protocol Guide — Dosing & Neuroprotective Research
**URL:** https://www.pathtopeptides.com/cerebrolysin-protocol
**Last reviewed:** 2026-04-07

**Summary:** Cerebrolysin is a brain-derived peptide preparation containing low-molecular-weight neuropeptides and free amino acids obtained from purified porcine brain tissue. Approved as a pharmaceutical in over 40 countries for stroke recovery, traumatic brain injury, and dementia, it contains neurotrophic factors that mimic BDNF, GDNF, NGF, and CNTF. Cerebrolysin is one of the most clinically studied neuroprotective agents with over 200 clinical trials. This protocol covers administration from a 10mL pre-mixed solution via intramuscular injection at 5mL daily in 10-20 day cycles, and neuroprotective stacking.

**Protocol Overview:**
- **Compound:** Cerebrolysin (Standardized porcine brain protein hydrolysate — peptide complex)
- **Category:** Neurotrophic Complex / Neuroprotective
- **Mechanism:** Contains BDNF, NGF, CNTF, and other neurotrophic factors; promotes neuronal survival, synaptogenesis, and neuroprotection
- **Structure:** Low-molecular-weight neuropeptides and free amino acids from purified porcine brain tissue
- **Half-Life:** ~hours (peptide mixture, bioactive components)
- **Vial Size:** 10mL pre-mixed ampule (215.2 mg/mL, pharmaceutical grade)
- **Reconstitution:** None required — pre-mixed solution, draw directly from ampule
- **Route:** Intramuscular (IM) injection or slow IV infusion (clinical settings only)
- **Frequency:** Daily × 10–20 days per cycle (Khavinson protocol)
- **Cycle Length:** 10–20 days on, 2–3 months off; 2–3 cycles per year

**Dosing (sample):**
```
Standard | 5mL | Once daily | Intramuscular (IM) | 10-20 day cycle
Intensive | 10mL | Once daily | Intramuscular (IM) | 10-20 day cycle
```

**FAQs:**
- **Q: What is the standard Cerebrolysin dosing protocol?**
  - A: The standard Cerebrolysin research protocol uses 5mL administered via intramuscular (IM) injection once daily for 10-20 day cycles (Khavinson protocol). Intensive protocols use up to 10mL daily. Cycles are followed by 2-3 months off, with 2-3 cycles per year.
- **Q: Does Cerebrolysin require reconstitution?**
  - A: No. Cerebrolysin comes as a pre-mixed solution in ampules. Draw directly from the ampule — no reconstitution is needed. Do not store partially used ampules.
- **Q: What is the route of administration for Cerebrolysin?**
  - A: Cerebrolysin is administered via intramuscular (IM) injection using a 21-23 gauge needle. It is NOT administered subcutaneously. For volumes above 5mL, split the dose between two injection sites.

---

## CJC-1295 + GHRP-2 Stack Protocol — Dosing
**URL:** https://www.pathtopeptides.com/cjc-1295-ghrp-2-stack-protocol
**Last reviewed:** 2026-04-07

**Summary:** CJC-1295 (no DAC) combined with GHRP-2 creates one of the most well-characterized synergistic growth hormone releasing stacks in peptide research. CJC-1295 is a modified GHRH (growth hormone releasing hormone) analog that amplifies GH pulse amplitude, while GHRP-2 is a potent ghrelin mimetic that initiates GH pulses through a separate receptor pathway. When administered together, they produce GH release 3-5 times greater than either peptide alone, closely mimicking the natural pulsatile pattern of endogenous GH secretion. This protocol covers combined SubQ dosing, timing optimization, reconstitution for both peptides, cycling, and advanced stacking strategies.

**Protocol Overview:**
- **Compounds:** CJC-1295 no DAC (Mod GRF 1-29) + GHRP-2
- **Category:** Growth Hormone Optimization Stack
- **Mechanism:** GHRH analog + Ghrelin mimetic; synergistic pituitary GH release via dual-receptor activation (GHRH-R + GHS-R1a)
- **Half-Life:** CJC-1295: ~30 min | GHRP-2: ~15-25 min
- **Form:** Lyophilized powder (CJC-1295 2mg, GHRP-2 5mg vials)
- **Route:** Subcutaneous
- **Frequency:** 2-3x daily on empty stomach
- **Cycle Length:** 12-16 weeks on, 4-8 weeks off

**Dosing (sample):**
```
Introductory | 100 mcg | 100 mcg | 2x daily (AM + PM) | 2 weeks
Standard | 100 mcg | 100 mcg | 3x daily (AM, post-WO, PM) | 12-16 weeks
Advanced | 100 mcg | 200 mcg | 3x daily (AM, post-WO, PM) | 12-16 weeks
Saturation | 1 mcg/kg | 1-2 mcg/kg | 3x daily | 12-16 weeks
```

**FAQs:**
- **Q: Why combine CJC-1295 with GHRP-2?**
  - A: CJC-1295 (GHRH analog) and GHRP-2 (ghrelin mimetic) work through different but complementary mechanisms. CJC-1295 amplifies GH pulse amplitude while GHRP-2 initiates GH pulses. Together they produce synergistic GH release 3-5x greater than either peptide alone, closely mimicking natural pulsatile GH secretion.
- **Q: What is the standard CJC-1295 + GHRP-2 dosing protocol?**
  - A: The standard protocol uses 100mcg CJC-1295 (no DAC) combined with 100-200mcg GHRP-2, administered subcutaneously 2-3 times daily. Optimal timing is upon waking, post-workout, and before bed. Doses should be taken on an empty stomach (no food 30 minutes before or after).
- **Q: Does CJC-1295 + GHRP-2 suppress natural GH production?**
  - A: Unlike exogenous GH, the CJC-1295 + GHRP-2 stack works by stimulating the pituitary to release its own GH. This preserves the natural feedback loop and does not suppress endogenous GH production when used at standard doses with appropriate cycling (12-16 weeks on, 4-8 weeks off).

---

## CJC/Ipamorelin + MK-677 Stack Protocol
**URL:** https://www.pathtopeptides.com/cjc-1295-ipamorelin-mk677-stack-protocol
**Last reviewed:** 2026-04-07

**Summary:** The CJC-1295/Ipamorelin + MK-677 stack combines injectable GHRH/GHRP peptides with an oral GH secretagogue for the most comprehensive growth hormone axis optimization available. CJC-1295 (Mod GRF 1-29) amplifies GH pulse amplitude via the GHRH receptor, Ipamorelin initiates clean GH pulses via ghrelin receptor without elevating cortisol or prolactin, and MK-677 (Ibutamoren) provides sustained 24-hour GH elevation and robust IGF-1 increase through oral ghrelin mimetic activity with a ~24-hour half-life. This triple approach optimizes both pulsatile and tonic GH secretion, producing superior IGF-1 elevation and body composition improvements. Protocol covers combined SubQ + oral dosing, insulin sensitivity monitoring, timing optimization, and advanced cycling strategies.

**Protocol Overview:**
- **Compounds:** CJC-1295 no DAC + Ipamorelin + MK-677 (Ibutamoren)
- **Category:** Growth Hormone Optimization (Advanced)
- **Mechanism:** GHRH analog + selective GHRP + oral ghrelin mimetic; triple-axis GH optimization via pulsatile + tonic secretion
- **Route:** SubQ (CJC/Ipa) + Oral (MK-677)
- **Frequency:** CJC/Ipa: 2x daily SubQ | MK-677: 1x daily oral (PM)
- **Cycle Length:** 12-16 weeks on, 4-8 weeks off

**Dosing (sample):**
```
Standard | 100 mcg 2x/day | 100 mcg 2x/day | 12.5 mg at night | 12-16 weeks
Advanced | 100 mcg 2x/day | 100 mcg 2x/day | 25 mg at night | 12-16 weeks
Alternating | 100 mcg 2x/day | 100 mcg 2x/day | 25 mg (non-inj. days) | 12-16 weeks
```

**FAQs:**
- **Q: Why combine CJC/Ipamorelin with MK-677?**
  - A: CJC-1295/Ipamorelin provides acute pulsatile GH release mimicking natural physiology, while MK-677 provides sustained baseline GH elevation and IGF-1 increase over 24 hours through oral ghrelin mimetic activity. Combined, they optimize both the pulsatile and tonic components of GH secretion, producing superior IGF-1 elevation and body composition improvements compared to either approach alone.
- **Q: What is the standard CJC/Ipa + MK-677 stack dosing?**
  - A: The standard protocol uses 100mcg CJC-1295 + 100mcg Ipamorelin subcutaneously 2x daily (AM fasted + pre-bed), combined with MK-677 12.5-25mg orally at bedtime. Some protocols use MK-677 only on non-injection days to reduce insulin resistance risk from continuous GH elevation.
- **Q: What are the insulin sensitivity concerns with this stack?**
  - A: Sustained GH elevation from MK-677 combined with pulsatile GH from CJC/Ipa can reduce insulin sensitivity over time. Monitor fasting glucose and HbA1c. Strategies to mitigate this include: using MK-677 only on non-injection days, starting MK-677 at 12.5mg, adding berberine or metformin, and incorporating regular fasted-state exercise.

---

## CJC-1295 / Ipamorelin Protocol Guide — Dosing, Reconstitution & Administration
**URL:** https://www.pathtopeptides.com/cjc-1295-ipamorelin-protocol
**Last reviewed:** 2026-04-10

**Summary:** CJC-1295 (GHRH analog) combined with Ipamorelin (GH secretagogue) provides synergistic growth hormone release through complementary pathways.

**Protocol Overview:**
- **Compound:** CJC-1295 / Ipamorelin (CJC-1295 (no DAC) 5mg + Ipamorelin 5mg)
- **Category:** Growth Hormone Blend
- **Vial Size:** 10mg total (10,000mcg)
- **Reconstitution:** 2mL bacteriostatic water (5mg/mL)
- **Route:** Subcutaneous injection
- **Frequency:** 2–3x daily, 5 days/week

**Dosing (sample):**
```
Standard | 300mcg blend (6 units) | 3x daily (AM, post-workout, before bed) | 900mcg | 4,500mcg
Moderate | 300mcg blend (6 units) | 2x daily (AM, before bed) | 600mcg | 3,000mcg
Beginner | 300mcg blend (6 units) | 1x daily (before bed) | 300mcg | 1,500mcg
```

**FAQs:**
- **Q: What is the standard CJC-1295 / Ipamorelin dosing protocol?**
  - A: The standard CJC-1295/Ipamorelin blend protocol uses 300-500mcg of total blend per injection, administered 2-3 times daily on an empty stomach. The bedtime dose is most important. A 10mg vial lasts approximately 11-33 days depending on protocol.
- **Q: How do you reconstitute CJC-1295 / Ipamorelin?**
  - A: Add 2mL of bacteriostatic water to a 10mg blend vial for a concentration of 5mg/mL total. Always use sterile techniques.
- **Q: What are the storage requirements for CJC-1295 / Ipamorelin?**
  - A: Lyophilized (powder): Room temperature or refrigerated, protect from light. Reconstituted: Refrigerated 36-46F (2-8C), use within 28 days.

---

## CJC-1295 No DAC Protocol Guide — Dosing, Reconstitution & GH Research
**URL:** https://www.pathtopeptides.com/cjc-1295-no-dac-protocol
**Last reviewed:** 2026-04-07

**Summary:** CJC-1295 without DAC (also known as Mod GRF 1-29 or Modified GRF) is a short-acting growth hormone-releasing hormone (GHRH) analog with a half-life of approximately 30 minutes. It stimulates pulsatile GH release from the pituitary gland, mimicking natural GH secretion patterns. Best administered before bed to synergize with natural nocturnal GH pulses, CJC-1295 No DAC is most effective when combined with a GHRP such as Ipamorelin for amplified GH output. This protocol covers reconstitution from a 2mg vial with 2mL bacteriostatic water, subcutaneous dosing at 100mcg before bed, and stacking recommendations.

**Protocol Overview:**
- **Compound:** CJC-1295 No DAC (Mod GRF 1-29)
- **Category:** GHRH Analog / GH Secretagogue
- **Mechanism:** Stimulates pulsatile GH release from pituitary somatotrophs via GHRH receptor activation; short-acting for natural GH pulse patterns
- **Structure:** 29 amino acids, modified GRF(1-29) with four substitutions for enzymatic stability
- **Half-Life:** ~30 minutes
- **Vial Size:** 2mg lyophilized powder
- **Route:** Subcutaneous injection
- **Frequency:** 2–3x daily, fasted (best: pre-workout, post-workout, and before bed)
- **Cycle Length:** 8-12 weeks (no cycling required)

**Dosing (sample):**
```
Conservative Start | 100 mcg | 1x daily (before bed) | Subcutaneous | Weeks 1–2 only
Standard Protocol | 100–200 mcg | 2x daily (pre-workout + before bed) | Subcutaneous | 8–12 weeks
Optimized Protocol | 100–300 mcg | 3x daily (pre-workout, post-workout, before bed) | Subcutaneous | 8–12 weeks
```

**FAQs:**
- **Q: What is the standard CJC-1295 No DAC dosing protocol?**
  - A: The standard CJC-1295 No DAC research protocol uses 100mcg administered subcutaneously once daily before bed, 7 days per week. The weekly total is 700mcg. It is best paired with a GHRP like Ipamorelin for synergistic GH release, as GHRH analogs amplify GHRP-initiated GH pulses.
- **Q: How do you reconstitute a 2mg vial of CJC-1295 No DAC?**
  - A: Add 2mL of bacteriostatic water to a 2mg vial for a concentration of 1mg/mL (1000mcg/mL). Each 10 units on an insulin syringe equals 100mcg. The reconstituted vial should be refrigerated at 2-8 degrees Celsius and used within 20 days.
- **Q: What is the difference between CJC-1295 with and without DAC?**
  - A: CJC-1295 without DAC (Mod GRF 1-29) has a short half-life of approximately 30 minutes, producing natural pulsatile GH release. CJC-1295 with DAC has an extended half-life of 6-8 days due to Drug Affinity Complex binding to albumin, creating sustained elevated GH levels. The no-DAC version is generally preferred for more physiological GH pulsatility.

---

## CJC-1295 with DAC Protocol Guide — Dosing, Reconstitution & Administration
**URL:** https://www.pathtopeptides.com/cjc-1295-with-dac-protocol
**Last reviewed:** 2026-04-10

**Summary:** CJC-1295 with DAC is a long-acting growth hormone-releasing hormone (GHRH) analog. The Drug Affinity Complex (DAC) binds to albumin in the bloodstream, extending the half-life to 8+ days. This allows once-weekly dosing for sustained GH elevation.

**Protocol Overview:**
- **Compound:** CJC-1295 with DAC (Modified GRF with Drug Affinity Complex)
- **Category:** GHRH Analog (Long-Acting)
- **Vial Size:** 2mg (2,000mcg)
- **Reconstitution:** 2mL bacteriostatic water (1mg/mL)
- **Route:** Subcutaneous injection
- **Frequency:** Once weekly

**Dosing (sample):**
```
Monday (or any set day) | 200 (full vial) | 2mg (2,000mcg) | Before bed
```

**FAQs:**
- **Q: What is the standard CJC-1295 with DAC dosing protocol?**
  - A: CJC-1295 with DAC is administered at 2mg (2,000mcg) once weekly subcutaneously. The DAC (Drug Affinity Complex) extends the half-life to 8+ days, allowing weekly dosing. A 2mg vial provides 1 dose.
- **Q: How do you reconstitute CJC-1295 with DAC?**
  - A: Add 2mL of bacteriostatic water to a 2mg vial for a concentration of 1mg/mL. Use the full vial (200 units) for a standard 2mg dose.
- **Q: What are the storage requirements for CJC-1295 with DAC?**
  - A: Lyophilized (powder): Room temperature or refrigerated, protect from light. Reconstituted: Refrigerated 36-46F (2-8C), use within 28 days.

---

## CJC-1295 without DAC Protocol Guide — Dosing, Reconstitution & Administration
**URL:** https://www.pathtopeptides.com/cjc-1295-without-dac-protocol
**Last reviewed:** 2026-04-10

**Summary:** CJC-1295 without DAC (also known as Mod GRF 1-29) is a short-acting GHRH analog with a half-life of approximately 30 minutes. It stimulates pulsatile GH release from the pituitary. Best administered before bed to synergize with natural nocturnal GH pulses. This is a solo protocol, NOT a blend.

**Protocol Overview:**
- **Compound:** CJC-1295 without DAC (Modified GRF (1-29) / Mod GRF 1-29)
- **Category:** GHRH Analog (Short-Acting)
- **Vial Size:** 2mg (2,000mcg)
- **Reconstitution:** 2mL bacteriostatic water (1mg/mL)
- **Route:** Subcutaneous injection
- **Frequency:** 7 days/week

**Dosing (sample):**
```
Monday | 10 | 100mcg | Before bed
Tuesday | 10 | 100mcg | Before bed
Wednesday | 10 | 100mcg | Before bed
Thursday | 10 | 100mcg | Before bed
Friday | 10 | 100mcg | Before bed
Saturday | 10 | 100mcg | Before bed
Sunday | 10 | 100mcg | Before bed
```

**FAQs:**
- **Q: What is the standard CJC-1295 without DAC dosing protocol?**
  - A: The standard CJC-1295 without DAC research protocol uses 100mcg administered before bed on protocol days. Weekly Total: 70 units (700mcg) • Vial Duration: ~20 days
- **Q: How do you reconstitute CJC-1295 without DAC?**
  - A: Using 2mL of bacteriostatic water results in a concentration of 1mg/mL. Always use sterile techniques.
- **Q: What are the storage requirements for CJC-1295 without DAC?**
  - A: Lyophilized (powder): Room temperature or refrigerated, protect from light. Reconstituted: Refrigerated 36-46F (2-8C), use within 28 days.

---

## CJC-1295: Protocol, Dosage & Research Guide
**URL:** https://www.pathtopeptides.com/cjc-1295
**Last reviewed:** 2026-04-07

**Summary:** CJC-1295 is a synthetic analog of growth hormone-releasing hormone (GHRH), available in two formulations: with Drug Affinity Complex (DAC) for extended 6–8 day half-life enabling weekly dosing, and without DAC (Modified GRF 1-29) for pulsatile GH release with 30-minute half-life. Both variants are studied for GH secretagogue activity, body composition, and anti-aging effects, with Grade B+ evidence from human pharmacokinetic and GH-stimulation studies.

**FAQs:**
- **Q: What is the difference between CJC-1295 DAC and CJC-1295 no DAC?**
  - A: CJC-1295 with DAC (Drug Affinity Complex) includes a lysine-maleimide modification that covalently binds to serum albumin, extending half-life to 6–8 days and creating sustained GH elevation. CJC-1295 without DAC (also called Modified GRF 1-29) has a 30-minute half-life, producing discrete GH pulses that more closely mimic natural pulsatile GH release.
- **Q: Which is better: CJC-1295 with DAC or without?**
  - A: For GH pulse preservation (important for preserving GH receptor sensitivity), CJC-1295 no DAC stacked with Ipamorelin is generally preferred. CJC-1295 DAC produces continuous GH elevation useful for specific anabolic or therapeutic goals but may blunt natural pulse architecture over time.
- **Q: What dose of CJC-1295 is used in research?**
  - A: CJC-1295 no DAC: 100–300 mcg per injection, typically 2–3 times daily, ideally fasted. CJC-1295 with DAC: 2 mg once weekly or every 2 weeks due to its extended half-life.

---

## Collagen Peptides Protocol Guide — Dosing, Reconstitution & Administration
**URL:** https://www.pathtopeptides.com/collagen-peptides-protocol
**Last reviewed:** 2026-04-10

**Summary:** Collagen Peptides are hydrolyzed collagen protein fragments studied for skin elasticity, joint health, bone density, and connective tissue support. The hydrolyzed form has enhanced bioavailability, allowing absorption as di- and tripeptides that serve as building blocks and signaling molecules for collagen synthesis.

**Protocol Overview:**
- **Compound:** Collagen Peptides (Hydrolyzed Collagen (Types I, II, III))
- **Category:** Oral Supplement Powder
- **Vial Size:** Bulk Powder (N/A)
- **Reconstitution:** N/A (oral powder)
- **Route:** Oral (powder mixed in liquid)
- **Frequency:** 7 days/week

**Dosing (sample):**
```
Monday | Oral | 10-15g | Morning
Tuesday | Oral | 10-15g | Morning
Wednesday | Oral | 10-15g | Morning
Thursday | Oral | 10-15g | Morning
Friday | Oral | 10-15g | Morning
Saturday | Oral | 10-15g | Morning
Sunday | Oral | 10-15g | Morning
```

**FAQs:**
- **Q: What is the standard Collagen Peptides dosing protocol?**
  - A: The standard Collagen Peptides research protocol uses 10-15g administered morning on protocol days. Weekly Total: 70-105g per week • Vial Duration: Depends on container size
- **Q: How do you reconstitute Collagen Peptides?**
  - A: Collagen Peptides are supplied as an oral powder. No reconstitution with bacteriostatic water is required. Mix directly into liquid (water, coffee, smoothie) and consume orally.
- **Q: What are the storage requirements for Collagen Peptides?**
  - A: Lyophilized (powder): Room temperature or refrigerated, protect from light. Reconstituted: Refrigerated 36-46F (2-8C), use within 28 days.

---

## Cortagen Protocol Guide — Dosing, Reconstitution & Administration
**URL:** https://www.pathtopeptides.com/cortagen-protocol
**Last reviewed:** 2026-04-10

**Summary:** Cortagen is a synthetic tetrapeptide bioregulator studied for its effects on cerebral cortex function and neuroprotection. Research suggests it may normalize cortical gene expression, support neuronal recovery, and exhibit geroprotective properties. Typically administered in 10-day cycles.

**Protocol Overview:**
- **Compound:** Cortagen (Tetrapeptide Bioregulator (Ala-Glu-Asp-Pro))
- **Category:** Cortex Bioregulator Peptide
- **Vial Size:** 10mg (10,000mcg)
- **Reconstitution:** 2mL bacteriostatic water (5mg/mL)
- **Route:** Subcutaneous injection
- **Frequency:** 7 days/week

**Dosing (sample):**
```
Monday | 4 | 200mcg | Morning
Tuesday | 4 | 200mcg | Morning
Wednesday | 4 | 200mcg | Morning
Thursday | 4 | 200mcg | Morning
Friday | 4 | 200mcg | Morning
Saturday | 4 | 200mcg | Morning
Sunday | 4 | 200mcg | Morning
```

**FAQs:**
- **Q: What is the standard Cortagen dosing protocol?**
  - A: The standard Cortagen research protocol uses 200mcg administered morning on protocol days. Weekly Total: 28 units (1,400mcg) • Vial Duration: ~50 days
- **Q: How do you reconstitute Cortagen?**
  - A: Using 2mL of bacteriostatic water results in a concentration of 5mg/mL (5000mcg/mL). Administer in 10-day cycles. Always use sterile techniques.
- **Q: What are the storage requirements for Cortagen?**
  - A: Lyophilized (powder): Room temperature or refrigerated, protect from light. Reconstituted: Refrigerated 36-46F (2-8C), use within 28 days.

---

## Danuglipron Protocol Guide — Dosing, Reconstitution & Administration
**URL:** https://www.pathtopeptides.com/danuglipron-protocol
**Last reviewed:** 2026-04-10

**Summary:** Danuglipron is an oral small-molecule GLP-1 receptor agonist developed for weight management and type 2 diabetes research. As an oral formulation, it offers an alternative to injectable GLP-1 therapies. It is being studied in both twice-daily and sustained-release once-daily formulations.

**Protocol Overview:**
- **Compound:** Danuglipron (Small-Molecule GLP-1 Agonist for Weight and T2D Research)
- **Category:** Oral GLP-1 Receptor Agonist
- **Vial Size:** Oral tablet (Per label)
- **Reconstitution:** N/A (oral tablet)
- **Route:** Oral
- **Frequency:** 7 days/week

**Dosing (sample):**
```
Monday | 1 tab | Per label | Morning
Tuesday | 1 tab | Per label | Morning
Wednesday | 1 tab | Per label | Morning
Thursday | 1 tab | Per label | Morning
Friday | 1 tab | Per label | Morning
Saturday | 1 tab | Per label | Morning
Sunday | 1 tab | Per label | Morning
```

**FAQs:**
- **Q: What is the standard Danuglipron dosing protocol?**
  - A: The standard Danuglipron research protocol uses Per label administered morning on protocol days. Weekly Total: 7 tablets per week • Vial Duration: Per label
- **Q: How do you reconstitute Danuglipron?**
  - A: Danuglipron is an oral tablet requiring no reconstitution. Take with or without food as directed per dosing protocol.
- **Q: What are the storage requirements for Danuglipron?**
  - A: Lyophilized (powder): Room temperature, cool dry place, protect from moisture. Reconstituted: Room temperature, keep sealed, use within 90 days.

---

## Dihexa + Cerebrolysin Stack Protocol Guide — Dosing, Synergy & Research Protocol
**URL:** https://www.pathtopeptides.com/dihexa-cerebrolysin-stack-protocol
**Last reviewed:** 2026-04-08

**Summary:** The Dihexa + Cerebrolysin stack is an advanced neuroprotective combination for neuroplasticity and cognitive restoration. Dihexa is a HGF/c-Met receptor agonist reported to be millions of times more potent than BDNF at promoting synaptogenesis in animal models. Cerebrolysin is a porcine brain-derived peptide preparation containing neurotrophic factors used clinically for decades in Europe/Asia for stroke recovery, TBI, and cognitive decline. Together, Dihexa drives new synapse formation while Cerebrolysin provides neurotrophic support for neuronal survival and repair. This is an advanced/experimental stack due to limited human data on Dihexa.

**Protocol Overview:**
- **Compounds:** Dihexa + Cerebrolysin
- **Category:** Neuroprotection / Neuroplasticity
- **Mechanism:** Dihexa: HGF/c-Met agonism, synaptogenesis. Cerebrolysin: neurotrophic factor blend, neuronal survival, synaptic plasticity
- **Half-Life:** Dihexa: ~12 hrs (oral) | Cerebrolysin: variable
- **Route:** Dihexa: Oral or SubQ | Cerebrolysin: IM or IV
- **Frequency:** Dihexa: 1x daily | Cerebrolysin: 5x/week
- **Cycle Length:** 4-8 weeks (with breaks)

**Dosing (sample):**
```
Conservative | Dihexa 10mg oral daily | Cerebrolysin 5mL IM 5x/week | AM oral, AM IM | 4 weeks
Standard | Dihexa 20mg oral daily | Cerebrolysin 5mL IM 5x/week | AM | 4-8 weeks
Research | Dihexa 5mg SubQ daily | Cerebrolysin 10mL IM 5x/week | AM | 4 weeks on, 2 off
```

**FAQs:**
- **Q: How does the Dihexa + Cerebrolysin stack improve cognition?**
  - A: Dihexa drives new synapse formation through HGF/c-Met receptor activation. Cerebrolysin provides neurotrophic factors that support neuronal survival and synaptic plasticity. Together they create new neural connections and nourish existing ones.
- **Q: Is Dihexa safe for human use?**
  - A: Dihexa has remarkable animal model results but very limited human safety data. The HGF/c-Met pathway is also involved in certain cancers, making cancer history a contraindication. Short cycling with breaks is recommended.
- **Q: How long do cognitive benefits last after stopping?**
  - A: Cerebrolysin benefits persist 2-3 months after a course in clinical studies. Dihexa-driven synaptogenesis may create lasting changes if consolidated through cognitive engagement. Ongoing research needed for long-term data.

---

## Dihexa Protocol Guide — Dosing, Reconstitution & Administration
**URL:** https://www.pathtopeptides.com/dihexa-protocol
**Last reviewed:** 2026-04-10

**Summary:** Dihexa (N-hexanoyl-Tyr-Ile-(6)-aminohexanoic amide) is a synthetic hexapeptide derived from angiotensin IV and studied as a potent hepatocyte growth factor (HGF) potentiator — reported to be approximately one million times more potent than BDNF in promoting synaptic connectivity. It is administered orally (capsule/powder) or transdermally (1–5% cream), NOT by subcutaneous injection. Due to its extreme potency and long duration of action, it is dosed 1–3x per week rather than daily.

**Protocol Overview:**
- **Compound:** Dihexa (N-hexanoyl-Tyr-Ile-(6)-aminohexanoic amide)
- **Category:** Nootropic Research Peptide / HGF Potentiator
- **Vial Size:** 10mg powder (oral/transdermal use)
- **Reconstitution:** Oral: none required (capsule or powder). Transdermal: compound into 1–5% cream base.
- **Route:** Oral (capsule/powder) or transdermal cream — NOT subcutaneous injection
- **Frequency:** 1–3x per week (long duration of action — do not dose daily)

**Dosing (sample):**
```
Oral (capsule/powder) | 10–100mg per dose | 1–3x per week | 4–8 weeks on, 4 weeks off
Transdermal (1–5% cream) | Applied topically daily | Once daily (cream route only) | 4–8 weeks on, 4 weeks off
```

**FAQs:**
- **Q: What is the standard Dihexa dosing protocol?**
  - A: Dihexa is primarily oral at 10-20mg per day (capsule or sublingual). SubQ injection uses 1-5mg per day. Cycles are typically 4-8 weeks on, 4 weeks off. Take on an empty stomach in the morning.
- **Q: How do you reconstitute Dihexa?**
  - A: Oral Dihexa does not require reconstitution. For subQ use, add 2mL of bacteriostatic water to a 10mg vial for a concentration of 5mg/mL.
- **Q: What are the storage requirements for Dihexa?**
  - A: Lyophilized (powder): Room temperature or refrigerated, protect from light. Reconstituted: Refrigerated 36-46F (2-8C), use within 28 days.

---

## Dihexa Protocol Guide — Dosage, Mechanism & Cognitive Enhancement Research
**URL:** https://www.pathtopeptides.com/dihexa
**Last reviewed:** 2026-04-07

**Summary:** Dihexa research protocol: HGF/MET pathway cognitive enhancer. 10–40 mg/day oral or intranasal. Synaptogenesis, memory enhancement, Alzheimer's research. Evidence Grade C+.

**FAQs:**
- **Q: What is Dihexa and how does it enhance cognition?**
  - A: Dihexa (PNB-0408) is a small peptide derived from angiotensin IV. It acts as a potent agonist of the HGF/MET receptor tyrosine kinase pathway with approximately 7 orders of magnitude greater potency than hepatocyte growth factor (HGF) itself. MET receptor activation promotes synaptogenesis — the formation of new synaptic connections — and neuronal survival, both of which underlie its cognitive enhancement effects in animal models of Alzheimer's disease and cognitive impairment.
- **Q: What is the typical Dihexa dosing protocol?**
  - A: Based on animal studies, extrapolated human research dosing ranges from 10–40 mg/day administered orally or intranasally. The oral bioavailability is notable compared to most peptides due to its small, lipophilic structure. A common protocol is 10–20 mg/day oral for cognitive enhancement, or 1–5 mg intranasal for more direct CNS delivery. Cycles of 4–8 weeks are typical with breaks between cycles. No formal human clinical data validates these doses.
- **Q: How does Dihexa compare to other nootropic peptides like Semax?**
  - A: Semax (ACTH fragment) primarily activates BDNF/TrkB signaling and modulates serotonin/dopamine systems, with short-term cognitive enhancement effects. Dihexa works through the HGF/MET pathway to promote structural synaptogenesis — potentially more durable changes. However, Semax has more published human data (Russian clinical trials), while Dihexa evidence is preclinical only. They can be combined as they act via distinct mechanisms.

---

## DSIP Protocol Guide — Dosing, Reconstitution & Administration
**URL:** https://www.pathtopeptides.com/dsip-protocol
**Last reviewed:** 2026-04-10

**Summary:** DSIP (Delta Sleep Inducing Peptide) is a naturally occurring nonapeptide studied for its role in sleep regulation, stress modulation, and neuroendocrine function. Research suggests it may promote delta wave sleep patterns and normalize circadian rhythms.

**Protocol Overview:**
- **Compound:** DSIP (Nonapeptide Sleep Research Compound)
- **Category:** Delta Sleep Inducing Peptide
- **Vial Size:** 5mg (5,000mcg)
- **Reconstitution:** 2mL bacteriostatic water (2.5mg/mL)
- **Route:** Subcutaneous injection
- **Frequency:** 7 days/week

**Dosing (sample):**
```
Monday | 4 | 100mcg | Before bed
Tuesday | 4 | 100mcg | Before bed
Wednesday | 4 | 100mcg | Before bed
Thursday | 4 | 100mcg | Before bed
Friday | 4 | 100mcg | Before bed
Saturday | 4 | 100mcg | Before bed
Sunday | 4 | 100mcg | Before bed
```

**FAQs:**
- **Q: What is the standard DSIP dosing protocol?**
  - A: The standard DSIP research protocol uses 100mcg administered before bed on protocol days. Weekly Total: 28 units (700mcg) • Vial Duration: ~50 days
- **Q: How do you reconstitute DSIP?**
  - A: Using 2mL of bacteriostatic water results in a concentration of 2.5mg/mL (2500mcg/mL). Always use sterile techniques.
- **Q: What are the storage requirements for DSIP?**
  - A: Lyophilized (powder): Room temperature or refrigerated, protect from light. Reconstituted: Refrigerated 36-46F (2-8C), use within 28 days.

---

## Dulaglutide Protocol Guide — Dosing, Reconstitution & Administration
**URL:** https://www.pathtopeptides.com/dulaglutide-protocol
**Last reviewed:** 2026-04-10

**Summary:** Dulaglutide is a long-acting GLP-1 receptor agonist fused to a modified IgG4 Fc fragment, providing an extended half-life for once-weekly dosing. It is studied for glycemic control and weight management in type 2 diabetes research.

**Protocol Overview:**
- **Compound:** Dulaglutide (Trulicity - Weekly GLP-1 for Weight and T2D Research)
- **Category:** GLP-1 Receptor Agonist
- **Vial Size:** 3mg (3,000mcg)
- **Reconstitution:** 2mL bacteriostatic water (1.5mg/mL)
- **Route:** Subcutaneous injection
- **Frequency:** Once weekly

**Dosing (sample):**
```
Monday | 50 | 0.75mg | Morning
```

**FAQs:**
- **Q: What is the standard Dulaglutide dosing protocol?**
  - A: The standard Dulaglutide research protocol uses 0.75mg administered morning on protocol days. Weekly Total: 50 units (0.75mg) • Vial Duration: ~4 weeks at starting dose
- **Q: How do you reconstitute Dulaglutide?**
  - A: Using 2mL of bacteriostatic water results in a concentration of 1.5mg/mL. Start at 0.75mg and titrate. Always use sterile techniques.
- **Q: What are the storage requirements for Dulaglutide?**
  - A: Lyophilized (powder): Room temperature or refrigerated, protect from light. Reconstituted: Refrigerated 36-46F (2-8C), use within 28 days.

---

## Enclomiphene Protocol Guide — Dosing, Cycle & Administration
**URL:** https://www.pathtopeptides.com/enclomiphene-protocol
**Last reviewed:** 2026-04-10

**Summary:** Enclomiphene is the trans-isomer of clomiphene citrate, a selective estrogen receptor modulator (SERM). It is researched for its ability to stimulate endogenous testosterone production by blocking estrogen negative feedback at the hypothalamus and pituitary, increasing LH and FSH secretion without testicular suppression.

**Protocol Overview:**
- **Compound:** Enclomiphene (Enclomiphene Citrate (trans-Clomiphene))
- **Category:** SERM for Testosterone Enhancement
- **Vial Size:** 25mg capsules
- **Reconstitution:** N/A — oral compound
- **Route:** Oral (capsule or liquid)
- **Frequency:** 7 days/week

**Dosing (sample):**
```
Monday | 1 cap | 12.5-25mg | Morning
Tuesday | 1 cap | 12.5-25mg | Morning
Wednesday | 1 cap | 12.5-25mg | Morning
Thursday | 1 cap | 12.5-25mg | Morning
Friday | 1 cap | 12.5-25mg | Morning
Saturday | 1 cap | 12.5-25mg | Morning
Sunday | 1 cap | 12.5-25mg | Morning
```

**FAQs:**
- **Q: What is the standard Enclomiphene dosing protocol?**
  - A: The standard Enclomiphene research protocol uses 12.5-25mg administered morning on protocol days. Weekly Total: 7 capsules (87.5-175mg) • Supply Duration: ~25-50 days per bottle of 25mg caps
- **Q: How do you take Enclomiphene?**
  - A: Enclomiphene is an oral compound supplied as capsules. No reconstitution is required. Swallow the capsule with water at the same time each day.
- **Q: What are the storage requirements for Enclomiphene?**
  - A: Store capsules at room temperature in a cool, dry place. Keep tightly sealed, away from moisture and direct light. Use within 90 days of opening.

---

## Epitalon Protocol Guide — Dosing, Reconstitution & Administration
**URL:** https://www.pathtopeptides.com/epitalon-protocol
**Last reviewed:** 2026-04-10

**Summary:** Epitalon (Epithalon) is a synthetic tetrapeptide studied for its effects on telomerase activation and telomere elongation. Research suggests it may regulate melatonin production and support cellular longevity through telomere maintenance. Typically administered in 10-20 day cycles.

**Protocol Overview:**
- **Compound:** Epitalon (Tetrapeptide Bioregulator (Ala-Glu-Asp-Gly))
- **Category:** Telomere Extension Peptide
- **Vial Size:** 10mg (10,000mcg)
- **Reconstitution:** 2mL bacteriostatic water (5mg/mL)
- **Route:** Subcutaneous injection
- **Frequency:** 7 days/week

**Dosing (sample):**
```
Monday | 50+50 | 2500+2500mcg | AM + PM
Tuesday | 50+50 | 2500+2500mcg | AM + PM
Wednesday | 50+50 | 2500+2500mcg | AM + PM
Thursday | 50+50 | 2500+2500mcg | AM + PM
Friday | 50+50 | 2500+2500mcg | AM + PM
Saturday | 50+50 | 2500+2500mcg | AM + PM
Sunday | 50+50 | 2500+2500mcg | AM + PM
```

**FAQs:**
- **Q: What is the standard Epitalon dosing protocol?**
  - A: The standard Epitalon research protocol uses 2500+2500mcg administered am + pm on protocol days. Weekly Total: 700 units (35,000mcg / 35mg) • Vial Duration: ~2 days at 5mg/day
- **Q: How do you reconstitute Epitalon?**
  - A: Using 2mL of bacteriostatic water results in a concentration of 5mg/mL (5000mcg/mL). Administer in 10-20 day cycles. Always use sterile techniques.
- **Q: What are the storage requirements for Epitalon?**
  - A: Lyophilized (powder): Room temperature or refrigerated, protect from light. Reconstituted: Refrigerated 36-46F (2-8C), use within 28 days.

---

## Epithalon + MOTS-c Stack Protocol Guide — Dosing, Synergy & Research Protocol
**URL:** https://www.pathtopeptides.com/epithalon-mots-c-stack-protocol
**Last reviewed:** 2026-04-08

**Summary:** The Epithalon + MOTS-c stack targets the two most critical pillars of cellular aging: telomere shortening and mitochondrial decline. Epithalon (AEDG peptide) activates telomerase, the enzyme that lengthens telomeres, effectively slowing the cellular clock. Discovered by Professor Vladimir Khavinson, epithalon extends lifespan in animal models and normalizes circadian rhythms. MOTS-c is a mitochondrial-derived peptide that activates AMPK, enhances mitochondrial function, and improves insulin sensitivity. Together, epithalon preserves chromosomal integrity while MOTS-c ensures cellular powerhouses remain efficient.

**Protocol Overview:**
- **Compounds:** Epithalon + MOTS-c
- **Category:** Longevity / Anti-Aging
- **Mechanism:** Epithalon: telomerase activation, pineal regulation, melatonin normalization. MOTS-c: AMPK activation, mitochondrial biogenesis, insulin sensitization
- **Half-Life:** Epithalon: ~30 min | MOTS-c: ~4-6 hrs
- **Route:** Both subcutaneous injection
- **Frequency:** Epithalon: daily (10-day cycles) | MOTS-c: 3-5x/week
- **Cycle Length:** Epithalon: 10-day cycles 2-3x/year | MOTS-c: 8-12 weeks

**Dosing (sample):**
```
Standard | Epithalon 5mg/day x 10 days | MOTS-c 5mg 3x/week | AM both | Epi: 10 days, MOTS-c: 8-12 wk
Enhanced | Epithalon 10mg/day x 10 days | MOTS-c 5mg 5x/week | AM both | Epi: 10 days, MOTS-c: 12 wk
Maintenance | Epi 5mg/day x 10 days, 2x/year | MOTS-c 5mg 2x/week | AM | Ongoing cycles
```

**FAQs:**
- **Q: How does the Epithalon + MOTS-c stack address aging?**
  - A: Epithalon activates telomerase to slow telomere shortening (chromosomal aging). MOTS-c activates AMPK and enhances mitochondrial function (metabolic aging). Together they target both fundamental mechanisms of cellular decline.
- **Q: How often should you cycle Epithalon?**
  - A: 10 consecutive days, repeated 2-3 times per year. Khavinson research suggests these short courses sufficiently activate telomerase for months. Continuous use not recommended.
- **Q: Can MOTS-c improve exercise performance?**
  - A: Yes, MOTS-c enhances mitochondrial metabolism and AMPK-mediated energy pathways. Subjects report improved endurance, faster recovery, and better glucose utilization. It is sometimes called the exercise mimetic peptide.

---

## Epithalon Protocol Guide — Dosing, Reconstitution & Telomere Research
**URL:** https://www.pathtopeptides.com/epithalon-protocol
**Last reviewed:** 2026-04-07

**Summary:** Epithalon (Epitalon) is a synthetic tetrapeptide (Ala-Glu-Asp-Gly) originally developed by Professor Vladimir Khavinson at the St. Petersburg Institute of Bioregulation and Gerontology. It is the synthetic version of the naturally occurring Epithalamin, extracted from the pineal gland. Epithalon is researched primarily for its ability to activate telomerase, the enzyme responsible for maintaining telomere length, and for regulating melatonin production. This protocol covers reconstitution from a 10mg vial, subcutaneous dosing at 5mg/day split AM/PM across 10-20 day cycles, and longevity stacking recommendations.

**Protocol Overview:**
- **Compound:** Epithalon (Epitalon / Epithalamin)
- **Category:** Longevity / Telomere Bioregulator
- **Mechanism:** Activates telomerase enzyme to elongate telomeres, regulates melatonin synthesis in the pineal gland, modulates neuroendocrine aging markers
- **Sequence:** 4 amino acids (Ala-Glu-Asp-Gly)
- **Half-Life:** ~2-4 hours
- **Vial Size:** 10mg lyophilized powder
- **Route:** Subcutaneous injection
- **Frequency:** Twice daily (AM/PM)
- **Cycle Length:** 10-20 days, then 4-6 month break

**Dosing (sample):**
```
Standard (Khavinson) | 5 mg/day (2.5mg x2) | 2x daily (AM/PM) | Subcutaneous | 10 days, repeat q4-6 months
Extended Cycle | 5 mg/day (2.5mg x2) | 2x daily (AM/PM) | Subcutaneous | 20 days, repeat q6 months
Low-Dose Protocol | 2.5 mg/day | 1x daily (PM) | Subcutaneous | 10-20 days, repeat q4-6 months
```

**FAQs:**
- **Q: What is the standard Epithalon dosing protocol?**
  - A: The standard Epithalon research protocol uses 5mg per day, split into two 2.5mg doses (AM and PM), administered subcutaneously. Cycles run for 10-20 consecutive days, followed by a 4-6 month break before repeating. This cycling pattern mirrors the original Khavinson research protocol.
- **Q: How does Epithalon work on telomeres?**
  - A: Epithalon activates telomerase, the enzyme responsible for maintaining telomere length on chromosomes. By stimulating telomerase activity, Epithalon may slow or partially reverse telomere shortening associated with cellular aging. Research by Professor Vladimir Khavinson demonstrated increased telomerase activity and telomere elongation in human cell cultures.
- **Q: How do you reconstitute a 10mg vial of Epithalon?**
  - A: Add 2mL of bacteriostatic water to a 10mg vial for a concentration of 5mg/mL (5000mcg/mL). At the standard dose of 2.5mg (2500mcg) per injection, each 50 units on an insulin syringe delivers one dose. The vial provides 2 days of dosing at 5mg/day.

---

## Epithalon (Epitalon): Complete Research Guide | PtP Wiki
**URL:** https://www.pathtopeptides.com/epithalon
**Last reviewed:** 2026-04-08

**Summary:** Epithalon (also spelled Epitalon or Epithalone) is a synthetic tetrapeptide with the sequence Ala-Glu-Asp-Gly. It is the synthetic version of the active component of epithalamin, a polypeptide extract from the bovine pineal gland. Epithalon is primarily studied for its ability to activate telomerase, the enzyme responsible for maintaining telomere length at chromosome ends, and for its regulation of pineal gland melatonin production.

**FAQs:**
- **Q: What is the relationship between Epithalon and Epithalamin?**
  - A: Epithalamin is a natural extract from bovine pineal gland that was studied extensively by Professor Vladimir Khavinson at the St. Petersburg Institute of Bioregulation and Gerontology. Epithalon (Ala-Glu-Asp-Gly) is the synthetic tetrapeptide identified as the active component of epithalamin. Epithalon reproduces the key biological activities of the crude extract in a standardized, synthetic form.
- **Q: Does Epithalon actually lengthen telomeres?**
  - A: Epithalon activates telomerase, the enzyme that adds telomeric repeats (TTAGGG) to chromosome ends. In vitro studies have demonstrated that Epithalon treatment increases telomerase activity in human somatic cells and extends the replicative lifespan of human fibroblast cultures beyond the Hayflick limit. Whether this translates to measurable telomere lengthening in vivo in humans requires further clinical investigation.
- **Q: How is Epithalon typically administered?**
  - A: Epithalon is administered via subcutaneous injection in most research protocols. The standard research protocol involves 5-10 mg daily for 10-20 consecutive days, repeated 1-2 times per year. Some protocols use intramuscular injection. Oral bioavailability is poor due to rapid enzymatic degradation, making injection the preferred route.

---

## Exenatide Protocol Guide — Dosing, Reconstitution & Administration
**URL:** https://www.pathtopeptides.com/exenatide-protocol
**Last reviewed:** 2026-04-10

**Summary:** Exenatide is a synthetic version of exendin-4, a peptide originally isolated from Gila monster venom. It was the first GLP-1 receptor agonist approved for clinical use. It stimulates glucose-dependent insulin secretion, suppresses glucagon, slows gastric emptying, and promotes satiety.

**Protocol Overview:**
- **Compound:** Exenatide (Byetta - First-in-Class GLP-1 Mimetic)
- **Category:** GLP-1 Receptor Agonist
- **Vial Size:** 5mg (5,000mcg)
- **Reconstitution:** 2mL bacteriostatic water (2.5mg/mL)
- **Route:** Subcutaneous injection
- **Frequency:** Twice daily (Byetta protocol)

**Dosing (sample):**
```
Starting (Byetta) | 5mcg | Twice daily (before meals) | First month
Standard (Byetta) | 10mcg | Twice daily (before meals) | Ongoing
Extended-Release (Bydureon) | 2mg | Once weekly | Ongoing
```

**FAQs:**
- **Q: What is the standard Exenatide dosing protocol?**
  - A: Exenatide (Byetta) starts at 5mcg twice daily (before meals) for the first month, then increases to 10mcg twice daily. The extended-release form (Bydureon) uses 2mg once weekly. Weekly total: 70-140mcg (Byetta) or 2mg (Bydureon).
- **Q: How do you reconstitute Exenatide?**
  - A: Using 2mL of bacteriostatic water results in a concentration of 2.5mg/mL. Always use sterile techniques.
- **Q: What are the storage requirements for Exenatide?**
  - A: Lyophilized (powder): Room temperature or refrigerated, protect from light. Reconstituted: Refrigerated 36-46F (2-8C), use within 28 days.

---

## Follistatin 344 Protocol Guide — Dosing, Reconstitution & Administration
**URL:** https://www.pathtopeptides.com/follistatin-344-protocol
**Last reviewed:** 2026-04-10

**Summary:** Follistatin 344 is an activin-binding protein that functions as a myostatin inhibitor. By binding and neutralizing myostatin (a negative regulator of muscle growth), it is studied for its potential role in muscle hypertrophy and tissue remodeling. Administered subcutaneously every other day.

**Protocol Overview:**
- **Compound:** Follistatin 344 (Follistatin 344 (FST-344))
- **Category:** Myostatin Inhibitor
- **Vial Size:** 1mg (1,000mcg)
- **Reconstitution:** 1mL bacteriostatic water (1mg/mL)
- **Route:** Subcutaneous injection
- **Frequency:** 4 days/week

**Dosing (sample):**
```
Monday | 10 | 100mcg | Morning
Wednesday | 10 | 100mcg | Morning
Friday | 10 | 100mcg | Morning
Sunday | 10 | 100mcg | Morning
```

**FAQs:**
- **Q: What is the standard Follistatin 344 dosing protocol?**
  - A: The standard Follistatin 344 research protocol uses 100mcg administered morning on protocol days. Weekly Total: 40 units (400mcg) • Vial Duration: ~18 days (10 doses)
- **Q: How do you reconstitute Follistatin 344?**
  - A: Using 1mL of bacteriostatic water results in a concentration of 1mg/mL. Always use sterile techniques.
- **Q: What are the storage requirements for Follistatin 344?**
  - A: Lyophilized (powder): Room temperature or refrigerated, protect from light. Reconstituted: Refrigerated 36-46F (2-8C), use within 28 days.

---

## FOXO4-DRI + Epithalon Stack Protocol Guide — Dosing, Synergy & Research Protocol
**URL:** https://www.pathtopeptides.com/foxo4-dri-epithalon-stack-protocol
**Last reviewed:** 2026-04-08

**Summary:** The FOXO4-DRI + Epithalon stack is an advanced longevity protocol combining senolytic therapy with telomere preservation. FOXO4-DRI selectively induces apoptosis in senescent cells by disrupting the FOXO4-p53 interaction that keeps zombie cells alive. Senescent cells accumulate with age, secreting inflammatory SASP factors that damage surrounding tissue. Epithalon activates telomerase to protect telomere length in healthy cells. The synergy: FOXO4-DRI clears damaged senescent cells while epithalon ensures remaining healthy cells maintain replicative capacity. This is experimental due to limited FOXO4-DRI human data.

**Protocol Overview:**
- **Compounds:** FOXO4-DRI + Epithalon
- **Category:** Senolytic + Telomere Longevity
- **Mechanism:** FOXO4-DRI: disrupts FOXO4-p53 in senescent cells, triggers apoptosis. Epithalon: telomerase activation, pineal regulation
- **Half-Life:** FOXO4-DRI: ~6-12 hrs | Epithalon: ~30 min
- **Route:** FOXO4-DRI: SubQ or IV | Epithalon: SubQ
- **Frequency:** FOXO4-DRI: 3 days/cycle | Epithalon: 10 days/cycle
- **Cycle Length:** FOXO4-DRI: quarterly | Epithalon: 2-3x/year

**Dosing (sample):**
```
Standard | FOXO4-DRI 5mg/kg x 3 days | Epithalon 5mg/day x 10 days | Quarterly + biannual | 3 + 10 days/cycle
Conservative | FOXO4-DRI 3mg/kg x 3 days | Epithalon 5mg/day x 10 days | Quarterly + biannual | 3 + 10 days
Sequential | FOXO4-DRI 5mg/kg x 3 days, then Epi day 7 | Epithalon 10mg/day x 10 days | Sequential | ~2 weeks combined
```

**FAQs:**
- **Q: What is the rationale for combining FOXO4-DRI with Epithalon?**
  - A: FOXO4-DRI clears senescent cells releasing inflammatory SASP factors. Epithalon then activates telomerase in remaining healthy cells. This clear-and-protect approach addresses aging from both damage removal and preservation angles.
- **Q: How often should FOXO4-DRI cycles be repeated?**
  - A: Quarterly (every 3 months) based on animal research. Each cycle is only 3 days. Conservative cycling with thorough monitoring is essential given limited human data.
- **Q: Is FOXO4-DRI the same as quercetin/dasatinib senolytic therapy?**
  - A: No. FOXO4-DRI selectively disrupts FOXO4-p53 binding specific to senescent cells, offering more precise targeting than Q+D. However, it is much less studied in humans and more expensive. Q+D remains more established.

---

## FOXO4-DRI Protocol Guide — Dosing, Reconstitution & Administration
**URL:** https://www.pathtopeptides.com/foxo4-dri-protocol
**Last reviewed:** 2026-04-10

**Summary:** FOXO4-DRI is a D-retro-inverso peptide that disrupts the FOXO4-p53 interaction in senescent cells, studied for senolytic (senescent cell clearance) properties. Research suggests it may selectively induce apoptosis in senescent cells while sparing healthy cells, with applications in aging and longevity research.

**Protocol Overview:**
- **Compound:** FOXO4-DRI (D-Retro-Inverso FOXO4 Peptide)
- **Category:** Senolytic Research Peptide
- **Vial Size:** 10mg (10,000mcg)
- **Reconstitution:** 2mL bacteriostatic water (5mg/mL)
- **Route:** Subcutaneous injection
- **Frequency:** 3 consecutive days per quarter (mg/kg dosing)

**Dosing (sample):**
```
60 kg (132 lbs) | 180 mg | 300 mg | 36–60 mL
70 kg (154 lbs) | 210 mg | 350 mg | 42–70 mL
80 kg (176 lbs) | 240 mg | 400 mg | 48–80 mL
90 kg (198 lbs) | 270 mg | 450 mg | 54–90 mL
100 kg (220 lbs) | 300 mg | 500 mg | 60–100 mL
```

**FAQs:**
- **Q: What is the standard FOXO4-DRI dosing protocol?**
  - A: The standard FOXO4-DRI research protocol uses 500mcg administered morning on protocol days. Weekly Total: 30 units (1,500mcg) • Vial Duration: ~33 days
- **Q: How do you reconstitute FOXO4-DRI?**
  - A: Using 2mL of bacteriostatic water results in a concentration of 5mg/mL (5000mcg/mL). Always use sterile techniques.
- **Q: What are the storage requirements for FOXO4-DRI?**
  - A: Lyophilized (powder): Room temperature or refrigerated, protect from light. Reconstituted: Refrigerated 36-46F (2-8C), use within 28 days.

---

## FOXO4-DRI (Senolytic Peptide) Protocol Guide — Dosage, Mechanism & Research
**URL:** https://www.pathtopeptides.com/foxo4-dri
**Last reviewed:** 2026-04-07

**Summary:** FOXO4-DRI research protocol: senolytic peptide targeting FOXO4-p53 interaction in senescent cells. Experimental dosing, mechanism of action, clinical evidence. Evidence Grade C+.

**FAQs:**
- **Q: What is FOXO4-DRI and how does it work as a senolytic?**
  - A: FOXO4-DRI is a retro-inverso D-amino acid peptide derived from the FOXO4 CR3 domain. In senescent cells, FOXO4 binds p53 in the nucleus to prevent apoptosis — allowing senescent cells to persist and secrete the SASP (senescence-associated secretory phenotype). FOXO4-DRI competitively disrupts this FOXO4-p53 interaction, releasing p53 to activate apoptotic transcription programs (Puma, NOXA), specifically killing senescent cells while leaving healthy cells unaffected.
- **Q: What is the experimental dosing for FOXO4-DRI?**
  - A: Based on the 2017 de Keizer mouse study, the effective dose in animals was 5 mg/kg administered 3 times per week for 3 weeks. Translating to human equivalent dose (HED) using standard FDA conversion (divide by 12.3), this approximates 0.4 mg/kg HED. A common extrapolated human research protocol is 1–3 mg/kg every 3–7 days for 3–5 administrations, or intermittent monthly pulsing. No formal human clinical data exists.
- **Q: Is FOXO4-DRI safe for human use?**
  - A: No formal human safety data exists for FOXO4-DRI. The 2017 mouse study did not report significant organ toxicity at effective doses, and the selectivity mechanism (targeting p21-high senescent cells) theoretically spares healthy tissue. However, given Grade C+ evidence, unknown pharmacokinetics in humans, and the experimental nature of senolytic therapy, FOXO4-DRI is classified as high-risk research only.

---

## GHK-Cu Protocol Guide — Dosing, Reconstitution & Administration
**URL:** https://www.pathtopeptides.com/ghk-cu-protocol
**Last reviewed:** 2026-04-10

**Summary:** GHK-Cu is a naturally occurring copper-binding tripeptide found in human plasma, studied for wound healing, skin remodeling, anti-inflammatory signaling, and hair growth research.

**Protocol Overview:**
- **Compound:** GHK-Cu (Copper Peptide (Glycyl-L-Histidyl-L-Lysine:Copper))
- **Category:** Research Peptide
- **Vial Size:** 100mg (100,000mcg)
- **Reconstitution:** 5mL bacteriostatic water (20mg/mL)
- **Route:** Subcutaneous injection
- **Frequency:** 5 days/week

**Dosing (sample):**
```
Monday | 5 | 1mg | Morning
Tuesday | 5 | 1mg | Morning
Wednesday | 5 | 1mg | Morning
Thursday | 5 | 1mg | Morning
Friday | 5 | 1mg | Morning
```

**FAQs:**
- **Q: What is the standard GHK-Cu dosing protocol?**
  - A: The standard GHK-Cu research protocol uses 1mg administered morning on protocol days. Weekly Total: 25 units (5mg) • Vial Duration: ~100 days
- **Q: How do you reconstitute GHK-Cu?**
  - A: Using 5mL of bacteriostatic water results in a concentration of 20mg/mL. GHK-Cu has a blue color when reconstituted due to copper. Always use sterile techniques.
- **Q: What are the storage requirements for GHK-Cu?**
  - A: Lyophilized (powder): Room temperature or refrigerated, protect from light. Reconstituted: Refrigerated 36-46F (2-8C), use within 28 days.

---

## GHK-Cu (Copper Peptide): Complete Research Guide | PtP Wiki
**URL:** https://www.pathtopeptides.com/ghk-cu
**Last reviewed:** 2026-04-08

**Summary:** GHK-Cu (glycyl-L-histidyl-L-lysine:copper(II)) is a naturally occurring copper-binding tripeptide found in human plasma, saliva, and urine. It is one of the most extensively studied peptides in wound healing, tissue remodeling, and anti-aging research, with a body of literature spanning over five decades. GHK-Cu's biological significance extends far beyond copper transport, as it has been shown to modulate the expression of over 4,000 human genes involved in tissue repair, antioxidant defense, inflammation, and stem cell activity.

**FAQs:**
- **Q: Is GHK-Cu naturally found in the human body?**
  - A: Yes, GHK-Cu is a naturally occurring peptide-copper complex found in human plasma, saliva, and urine. Plasma levels are approximately 200 ng/mL in young adults (age 20) and decline to approximately 80 ng/mL by age 60. This age-related decline has been hypothesized to contribute to reduced tissue repair capacity and other aging-related changes.
- **Q: Can GHK-Cu be applied topically or must it be injected?**
  - A: GHK-Cu can be administered both topically and via injection. Topical formulations (creams, serums) are widely used in cosmetic skincare for anti-aging and wound healing applications. For systemic or deeper tissue effects, subcutaneous injection is used in research contexts. Topical GHK-Cu penetrates the epidermis effectively and has demonstrated clinical efficacy for improving skin thickness, elasticity, and firmness.
- **Q: How many genes does GHK-Cu affect?**
  - A: Broad gene expression analyses have demonstrated that GHK-Cu modulates the activity of over 4,000 human genes, representing approximately 6% of the human genome. Of these, 59% are upregulated and 41% are downregulated. The affected genes are involved in tissue remodeling, antioxidant defense, anti-inflammatory response, stem cell activity, and DNA repair pathways.

---

## GHK Peptide Protocol — Wound Healing & Skin
**URL:** https://www.pathtopeptides.com/ghk-protocol
**Last reviewed:** 2026-04-07

**Summary:** GHK (glycyl-L-histidyl-L-lysine) is a naturally occurring tripeptide first isolated from human plasma whose concentration declines significantly with age. Unlike GHK-Cu, this copper-free form retains potent bioactivity including wound healing acceleration, collagen and elastin synthesis stimulation, anti-inflammatory gene modulation, and the ability to reset approximately 4,000 human genes toward healthier expression patterns. This protocol covers subcutaneous dosing at 100-200mcg daily, topical application options, cycling strategies, and stacking for comprehensive tissue repair and rejuvenation research.

**Protocol Overview:**
- **Compound:** GHK (Glycyl-L-Histidyl-L-Lysine)
- **Category:** Wound Healing / Skin Rejuvenation
- **Mechanism:** Naturally occurring tripeptide that modulates gene expression, stimulates collagen synthesis, accelerates wound healing, and exerts anti-inflammatory effects
- **Molecular Weight:** 340.38 g/mol
- **Half-Life:** ~2-4 hours (SubQ)
- **Form:** Lyophilized powder (5mg vials)
- **Route:** Subcutaneous / Topical
- **Frequency:** 1x daily (SubQ) or 2x daily (topical)
- **Cycle Length:** 4-8 weeks on, 2-4 weeks off

**Dosing (sample):**
```
Introductory | 100 mcg | 1x daily | SubQ | 1 week
Standard | 200 mcg | 1x daily | SubQ | 4-8 weeks
Topical | 0.5-1% serum | 2x daily | Topical | Ongoing
Advanced | 200 mcg + topical | SubQ 1x + topical 2x | Combined | 4-8 weeks
```

**FAQs:**
- **Q: What is GHK and how does it differ from GHK-Cu?**
  - A: GHK (glycyl-L-histidyl-L-lysine) is a naturally occurring tripeptide that was first isolated from human plasma. While GHK-Cu is the copper-bound form, free GHK retains significant bioactivity on its own, including wound healing acceleration, collagen synthesis, and anti-inflammatory gene modulation. GHK naturally binds available copper ions in the body after administration.
- **Q: What is the standard GHK dosing protocol?**
  - A: The standard research protocol uses 100-200mcg administered subcutaneously once daily. Topical application of 0.5-1% GHK serum is also used for localized skin research. Cycles typically run 4-8 weeks with a 2-4 week off period.
- **Q: What are the primary research applications of GHK?**
  - A: GHK is researched primarily for wound healing acceleration, skin rejuvenation, collagen and elastin synthesis, anti-inflammatory effects, and gene expression modulation. It has been shown to reset approximately 4,000 genes toward a healthier expression pattern in preclinical studies.

---

## GHRP-2 Protocol Guide — Dosing, Reconstitution & Administration
**URL:** https://www.pathtopeptides.com/ghrp-2-protocol
**Last reviewed:** 2026-04-10

**Summary:** GHRP-2 is a potent growth hormone-releasing peptide that acts on the ghrelin receptor to stimulate GH release from the pituitary. It produces strong GH release and moderate appetite stimulation. GHRP-2 is considered one of the most effective GHRPs with a favorable side effect profile.

**Protocol Overview:**
- **Compound:** GHRP-2 (GHRP-2 (Growth Hormone Releasing Peptide-2))
- **Category:** Growth Hormone-Releasing Peptide
- **Vial Size:** 5mg (5,000mcg)
- **Reconstitution:** 2mL bacteriostatic water (2.5mg/mL)
- **Route:** Subcutaneous injection
- **Frequency:** 2-3x daily, 5 days/week

**Dosing (sample):**
```
Monday | 24 | 600mcg (3x 200mcg) | AM fasted, post-workout, before bed
Tuesday | 24 | 600mcg (3x 200mcg) | AM fasted, post-workout, before bed
Wednesday | 24 | 600mcg (3x 200mcg) | AM fasted, post-workout, before bed
Thursday | 24 | 600mcg (3x 200mcg) | AM fasted, post-workout, before bed
Friday | 24 | 600mcg (3x 200mcg) | AM fasted, post-workout, before bed
Saturday | Rest day
Sunday | Rest day
```

**FAQs:**
- **Q: What is the standard GHRP-2 dosing protocol?**
  - A: The standard GHRP-2 research protocol uses 100-300mcg per injection, administered 2-3 times daily (AM fasted, post-workout, before bed), 5 days per week. Standard dose: 200mcg 3x/day = 3,000mcg/week (120 units). Vial Duration: ~12 days. Cycle 4-8 weeks on, 2-4 weeks off.
- **Q: How do you reconstitute GHRP-2?**
  - A: Using 2mL of bacteriostatic water results in a concentration of 2.5mg/mL. Always use sterile techniques.
- **Q: What are the storage requirements for GHRP-2?**
  - A: Lyophilized (powder): Room temperature or refrigerated, protect from light. Reconstituted: Refrigerated 36-46F (2-8C), use within 28 days.

---

## GHRP-6 Protocol Guide — Dosing, Reconstitution & Administration
**URL:** https://www.pathtopeptides.com/ghrp-6-protocol
**Last reviewed:** 2026-04-10

**Summary:** GHRP-6 is a potent growth hormone-releasing peptide that acts on the ghrelin receptor. It produces robust GH release and is notable for causing strong appetite stimulation (via ghrelin mimicry). It is commonly used in research studying both GH pathways and appetite regulation.

**Protocol Overview:**
- **Compound:** GHRP-6 (GHRP-6 (Growth Hormone Releasing Peptide-6))
- **Category:** Growth Hormone-Releasing Peptide
- **Vial Size:** 5mg (5,000mcg)
- **Reconstitution:** 2mL bacteriostatic water (2.5mg/mL)
- **Route:** Subcutaneous injection
- **Frequency:** 2-3x daily, 5 days/week

**Dosing (sample):**
```
Monday | 24 | 600mcg (3x 200mcg) | AM fasted, post-workout, before bed
Tuesday | 24 | 600mcg (3x 200mcg) | AM fasted, post-workout, before bed
Wednesday | 24 | 600mcg (3x 200mcg) | AM fasted, post-workout, before bed
Thursday | 24 | 600mcg (3x 200mcg) | AM fasted, post-workout, before bed
Friday | 24 | 600mcg (3x 200mcg) | AM fasted, post-workout, before bed
Saturday | Rest day
Sunday | Rest day
```

**FAQs:**
- **Q: What is the standard GHRP-6 dosing protocol?**
  - A: The standard GHRP-6 research protocol uses 100-300mcg per injection, administered 2-3 times daily (AM fasted, post-workout, before bed), 5 days per week. Standard dose: 200mcg 3x/day = 3,000mcg/week (120 units). Vial Duration: ~12 days. Cycle 4-8 weeks on, 2-4 weeks off.
- **Q: How do you reconstitute GHRP-6?**
  - A: Using 2mL of bacteriostatic water results in a concentration of 2.5mg/mL. Always use sterile techniques.
- **Q: What are the storage requirements for GHRP-6?**
  - A: Lyophilized (powder): Room temperature or refrigerated, protect from light. Reconstituted: Refrigerated 36-46F (2-8C), use within 28 days.

---

## Glutathione Protocol Guide — Dosing, Reconstitution & Administration
**URL:** https://www.pathtopeptides.com/glutathione-protocol
**Last reviewed:** 2026-04-10

**Summary:** Glutathione is a tripeptide and the most abundant intracellular antioxidant, playing a crucial role in detoxification, immune function, and protection against oxidative stress.

**Protocol Overview:**
- **Compound:** Glutathione (L-Glutathione (Reduced))
- **Category:** Research Compound
- **Vial Size:** 200mg (200,000mcg)
- **Reconstitution:** 2mL bacteriostatic water (100mg/mL)
- **Route:** Subcutaneous injection
- **Frequency:** 3 days/week

**Dosing (sample):**
```
Monday | 50 | 50mg | Morning
Wednesday | 5 | 50mg | Morning
Friday | 50 | 50mg | Morning
```

**FAQs:**
- **Q: What is the standard Glutathione dosing protocol?**
  - A: The standard Glutathione research protocol uses 50mg administered morning on protocol days. Weekly Total: 150 units (150mg) • Vial Duration: ~4 doses (~1.3 weeks)
- **Q: How do you reconstitute Glutathione?**
  - A: Using 2mL of bacteriostatic water results in a concentration of 100mg/mL. Glutathione dissolves readily. Always use sterile techniques.
- **Q: What are the storage requirements for Glutathione?**
  - A: Lyophilized (powder): Room temperature or refrigerated, protect from light. Reconstituted: Refrigerated 36-46F (2-8C), use within 28 days.

---

## Gonadorelin Protocol Guide — Dosing, Reconstitution & Administration
**URL:** https://www.pathtopeptides.com/gonadorelin-protocol
**Last reviewed:** 2026-04-10

**Summary:** Gonadorelin is a synthetic analog of endogenous GnRH (gonadotropin-releasing hormone). It is used in research to maintain hypothalamic-pituitary-gonadal axis (HPTA) function, stimulating pulsatile LH and FSH release to preserve natural hormone signaling during exogenous hormone protocols.

**Protocol Overview:**
- **Compound:** Gonadorelin (GnRH — Gonadotropin-Releasing Hormone)
- **Category:** Reproductive Health Peptide / PCT Support
- **Chemical Name:** pyro-Glu-His-Trp-Ser-Tyr-Gly-Leu-Arg-Pro-Gly-NH2
- **Vial Size:** 10mg vial
- **Reconstitution:** 10mL bacteriostatic water → 1mg/mL (1,000mcg/mL)
- **Route:** Subcutaneous injection
- **Frequency:** 2–3x per week (protocol dependent)

**Dosing (sample):**
```
TRT Support (LH/FSH maintenance) | 250mcg | 2x/week (e.g., Mon/Thu) | SubQ | Ongoing with TRT
Conservative / Starter | 100mcg | 2–3x/week | SubQ | Ongoing or 8–12 weeks
Fertility Research | 500mcg | 3x/week | SubQ | 8–12 weeks
PCT Support | 250–500mcg | 2–3x/week | SubQ | 8–12 weeks
```

**FAQs:**
- **Q: What is the standard Gonadorelin dosing protocol?**
  - A: The standard Gonadorelin research protocol uses 100mcg administered morning on protocol days. Weekly Total: 20 units (200mcg) • Vial Duration: ~10 weeks
- **Q: How do you reconstitute Gonadorelin?**
  - A: Using 2mL of bacteriostatic water results in a concentration of 1mg/mL. Always use sterile techniques.
- **Q: What are the storage requirements for Gonadorelin?**
  - A: Lyophilized (powder): Room temperature or refrigerated, protect from light. Reconstituted: Refrigerated 36-46F (2-8C), use within 28 days.

---

## GW-501516 (Cardarine) Protocol Guide — Dosing & Administration
**URL:** https://www.pathtopeptides.com/gw-501516-cardarine-protocol
**Last reviewed:** 2026-04-14

**Summary:** GW-501516 (Cardarine) is a PPAR-delta receptor agonist researched for its role in enhancing endurance capacity and fatty acid oxidation. It is not a SARM but is commonly grouped with SARMs in research contexts. Studies suggest it may improve lipid profiles and increase metabolic rate. Capsule Content 10mg per capsule (10,000mcg per capsule) Route of Administration Oral (capsule)

**Protocol Overview:**
- **Compound:** GW-501516 (Cardarine) (Oral Research Compound - Endurance / Fat Oxidation)
- **Category:** PPAR-Delta Agonist
- **Form:** Capsules or Liquid
- **Route:** Oral (capsule or liquid)
- **Frequency:** 7 days/week

**Dosing (sample):**
```
Monday | 1 cap | 10mg | Morning
Tuesday | 1 cap | 10mg | Morning
Wednesday | 1 cap | 10mg | Morning
Thursday | 1 cap | 10mg | Morning
Friday | 1 cap | 10mg | Morning
Saturday | 1 cap | 10mg | Morning
Sunday | 1 cap | 10mg | Morning
```

**FAQs:**
- **Q: What is the standard GW-501516 (Cardarine) dosing protocol?**
  - A: The standard GW-501516 (Cardarine) research protocol uses 10-20mg taken orally once daily in the morning. Cycle Duration: 8-12 weeks on, 4 weeks off. No PCT needed.
- **Q: How do you take GW-501516 (Cardarine)?**
  - A: GW-501516 is taken orally as a capsule or liquid. No reconstitution or injection is needed. Take with or without food.
- **Q: What are the storage requirements for GW-501516 (Cardarine)?**
  - A: Capsules (sealed): Room temperature, cool dry place, protect from light. Capsules (opened): Keep tightly sealed, away from moisture and heat.

---

## GW-501516 (Cardarine) Protocol Guide — Dosing & Administration
**URL:** https://www.pathtopeptides.com/gw-501516-protocol
**Last reviewed:** 2026-04-08

**Summary:** GW-501516 (Cardarine) is a selective PPARdelta receptor agonist developed by GlaxoSmithKline. It dramatically enhances endurance, fat oxidation, and lipid metabolism. Development was abandoned after animal studies showed cancer at extreme doses. It is not a SARM.

**Protocol Overview:**
- **Compound:** GW-501516 (Cardarine / Endurobol)
- **Category:** PPARdelta Receptor Agonist (Metabolic Modulator)
- **Mechanism:** Activates PPARdelta, shifting cellular energy metabolism from glucose to fatty acid oxidation. Upregulates fat-burning genes, increases mitochondrial biogenesis, improves lipid profile (HDL up, LDL and triglycerides down), and dramatically enhances endurance capacity
- **Half-Life:** 16-24 hours
- **Form:** Oral liquid or capsule
- **Route:** Oral
- **Frequency:** Once daily
- **Cycle Length:** 8-12 weeks

**Dosing (sample):**
```
Standard | 10 mg | 1x daily | Oral | 8 weeks
Enhanced | 15 mg | 1x daily | Oral | 8-10 weeks
Maximum | 20 mg | 1x daily | Oral | 8-12 weeks
```

**FAQs:**
- **Q: Is Cardarine safe given the cancer concerns?**
  - A: The cancer risk is debated. Rodent studies used doses far exceeding typical human use (100x+) for extended periods. No human cancer data exists. However, the lack of long-term human safety data means the risk cannot be definitively quantified.
- **Q: Does Cardarine suppress testosterone?**
  - A: No. GW-501516 does not interact with androgen receptors or the HPTA axis. No PCT is needed. It is commonly stacked with SARMs because it adds endurance and fat loss without additional suppression.
- **Q: How quickly does Cardarine work?**
  - A: Many users report noticeable endurance improvement within 1-3 days of first dose. The effect on cardio capacity is often described as dramatic. Fat loss effects build over several weeks.

---

## HCG 5000IU Protocol Guide — Dosing, Reconstitution & Administration
**URL:** https://www.pathtopeptides.com/hcg-5000iu-protocol
**Last reviewed:** 2026-04-10

**Summary:** HCG is a naturally occurring hormone used in research for fertility preservation and as a TRT adjunct. It mimics luteinizing hormone (LH) to stimulate testicular function, supporting endogenous testosterone production and spermatogenesis during exogenous hormone protocols.

**Protocol Overview:**
- **Compound:** HCG 5000IU (Human Chorionic Gonadotropin)
- **Category:** Fertility Preservation / TRT Adjunct
- **Vial Size:** 5000IU (5,000 IU)
- **Reconstitution:** 2mL bacteriostatic water (2,500 IU/mL)
- **Route:** Subcutaneous injection
- **Frequency:** 3 days/week

**Dosing (sample):**
```
Monday | 10 | 250IU | Morning
Wednesday | 10 | 250IU | Morning
Friday | 10 | 250IU | Morning
```

**FAQs:**
- **Q: What is the standard HCG 5000IU dosing protocol?**
  - A: The standard HCG 5000IU research protocol uses 250IU administered morning on protocol days. Weekly Total: 30 units (750IU) • Vial Duration: ~20 injections at 250IU
- **Q: How do you reconstitute HCG 5000IU?**
  - A: Using 2mL of bacteriostatic water results in a concentration of 2,500 IU/mL. Always use sterile techniques.
- **Q: What are the storage requirements for HCG 5000IU?**
  - A: Lyophilized (powder): Room temperature or refrigerated, protect from light. Reconstituted: Refrigerated 36-46F (2-8C), use within 28 days.

---

## HCG (Human Chorionic Gonadotropin) Protocol Guide — Dosing & Administration
**URL:** https://www.pathtopeptides.com/hcg-protocol
**Last reviewed:** 2026-04-08

**Summary:** Human Chorionic Gonadotropin (HCG) is a naturally occurring glycoprotein hormone that mimics luteinizing hormone (LH). It directly stimulates Leydig cells in the testes to produce testosterone and maintain testicular function. Widely used to prevent testicular atrophy during TRT/steroid cycles, as PCT, and for fertility support.

**Protocol Overview:**
- **Compound:** HCG (Human Chorionic Gonadotropin)
- **Category:** Gonadotropin / LH Analog
- **Mechanism:** Binds to LH receptors on testicular Leydig cells, stimulating intratesticular testosterone production and maintaining spermatogenesis. Also stimulates steroidogenic enzyme expression and pregnenolone/DHEA production
- **Half-Life:** 24-36 hours
- **Form:** Lyophilized powder (5000-10000 IU vials) for reconstitution
- **Route:** Subcutaneous or intramuscular
- **Frequency:** 2-3x per week
- **Cycle Length:** Ongoing during TRT, or 4-8 weeks for PCT

**Dosing (sample):**
```
TRT Adjunct | 250 IU | 3x weekly (EOD) | Subcutaneous | Ongoing with TRT
TRT Adjunct (Standard) | 500 IU | 2x weekly | Subcutaneous | Ongoing with TRT
PCT Protocol | 1000-1500 IU | EOD | Subcutaneous | 2-3 weeks, then SERM
Fertility Support | 1000-2000 IU | 3x weekly | Subcutaneous/IM | Per physician guidance
Monotherapy | 1500-2000 IU | 3x weekly | Subcutaneous | Ongoing (with monitoring)
```

**FAQs:**
- **Q: Why use HCG during TRT?**
  - A: Exogenous testosterone suppresses LH, causing testicular atrophy and reduced fertility. HCG at 250-500 IU 2-3x weekly mimics LH, preserving testicular size, function, and fertility while on TRT. It also maintains neurosteroid production.
- **Q: How do you reconstitute HCG?**
  - A: Add the included bacteriostatic water to the vial (typically 5000 IU vial + 5mL BAC water = 1000 IU/mL). For a 250 IU dose, draw 0.25mL (25 units on an insulin syringe). Refrigerate and use within 28 days.
- **Q: Should HCG be used during PCT?**
  - A: HCG can jumpstart recovery in the first 2-3 weeks of PCT (1000-1500 IU EOD), followed by SERM-only for 4-6 weeks. Do not use HCG for the entire PCT as prolonged use can desensitize LH receptors.

---

## Hexarelin Protocol Guide — Dosing, Reconstitution & Administration
**URL:** https://www.pathtopeptides.com/hexarelin-protocol
**Last reviewed:** 2026-04-10

**Summary:** Hexarelin is the strongest of the GHRPs, producing the most potent GH release per dose. It acts on the ghrelin receptor (GHS-R1a) to stimulate pituitary GH secretion. Note: Hexarelin can raise cortisol and prolactin levels, particularly at higher doses. Desensitization may occur with prolonged continuous use.

**Protocol Overview:**
- **Compound:** Hexarelin (Hexarelin Acetate)
- **Category:** Growth Hormone-Releasing Peptide (GHRP)
- **Vial Size:** 5mg (5,000mcg)
- **Reconstitution:** 2mL bacteriostatic water (2.5mg/mL)
- **Route:** Subcutaneous injection
- **Frequency:** 2-3x daily, 5 days/week

**Dosing (sample):**
```
Monday | 24 | 600mcg (3x 200mcg) | AM fasted, post-workout, before bed
Tuesday | 24 | 600mcg (3x 200mcg) | AM fasted, post-workout, before bed
Wednesday | 24 | 600mcg (3x 200mcg) | AM fasted, post-workout, before bed
Thursday | 24 | 600mcg (3x 200mcg) | AM fasted, post-workout, before bed
Friday | 24 | 600mcg (3x 200mcg) | AM fasted, post-workout, before bed
Saturday | Rest day
Sunday | Rest day
```

**FAQs:**
- **Q: What is the standard Hexarelin dosing protocol?**
  - A: The standard Hexarelin research protocol uses 100-200mcg per injection, administered 2-3 times daily (AM fasted, post-workout, before bed), 5 days per week. Standard dose: 200mcg 3x/day = 3,000mcg/week (120 units). Vial Duration: ~12 days. Cycle 4-8 weeks on, 2-4 weeks off to avoid desensitization.
- **Q: How do you reconstitute Hexarelin?**
  - A: Using 2mL of bacteriostatic water results in a concentration of 2.5mg/mL. Always use sterile techniques.
- **Q: What are the storage requirements for Hexarelin?**
  - A: Lyophilized (powder): Room temperature or refrigerated, protect from light. Reconstituted: Refrigerated 36-46F (2-8C), use within 28 days.

---

## HGH + Ipamorelin Stack Protocol Guide — Dosing, Synergy & Research Protocol
**URL:** https://www.pathtopeptides.com/hgh-ipamorelin-stack-protocol
**Last reviewed:** 2026-04-08

**Summary:** The HGH + Ipamorelin stack combines exogenous recombinant human growth hormone with a selective GH secretagogue. Exogenous HGH provides reliable, dose-dependent GH supply bypassing pituitary limitations, while ipamorelin triggers additional natural GH pulses through ghrelin receptor activation without suppressing endogenous production at moderate doses. This allows lower HGH doses (reducing cost and side effects) while achieving superior outcomes through maintained pulsatile release.

**Protocol Overview:**
- **Compounds:** HGH (Recombinant) + Ipamorelin
- **Category:** Growth Hormone Optimization
- **Mechanism:** HGH: direct GH receptor activation, IGF-1, lipolysis, anabolism. Ipamorelin: selective GHSR agonism, pulsatile GH, no cortisol/prolactin
- **Half-Life:** HGH: ~3-4 hrs | Ipamorelin: ~2 hrs
- **Route:** Both subcutaneous injection
- **Frequency:** HGH: 1x daily (AM) | Ipamorelin: 1-2x daily
- **Cycle Length:** 12-24 weeks

**Dosing (sample):**
```
Anti-Aging | HGH 1-2 IU/day AM | Ipa 200mcg PM | AM HGH, PM Ipa | 16-24 weeks
Body Comp | HGH 2-3 IU/day AM | Ipa 200mcg 2x/day | AM HGH+Ipa, PM Ipa | 12-16 weeks
Performance | HGH 3-4 IU/day split | Ipa 300mcg 2x/day | AM/PM both | 12 weeks
```

**FAQs:**
- **Q: Why add Ipamorelin to HGH instead of just using more HGH?**
  - A: Ipamorelin preserves natural pituitary pulsatility, allowing 30-50% lower HGH doses with comparable IGF-1 levels. The evening ipamorelin augments the natural nocturnal GH surge, while lower HGH doses mean fewer side effects.
- **Q: Does Ipamorelin still work when taking exogenous HGH?**
  - A: Yes, at moderate HGH doses (1-3 IU), the pituitary is not fully suppressed and ipamorelin can still trigger additional GH pulses. At very high doses (5+ IU), endogenous production may be suppressed.
- **Q: What is the best HGH dose when stacking with Ipamorelin?**
  - A: Anti-aging: 1-2 IU daily plus evening ipamorelin. Body composition: 2-3 IU with twice-daily ipamorelin. The ipamorelin allows 30-50% less HGH while achieving comparable IGF-1 levels.

---

## HGH (Somatropin) 10IU Protocol Guide — Dosing, Reconstitution & Administration
**URL:** https://www.pathtopeptides.com/hgh-somatropin-10iu-protocol
**Last reviewed:** 2026-04-10

**Summary:** HGH (Somatropin) is recombinant human growth hormone identical to endogenous 191-amino acid GH. It directly elevates GH levels and subsequently IGF-1. Standard starting dose is 1-2IU per day. It is administered subcutaneously, typically in the morning or before bed.

**Protocol Overview:**
- **Compound:** HGH (Somatropin) 10IU (Somatropin (rDNA Origin))
- **Category:** Recombinant Human Growth Hormone
- **Vial Size:** 10IU (10IU (3.33mg))
- **Reconstitution:** N/A (typically pre-reconstituted) bacteriostatic water
- **Route:** Subcutaneous injection
- **Frequency:** 7 days/week

**Dosing (sample):**
```
Monday | 1-2IU | 1-2IU | Morning or before bed
Tuesday | 1-2IU | 1-2IU | Morning or before bed
Wednesday | 1-2IU | 1-2IU | Morning or before bed
Thursday | 1-2IU | 1-2IU | Morning or before bed
Friday | 1-2IU | 1-2IU | Morning or before bed
Saturday | 1-2IU | 1-2IU | Morning or before bed
Sunday | 1-2IU | 1-2IU | Morning or before bed
```

**FAQs:**
- **Q: What is the standard HGH (Somatropin) 10IU dosing protocol?**
  - A: The standard HGH (Somatropin) 10IU research protocol uses 1-2IU administered morning or before bed on protocol days. Weekly Total: 7-14IU (at 1-2IU/day) • Vial Duration: ~5-10 days per vial
- **Q: How do you reconstitute HGH (Somatropin) 10IU?**
  - A: HGH typically comes already reconstituted or as a lyophilized kit with provided diluent. Follow manufacturer instructions for reconstitution. If lyophilized, use the included sterile water or bacteriostatic water per kit directions.
- **Q: What are the storage requirements for HGH (Somatropin) 10IU?**
  - A: Lyophilized (powder): Room temperature or refrigerated, protect from light. Reconstituted: Refrigerated 36-46F (2-8C), use within 28 days.

---

## HGH (Somatropin) Protocol Guide — Dosing & Administration
**URL:** https://www.pathtopeptides.com/hgh-somatropin-protocol
**Last reviewed:** 2026-04-07

**Summary:** Human Growth Hormone (somatropin) is a recombinant 191-amino acid protein identical to endogenous pituitary growth hormone. FDA-approved for adult growth hormone deficiency (AGHD), it stimulates hepatic IGF-1 production, promotes lipolysis, enhances protein synthesis, and supports bone mineralization. In research and clinical settings, HGH is used for body composition optimization, recovery acceleration, anti-aging, and metabolic support. This protocol covers 1-4 IU daily subcutaneous dosing, timing strategies, critical blood work monitoring, and adjunct stacking.

**Protocol Overview:**
- **Compound:** Somatropin (rhGH, 191aa)
- **Category:** Recombinant Human Growth Hormone
- **Mechanism:** Binds GH receptor, stimulates hepatic IGF-1 production, activates JAK2/STAT5 signaling, promotes lipolysis, protein synthesis, chondrogenesis
- **MW:** 22,124 Da (191 amino acids)
- **Half-Life:** 3-5 hours (subcutaneous)
- **Form:** Lyophilized powder or pre-filled pen
- **Route:** Subcutaneous
- **Frequency:** Daily (5-7 days/week)
- **Cycle:** 3-6+ months continuous

**Dosing (sample):**
```
Anti-Aging / Wellness | 1-2 IU/day | Daily, AM fasted | Low-dose longevity approach; fewer side effects
Body Recomposition | 2-4 IU/day | Daily, split AM/pre-bed | Split dosing may improve tolerance
Recovery / Healing | 2-3 IU/day | Daily, AM fasted | Enhanced tissue repair and recovery
Clinical GHD | 0.2-0.5 mg/day | Daily, before bed | Physician-directed; mimics natural pulse
```

---

## Humanin Protocol Guide — Dosing, Reconstitution & Administration
**URL:** https://www.pathtopeptides.com/humanin-protocol
**Last reviewed:** 2026-04-10

**Summary:** Humanin is a mitochondrial-derived peptide encoded in the 16S rRNA region, studied for cytoprotective and longevity-promoting properties. Research suggests it may protect against oxidative stress, reduce apoptosis, and improve metabolic function. It interacts with IGFBP-3 and BAX pathways.

**Protocol Overview:**
- **Compound:** Humanin (Mitochondrial Open Reading Frame Cytoprotective Peptide)
- **Category:** Mitochondrial-Derived Longevity Peptide
- **Vial Size:** 5mg (5,000mcg)
- **Reconstitution:** 2mL bacteriostatic water (2.5mg/mL)
- **Route:** Subcutaneous injection
- **Frequency:** 7 days/week

**Dosing (sample):**
```
Monday | 4 | 100mcg | Morning
Tuesday | 4 | 100mcg | Morning
Wednesday | 4 | 100mcg | Morning
Thursday | 4 | 100mcg | Morning
Friday | 4 | 100mcg | Morning
Saturday | 4 | 100mcg | Morning
Sunday | 4 | 100mcg | Morning
```

**FAQs:**
- **Q: What is the standard Humanin dosing protocol?**
  - A: The standard Humanin research protocol uses 100mcg administered morning on protocol days. Weekly Total: 28 units (700mcg) • Vial Duration: ~71 days
- **Q: How do you reconstitute Humanin?**
  - A: Using 2mL of bacteriostatic water results in a concentration of 2.5mg/mL (2500mcg/mL). Always use sterile techniques.
- **Q: What are the storage requirements for Humanin?**
  - A: Lyophilized (powder): Room temperature or refrigerated, protect from light. Reconstituted: Refrigerated 36-46F (2-8C), use within 28 days.

---

## IGF-1 LR3 Protocol Guide — Dosing, Reconstitution & Administration
**URL:** https://www.pathtopeptides.com/igf-1-lr3-protocol
**Last reviewed:** 2026-04-10

**Summary:** IGF-1 LR3 is a modified form of Insulin-Like Growth Factor-1 with an extended half-life, approximately 2-3x more potent than standard IGF-1, studied for cell proliferation and growth signaling.

**Protocol Overview:**
- **Compound:** IGF-1 LR3 (Long Arg3 Insulin-Like Growth Factor-1)
- **Category:** Research Peptide
- **Vial Size:** 1mg (1,000mcg)
- **Reconstitution:** 1mL bacteriostatic water (1mg/mL)
- **Route:** Subcutaneous injection
- **Frequency:** 3 days/week

**Dosing (sample):**
```
Monday | 5 | 50mcg | Post-exercise
Wednesday | 5 | 50mcg | Post-exercise
Friday | 5 | 50mcg | Post-exercise
```

**FAQs:**
- **Q: What is the standard IGF-1 LR3 dosing protocol?**
  - A: The standard IGF-1 LR3 research protocol uses 50mcg administered post-exercise on protocol days. Weekly Total: 15 units (150mcg) • Vial Duration: ~20 doses (~7 weeks)
- **Q: How do you reconstitute IGF-1 LR3?**
  - A: Using 1mL of bacteriostatic water results in a concentration of 1mg/mL. Handle with care as IGF-1 LR3 is highly potent. Always use sterile techniques.
- **Q: What are the storage requirements for IGF-1 LR3?**
  - A: Lyophilized (powder): Room temperature or refrigerated, protect from light. Reconstituted: Refrigerated 36-46F (2-8C), use within 28 days.

---

## IGF-1 LR3 Protocol Guide — Dosing & Administration
**URL:** https://www.pathtopeptides.com/igf1-lr3-protocol
**Last reviewed:** 2026-04-07

**Summary:** IGF-1 LR3 (Long R3 Insulin-Like Growth Factor-1) is a modified analog of IGF-1 with 83 amino acids. The glutamic acid at position 3 is replaced with arginine, and a 13-amino acid extension peptide is added to the N-terminus. These modifications dramatically reduce binding to IGF binding proteins (IGFBPs), extending the half-life from ~15 minutes (native IGF-1) to 20-30 hours and increasing free bioactive IGF-1 signaling. It promotes muscle cell hyperplasia (new cell formation, not just hypertrophy), enhances protein synthesis, increases glucose uptake, and supports recovery. This protocol covers 20-60mcg daily dosing for 4-6 week cycles with mandatory glucose monitoring.

**Protocol Overview:**
- **Compound:** IGF-1 LR3 (Long R3 IGF-1)
- **Category:** Modified Growth Factor / Anabolic Peptide
- **Mechanism:** IGF-1 receptor agonist with reduced IGFBP binding; activates PI3K/Akt/mTOR pathway; promotes muscle hyperplasia + hypertrophy; enhances glucose uptake; anti-apoptotic signaling
- **MW:** ~9,111 Da (83 amino acids)
- **Half-Life:** 20-30 hours (vs ~15 min native IGF-1)
- **Vial:** 100mcg or 1mg lyophilized
- **Route:** Subcutaneous or intramuscular
- **Frequency:** Daily (post-workout preferred)
- **Cycle:** 4-6 weeks on / 4 weeks off

**Dosing (sample):**
```
Conservative | 20-30 mcg/day | Daily, post-workout | Start here; assess glucose response
Standard | 40-50 mcg/day | Daily, post-workout | Most common research dose
Advanced | 50-80 mcg/day | Daily, post-workout | Higher risk; experienced users only
```

---

## Ipamorelin + CJC-1295 + Tesamorelin Stack Protocol Guide — Dosing, Synergy & Research Protocol
**URL:** https://www.pathtopeptides.com/ipamorelin-cjc-1295-tesamorelin-stack-protocol
**Last reviewed:** 2026-04-08

**Summary:** The Ipamorelin + CJC-1295 + Tesamorelin triple stack is the most comprehensive growth hormone secretagogue protocol available. Ipamorelin is a selective GHSR agonist that triggers pulsatile GH release without cortisol or prolactin elevation. CJC-1295 DAC extends GHRH signaling with a half-life of 6-8 days, amplifying overall GH output. Tesamorelin is an FDA-approved GHRH analog specifically targeting visceral adipose tissue. Together, these three peptides synergize at different points: CJC-1295 provides sustained GHRH baseline, ipamorelin triggers acute GH pulses, and tesamorelin adds GHRH signaling with preferential visceral fat reduction.

**Protocol Overview:**
- **Compounds:** Ipamorelin + CJC-1295 DAC + Tesamorelin
- **Category:** GH Secretagogue Stack
- **Mechanism:** Ipamorelin: GHSR agonism (pulse trigger). CJC-1295 DAC: sustained GHRH analog. Tesamorelin: GHRH analog with visceral fat targeting
- **Half-Life:** Ipa: ~2 hrs | CJC DAC: 6-8 days | Tesa: ~26 min
- **Route:** All subcutaneous injection
- **Frequency:** Ipa: 2-3x daily | CJC DAC: 1-2x/week | Tesa: 1x daily
- **Cycle Length:** 12-16 weeks (4-week breaks)

**Dosing (sample):**
```
Standard | Ipa 200mcg 2x/day + CJC 2mg/wk | Tesa 2mg/day | AM/PM Ipa, weekly CJC, AM Tesa | 12 weeks
Advanced | Ipa 300mcg 3x/day + CJC 2mg/wk | Tesa 2mg/day | AM/pre-workout/PM | 16 weeks
Pulse | Ipa 200mcg 2x/day (5on/2off) + CJC 2mg/wk | Tesa 2mg daily | Weekdays Ipa | 12 weeks
```

**FAQs:**
- **Q: What makes the triple GH stack more effective than a dual stack?**
  - A: It targets three distinct GH axis points. CJC-1295 DAC provides sustained GHRH baseline, ipamorelin triggers acute GH pulses via ghrelin receptor, and tesamorelin adds GHRH stimulation with unique visceral fat targeting. This multi-point approach produces higher, more physiologic GH output.
- **Q: Is it safe to combine three GH secretagogues?**
  - A: When properly dosed and monitored via IGF-1 blood work, it has a good safety profile. Keep IGF-1 at 200-350 ng/mL. Cycling (12 weeks on, 4 off) prevents desensitization.
- **Q: How should you time injections in the triple GH stack?**
  - A: Tesamorelin and ipamorelin fasted AM (30 min apart), ipamorelin again before bed. CJC-1295 DAC once weekly. All fasted, since carbs and fats blunt GH release.

---

## Ipamorelin Protocol Guide — Dosing, Reconstitution & Administration
**URL:** https://www.pathtopeptides.com/ipamorelin-protocol
**Last reviewed:** 2026-04-10

**Summary:** Ipamorelin is a selective growth hormone secretagogue that stimulates the pituitary gland to release growth hormone without significantly affecting cortisol or prolactin levels.

**Protocol Overview:**
- **Compound:** Ipamorelin (Selective GH-Releasing Peptide)
- **Category:** Growth Hormone Secretagogue
- **Vial Size:** 5mg (5,000mcg)
- **Reconstitution:** 2mL bacteriostatic water (2.5mg/mL)
- **Route:** Subcutaneous injection
- **Frequency:** 2–3x daily, 5 days/week

**Dosing (sample):**
```
Standard | 200mcg (8 units) | 3x daily (AM, post-workout, before bed) | 600mcg | 3,000mcg (3mg)
Moderate | 200mcg (8 units) | 2x daily (AM, before bed) | 400mcg | 2,000mcg (2mg)
Beginner | 200mcg (8 units) | 1x daily (before bed) | 200mcg | 1,000mcg (1mg)
```

**FAQs:**
- **Q: What is the standard Ipamorelin dosing protocol?**
  - A: The standard Ipamorelin protocol is 200-300mcg per injection, administered 2-3 times daily (morning, post-workout, and before bed) on an empty stomach. Inject at least 2 hours after eating. A 5mg vial lasts approximately 8-25 days depending on dosing frequency.
- **Q: How do you reconstitute Ipamorelin?**
  - A: Add 2mL of bacteriostatic water to a 5mg vial for a concentration of 2.5mg/mL (2,500mcg/mL). Always use sterile techniques.
- **Q: What are the storage requirements for Ipamorelin?**
  - A: Lyophilized (powder): Room temperature or refrigerated, protect from light. Reconstituted: Refrigerated 36-46F (2-8C), use within 28 days.

---

## Ipamorelin: Complete Research Guide | PtP Wiki
**URL:** https://www.pathtopeptides.com/ipamorelin
**Last reviewed:** 2026-04-08

**Summary:** Ipamorelin is a synthetic pentapeptide growth hormone secretagogue (GHS) that selectively stimulates growth hormone (GH) release from the anterior pituitary by activating the ghrelin receptor (GHS-R1a). It is distinguished from other GH secretagogues by its remarkable selectivity, producing robust GH pulses without significantly elevating cortisol, prolactin, or ACTH levels, an attribute that has made it one of the most widely studied peptides in growth hormone research.

**FAQs:**
- **Q: What makes Ipamorelin different from other GH secretagogues?**
  - A: Ipamorelin is considered the most selective GH secretagogue because it stimulates growth hormone release without significantly raising cortisol, prolactin, or ACTH levels. Unlike GHRP-6 and GHRP-2, which broadly activate appetite and stress hormones, Ipamorelin produces a clean GH pulse with minimal off-target effects. This selectivity makes it attractive for research protocols where confounding hormonal changes must be minimized.
- **Q: How quickly does Ipamorelin elevate GH levels?**
  - A: In clinical studies, Ipamorelin produces a detectable rise in serum GH within 10-15 minutes of subcutaneous injection, with peak GH levels typically occurring at 30-45 minutes post-injection. The GH pulse returns to baseline within approximately 2-3 hours, mimicking a physiological GH secretion pattern rather than producing sustained supraphysiological elevation.
- **Q: Can Ipamorelin be combined with CJC-1295?**
  - A: Yes, combining Ipamorelin with CJC-1295 (no DAC) is one of the most commonly studied GH secretagogue stacks in research contexts. The rationale is synergistic: CJC-1295 acts as a GHRH analog that amplifies the amplitude of GH release, while Ipamorelin triggers the pulse via the ghrelin receptor. Together, they produce a larger, more sustained GH pulse than either compound alone.

---

## Kisspeptin Protocol Guide — Dosing, Reconstitution & Administration
**URL:** https://www.pathtopeptides.com/kisspeptin-protocol
**Last reviewed:** 2026-04-10

**Summary:** Kisspeptin is a neuropeptide that acts upstream of GnRH neurons in the hypothalamus. It is a critical regulator of reproductive hormone cascades and is researched for fertility applications, pubertal development, and as a diagnostic tool for hypothalamic function assessment.

**Protocol Overview:**
- **Compound:** Kisspeptin-10 (Metastin fragment 45-54)
- **Category:** Reproductive / Endocrine Research Peptide
- **Vial Size:** 5mg (5,000mcg)
- **Reconstitution:** 2mL bacteriostatic water → 2.5mg/mL (2,500mcg/mL)
- **Route:** Subcutaneous injection
- **Frequency:** 2–3x per week

**Dosing (sample):**
```
Conservative / Starter | 100mcg | 0.04mL (4 units) | 2–3x/week | 4–12 weeks
Standard SubQ | 200mcg | 0.08mL (8 units) | 2–3x/week | 4–12 weeks
Higher-Dose Research | 500mcg | 0.2mL (20 units) | 2–3x/week | 4–8 weeks
```

**FAQs:**
- **Q: What is the standard Kisspeptin dosing protocol?**
  - A: Kisspeptin-10 is administered subcutaneously at 100-500mcg per dose, 3 times per week. Clinical research uses IV bolus at 0.3-13.6 nmol/kg. A 1mg vial provides 3-10 doses depending on dose level.
- **Q: How do you reconstitute Kisspeptin?**
  - A: Add 1mL of bacteriostatic water to a 1mg vial for a concentration of 1mg/mL (1,000mcg/mL). Always use sterile techniques.
- **Q: What are the storage requirements for Kisspeptin?**
  - A: Lyophilized (powder): Room temperature or refrigerated, protect from light. Reconstituted: Refrigerated 36-46F (2-8C), use within 28 days.

---

## KPV Protocol Guide — Dosing, Reconstitution & Administration
**URL:** https://www.pathtopeptides.com/kpv-protocol
**Last reviewed:** 2026-04-10

**Summary:** KPV is a tripeptide fragment derived from alpha-melanocyte stimulating hormone (alpha-MSH). It retains the potent anti-inflammatory properties of the parent molecule without melanogenic effects. It is researched for inflammatory bowel conditions, skin inflammation, and systemic anti-inflammatory applications.

**Protocol Overview:**
- **Compound:** KPV (Lys-Pro-Val — C-terminal fragment of alpha-MSH)
- **Category:** Anti-Inflammatory Research Peptide / Gut Health
- **Vial Size:** 5mg (5,000mcg)
- **Reconstitution:** SubQ: 2mL bacteriostatic water → 2.5mg/mL. Oral: capsule form (no reconstitution)
- **Route:** Oral (capsule) OR subcutaneous injection — route depends on target indication
- **Frequency:** 1–2x daily (oral or SubQ)

**Dosing (sample):**
```
Oral (capsule) | 500mcg–2mg | 1–2x daily | GI inflammation, IBD, gut health | 4–8 weeks
SubQ injection | 200–500mcg | 1–2x daily | Systemic anti-inflammatory, skin | 4–8 weeks
```

**FAQs:**
- **Q: What is the standard KPV dosing protocol?**
  - A: The standard KPV research protocol uses 200mcg administered morning on protocol days. Weekly Total: 56 units (1,400mcg) • Vial Duration: ~25 days at 200mcg/day
- **Q: How do you reconstitute KPV?**
  - A: Using 2mL of bacteriostatic water results in a concentration of 2.5mg/mL. May also be taken orally in capsule form. Always use sterile techniques for injectable preparations.
- **Q: What are the storage requirements for KPV?**
  - A: Lyophilized (powder): Room temperature or refrigerated, protect from light. Reconstituted: Refrigerated 36-46F (2-8C), use within 28 days.

---

## L-Carnitine Protocol Guide — Dosing, Reconstitution & Administration
**URL:** https://www.pathtopeptides.com/l-carnitine-protocol
**Last reviewed:** 2026-04-10

**Summary:** L-Carnitine is a naturally occurring amino acid derivative essential for the transport of long-chain fatty acids into the mitochondrial matrix for beta-oxidation (fat burning). It is studied for fat metabolism enhancement, exercise performance, mitochondrial energy production, and recovery support.

**Protocol Overview:**
- **Compound:** L-Carnitine (L-Carnitine (Amino Acid Derivative))
- **Category:** Fat Metabolism / Mitochondrial Energy
- **Vial Size:** 500mg (500,000mcg)
- **Reconstitution:** None required (liquid for injection or oral capsules/liquid)
- **Route:** Oral, IM injection, or IV
- **Frequency:** 7 days/week

**Dosing (sample):**
```
Monday | Oral/IM | 500mg-2g | Morning
Tuesday | Oral/IM | 500mg-2g | Morning
Wednesday | Oral/IM | 500mg-2g | Morning
Thursday | Oral/IM | 500mg-2g | Morning
Friday | Oral/IM | 500mg-2g | Morning
Saturday | Oral/IM | 500mg-2g | Morning
Sunday | Oral/IM | 500mg-2g | Morning
```

**FAQs:**
- **Q: What is the standard L-Carnitine dosing protocol?**
  - A: L-Carnitine is dosed at 500mg-2g daily. Oral: 1-3g daily in capsule or liquid form. Injectable: 500-2000mg IM or IV. Weekly total: 3.5-14g per week depending on route and dose.
- **Q: How is L-Carnitine administered?**
  - A: L-Carnitine is available as oral capsules/liquid or injectable solution. No reconstitution is needed for either form. Injectable L-Carnitine comes as a pre-mixed liquid for IM or IV administration.
- **Q: What are the storage requirements for L-Carnitine?**
  - A: Oral forms: Room temperature, protect from moisture and light. Injectable vials: Room temperature or refrigerated, protect from light. Use opened injectable vials within 30 days.

---

## Lactoferrin Protocol Guide — Dosing, Reconstitution & Administration
**URL:** https://www.pathtopeptides.com/lactoferrin-protocol
**Last reviewed:** 2026-04-10

**Summary:** Lactoferrin is an iron-binding glycoprotein found in milk, saliva, and mucosal secretions. It is researched for broad-spectrum antimicrobial activity, immune modulation, gut barrier support, iron homeostasis, and anti-inflammatory properties. It supports innate immunity and healthy gut microbiome composition.

**Protocol Overview:**
- **Compound:** Lactoferrin (Lactoferrin (Lactotransferrin))
- **Category:** Immune and Gut Health Protein
- **Vial Size:** Oral supplement (250mg per serving)
- **Reconstitution:** N/A (oral capsule/powder)
- **Route:** Oral
- **Frequency:** 7 days/week

**Dosing (sample):**
```
Monday | 1 cap | 250mg | Morning
Tuesday | 1 cap | 250mg | Morning
Wednesday | 1 cap | 250mg | Morning
Thursday | 1 cap | 250mg | Morning
Friday | 1 cap | 250mg | Morning
Saturday | 1 cap | 250mg | Morning
Sunday | 1 cap | 250mg | Morning
```

**FAQs:**
- **Q: What is the standard Lactoferrin dosing protocol?**
  - A: The standard Lactoferrin research protocol uses 250mg administered morning on protocol days. Weekly Total: 7 capsules (1,750mg) • Vial Duration: ~30-60 days per bottle
- **Q: How do you reconstitute Lactoferrin?**
  - A: Lactoferrin is supplied as an oral capsule or powder. No reconstitution is required. Take by mouth with water, preferably on an empty stomach for optimal absorption.
- **Q: What are the storage requirements for Lactoferrin?**
  - A: Lyophilized (powder): Room temperature or refrigerated, protect from light. Reconstituted: Refrigerated 36-46F (2-8C), use within 28 days.

---

## LGD-3303 Protocol Guide — Dosing, Reconstitution & Administration
**URL:** https://www.pathtopeptides.com/lgd-3303-protocol
**Last reviewed:** 2026-04-10

**Summary:** LGD-3303 is a non-steroidal SARM that acts as a full agonist of the androgen receptor in muscle and bone tissue. Unlike partial agonists, full AR agonism may produce more pronounced anabolic effects. Research indicates strong effects on muscle mass and bone mineral density. It demonstrates high oral bioavailability and tissue selectivity in preclinical studies. Capsule Content 10mg per capsule (10,000mcg per capsule) Route of Administration Oral (capsule)

**Protocol Overview:**
- **Compound:** LGD-3303 (Oral Research Compound - Full AR Agonist / Lean Mass)
- **Category:** Selective Androgen Receptor Modulator
- **Vial Size:** Capsules
- **Reconstitution:** N/A (oral capsule)
- **Route:** Oral
- **Frequency:** 7 days/week

**Dosing (sample):**
```
Monday | 1 cap | 10mg | Morning
Tuesday | 1 cap | 10mg | Morning
Wednesday | 1 cap | 10mg | Morning
Thursday | 1 cap | 10mg | Morning
Friday | 1 cap | 10mg | Morning
Saturday | 1 cap | 10mg | Morning
Sunday | 1 cap | 10mg | Morning
```

**FAQs:**
- **Q: What is the standard LGD-3303 dosing protocol?**
  - A: The standard LGD-3303 research protocol uses 10mg administered morning on protocol days. Weekly Total: 7 capsules (70mg) • Cycle Duration: 8 weeks on, 4 weeks off
- **Q: Does LGD-3303 require reconstitution?**
  - A: No. LGD-3303 is supplied as an oral capsule and does not require reconstitution with bacteriostatic water. Take orally with water according to the dosing schedule; do not attempt to dissolve capsule contents or inject this compound.
- **Q: What are the storage requirements for LGD-3303?**
  - A: Store sealed capsules at room temperature in a cool, dry place, protected from light and moisture. Keep the bottle tightly closed between doses and away from direct sunlight and heat.

---

## LGD-4033 (Ligandrol) Protocol Guide — Dosing & Administration
**URL:** https://www.pathtopeptides.com/lgd-4033-ligandrol-protocol
**Last reviewed:** 2026-04-14

**Summary:** LGD-4033 (Ligandrol) is a non-steroidal selective androgen receptor modulator (SARM) studied for its potential to increase lean muscle mass and strength. It demonstrates high selectivity for muscle and bone tissue over prostate and sebaceous glands. Research suggests dose-dependent increases in lean body mass. Capsule Content 10mg per capsule (10,000mcg per capsule) Route of Administration Oral (capsule)

**Protocol Overview:**
- **Compound:** LGD-4033 (Ligandrol) (Oral Research Compound - Lean Mass / Strength)
- **Category:** Selective Androgen Receptor Modulator
- **Form:** Capsules or Liquid
- **Route:** Oral (capsule or liquid)
- **Frequency:** 7 days/week

**Dosing (sample):**
```
Monday | 1 cap | 10mg | Morning
Tuesday | 1 cap | 10mg | Morning
Wednesday | 1 cap | 10mg | Morning
Thursday | 1 cap | 10mg | Morning
Friday | 1 cap | 10mg | Morning
Saturday | 1 cap | 10mg | Morning
Sunday | 1 cap | 10mg | Morning
```

**FAQs:**
- **Q: What is the standard LGD-4033 (Ligandrol) dosing protocol?**
  - A: The standard LGD-4033 (Ligandrol) research protocol uses 5-10mg taken orally once daily in the morning. Cycle Duration: 8-12 weeks on, 4 weeks off. PCT recommended after cycle.
- **Q: How do you take LGD-4033 (Ligandrol)?**
  - A: LGD-4033 is taken orally as a capsule or liquid. No reconstitution or injection is needed. Take with or without food.
- **Q: What are the storage requirements for LGD-4033 (Ligandrol)?**
  - A: Capsules (sealed): Room temperature, cool dry place, protect from light. Capsules (opened): Keep tightly sealed, away from moisture and heat.

---

## LGD-4033 (Ligandrol) Protocol Guide — Dosing & Administration
**URL:** https://www.pathtopeptides.com/lgd-4033-protocol
**Last reviewed:** 2026-04-08

**Summary:** LGD-4033 (Ligandrol) is a selective androgen receptor modulator (SARM) developed by Ligand Pharmaceuticals for muscle wasting and osteoporosis. It selectively binds androgen receptors in muscle and bone tissue, promoting anabolic activity without the androgenic side effects of traditional steroids. This protocol covers oral dosing at 5-10mg daily, cycle length, PCT considerations, and bloodwork monitoring.

**Protocol Overview:**
- **Compound:** LGD-4033 (Ligandrol)
- **Category:** Selective Androgen Receptor Modulator (SARM)
- **Mechanism:** Selectively binds androgen receptors in skeletal muscle and bone, stimulating anabolic pathways (protein synthesis, nitrogen retention) with minimal activity in prostate and sebaceous glands
- **Half-Life:** 24-36 hours
- **Form:** Oral liquid or capsule
- **Route:** Oral
- **Frequency:** Once daily
- **Cycle Length:** 8-12 weeks

**Dosing (sample):**
```
Beginner | 5 mg | 1x daily | Oral | 8 weeks
Intermediate | 10 mg | 1x daily | Oral | 8-10 weeks
Advanced | 10 mg | 1x daily | Oral | 10-12 weeks
Recomp | 5-10 mg | 1x daily | Oral | 8-12 weeks
```

**FAQs:**
- **Q: What is the standard LGD-4033 dose?**
  - A: The standard research dose is 5-10mg taken orally once daily. Beginners typically start at 5mg for 8 weeks. Due to its long half-life of 24-36 hours, once-daily dosing maintains stable blood levels.
- **Q: Does LGD-4033 require PCT?**
  - A: Yes. LGD-4033 suppresses natural testosterone production in a dose-dependent manner. A PCT protocol using Enclomiphene (12.5-25mg/day) or Nolvadex (20mg/day for 4 weeks) is recommended after cycles of 8 weeks or longer.
- **Q: How much muscle can you gain on LGD-4033?**
  - A: Clinical trials showed 2-3 lbs of lean mass gain over 21 days at 1mg/day. At research doses of 5-10mg, users typically report 4-8 lbs of lean mass over an 8-12 week cycle, though some is water retention that subsides post-cycle.

---

## Liraglutide Protocol Guide — Dosing, Reconstitution & Administration
**URL:** https://www.pathtopeptides.com/liraglutide-protocol
**Last reviewed:** 2026-04-10

**Summary:** Liraglutide is a GLP-1 receptor agonist with 97% homology to native GLP-1. It is studied for weight management and metabolic research. It reduces appetite and caloric intake via central satiety pathways and delayed gastric emptying.

**Protocol Overview:**
- **Compound:** Liraglutide (Saxenda - Weight Loss Research Peptide)
- **Category:** GLP-1 Receptor Agonist
- **Vial Size:** 6mg (6,000mcg)
- **Reconstitution:** 2mL bacteriostatic water (3mg/mL)
- **Route:** Subcutaneous injection
- **Frequency:** 7 days/week

**Dosing (sample):**
```
Monday | 20 | 0.6mg | Morning
Tuesday | 20 | 0.6mg | Morning
Wednesday | 20 | 0.6mg | Morning
Thursday | 20 | 0.6mg | Morning
Friday | 20 | 0.6mg | Morning
Saturday | 20 | 0.6mg | Morning
Sunday | 20 | 0.6mg | Morning
```

**FAQs:**
- **Q: What is the standard Liraglutide dosing protocol?**
  - A: The standard Liraglutide research protocol uses 0.6mg administered morning on protocol days. Weekly Total: 140 units (4.2mg at starting dose) • Vial Duration: ~10 days at starting dose
- **Q: How do you reconstitute Liraglutide?**
  - A: Using 2mL of bacteriostatic water results in a concentration of 3mg/mL. Start at 0.6mg and titrate up weekly. Always use sterile techniques.
- **Q: What are the storage requirements for Liraglutide?**
  - A: Lyophilized (powder): Room temperature or refrigerated, protect from light. Reconstituted: Refrigerated 36-46F (2-8C), use within 28 days.

---

## LL-37 Protocol Guide — Dosing, Reconstitution & Administration
**URL:** https://www.pathtopeptides.com/ll-37-protocol
**Last reviewed:** 2026-04-10

**Summary:** LL-37 is the only human cathelicidin antimicrobial peptide. It plays a key role in innate immune defense against bacteria, viruses, and fungi. It is researched for antimicrobial properties, wound healing, biofilm disruption, and immune modulation in chronic infections.

**Protocol Overview:**
- **Compound:** LL-37 (Cathelicidin Antimicrobial Peptide, residues 134–170 of hCAP-18)
- **Category:** Antimicrobial / Immunomodulatory Research Peptide
- **Vial Size:** 5mg (5,000mcg)
- **Reconstitution:** 2mL bacteriostatic water (2.5mg/mL)
- **Route:** Subcutaneous injection
- **Frequency:** Daily or every other day
- **Cycle Length:** 4–8 weeks

**Dosing (sample):**
```
Conservative Start | 25–50 mcg | Daily | Subcutaneous | 1–2 weeks, then reassess
Standard Research | 100 mcg | Daily or every other day | Subcutaneous | 4–8 weeks
Immune Support (Higher) | 200 mcg | Daily | Subcutaneous | 4–6 weeks maximum
```

**FAQs:**
- **Q: What is the standard LL-37 dosing protocol?**
  - A: The standard LL-37 research protocol uses 100mcg administered morning on protocol days. Weekly Total: 20 units (500mcg) • Vial Duration: ~50 days
- **Q: How do you reconstitute LL-37?**
  - A: Using 2mL of bacteriostatic water results in a concentration of 2.5mg/mL. Always use sterile techniques.
- **Q: What are the storage requirements for LL-37?**
  - A: Lyophilized (powder): Room temperature or refrigerated, protect from light. Reconstituted: Refrigerated 36-46F (2-8C), use within 28 days.

---

## Matrixyl Protocol Guide — Dosing, Reconstitution & Administration
**URL:** https://www.pathtopeptides.com/matrixyl-protocol
**Last reviewed:** 2026-04-10

**Summary:** Matrixyl (Palmitoyl Pentapeptide-4) is a signal peptide that stimulates collagen synthesis by mimicking the appearance of broken-down collagen fragments. This triggers the skin to produce new collagen and repair the extracellular matrix, making it a key research compound for anti-aging and skin rejuvenation studies.

**Protocol Overview:**
- **Compound:** Matrixyl (Palmitoyl Pentapeptide-4 (Collagen Synthesis))
- **Category:** Topical Collagen-Boosting Peptide
- **Vial Size:** 500mg (500,000mcg)
- **Reconstitution:** N/A (topical solution)
- **Route:** Topical (serum/cream)
- **Frequency:** 7 days/week

**Dosing (sample):**
```
Monday | Topical | Apply 2x/day | AM and PM
Tuesday | Topical | Apply 2x/day | AM and PM
Wednesday | Topical | Apply 2x/day | AM and PM
Thursday | Topical | Apply 2x/day | AM and PM
Friday | Topical | Apply 2x/day | AM and PM
Saturday | Topical | Apply 2x/day | AM and PM
Sunday | Topical | Apply 2x/day | AM and PM
```

**FAQs:**
- **Q: What is the standard Matrixyl dosing protocol?**
  - A: The standard Matrixyl research protocol uses Apply 2x/day administered am and pm on protocol days. Weekly Total: 14 applications/week • Vial Duration: Varies by application area
- **Q: How do you reconstitute Matrixyl?**
  - A: Matrixyl is supplied as a ready-to-use topical solution. No reconstitution with bacteriostatic water is required. Apply directly to clean, dry skin.
- **Q: What are the storage requirements for Matrixyl?**
  - A: Lyophilized (powder): Room temperature or refrigerated, protect from light. Reconstituted: Refrigerated 36-46F (2-8C), use within 28 days.

---

## Melanotan II Protocol Guide — Dosing, Reconstitution & Administration
**URL:** https://www.pathtopeptides.com/melanotan-ii-protocol
**Last reviewed:** 2026-04-10

**Summary:** Melanotan II is a synthetic analog of alpha-melanocyte stimulating hormone (a-MSH) that stimulates melanogenesis, the process by which melanin pigment is produced in skin cells. It is studied for UV-free tanning and photoprotective research applications.

**Protocol Overview:**
- **Compound:** Melanotan II (Alpha-Melanocyte Stimulating Hormone Analog)
- **Category:** Tanning / Photoprotection Peptide
- **Vial Size:** 10mg (10,000mcg)
- **Reconstitution:** 2mL bacteriostatic water (5mg/mL)
- **Route:** Subcutaneous injection
- **Frequency:** 3 days/week

**Dosing (sample):**
```
Monday | 5 | 250mcg | Evening
Wednesday | 5 | 250mcg | Evening
Friday | 5 | 250mcg | Evening
```

**FAQs:**
- **Q: What is the standard Melanotan II dosing protocol?**
  - A: The standard Melanotan II research protocol uses 250mcg administered evening on protocol days, 3 days/week (maintenance). Loading phase: 250-500mcg daily for 7-14 days, then transition to maintenance at 1-2x/week. Weekly Total (maintenance): 15 units (750mcg) • Vial Duration: ~93 days (~13.3 weeks)
- **Q: How do you reconstitute Melanotan II?**
  - A: Using 2mL of bacteriostatic water results in a concentration of 5mg/mL. Start with low doses to assess tolerance. Always use sterile techniques.
- **Q: What are the storage requirements for Melanotan II?**
  - A: Lyophilized (powder): Room temperature or refrigerated, protect from light. Reconstituted: Refrigerated 36-46F (2-8C), use within 28 days.

---

## MK-677 (Ibutamoren) Protocol Guide — Dosing & Administration
**URL:** https://www.pathtopeptides.com/mk-677-ibutamoren-protocol
**Last reviewed:** 2026-04-14

**Summary:** MK-677 (Ibutamoren) is an oral, non-peptide GH secretagogue that mimics ghrelin signaling to stimulate growth hormone release. It has a 24-hour half-life allowing once-daily dosing. Standard dosing range is 10-25mg/day. It increases GH and IGF-1 levels without affecting cortisol.

**Protocol Overview:**
- **Compound:** MK-677 (Ibutamoren) (Ibutamoren Mesylate)
- **Category:** GH Secretagogue (Oral, Non-Peptide)
- **Form:** Capsules (10mg, 15mg, or 25mg)
- **Route:** Oral (capsule or liquid)
- **Frequency:** 7 days/week

**Dosing (sample):**
```
Monday | 1 capsule | 10-25mg | Morning w/ food
Tuesday | 1 capsule | 10-25mg | Morning w/ food
Wednesday | 1 capsule | 10-25mg | Morning w/ food
Thursday | 1 capsule | 10-25mg | Morning w/ food
Friday | 1 capsule | 10-25mg | Morning w/ food
Saturday | 1 capsule | 10-25mg | Morning w/ food
Sunday | 1 capsule | 10-25mg | Morning w/ food
```

**FAQs:**
- **Q: What is the standard MK-677 (Ibutamoren) dosing protocol?**
  - A: The standard MK-677 (Ibutamoren) research protocol uses 10-25mg taken orally once daily with food. Cycle Duration: 8-16 weeks (can run longer). No PCT needed.
- **Q: How do you reconstitute MK-677 (Ibutamoren)?**
  - A: MK-677 is an oral capsule and does not require reconstitution. Take by mouth with food. No injection or bacteriostatic water needed.
- **Q: What are the storage requirements for MK-677 (Ibutamoren)?**
  - A: Sealed container: Room temperature, cool dry place, protect from moisture. Opened container: Room temperature, keep sealed, use within 90 days.

---

## MK-677 (Ibutamoren) Protocol Guide — Dosing & Monitoring
**URL:** https://www.pathtopeptides.com/mk-677-protocol
**Last reviewed:** 2026-04-07

**Summary:** MK-677 (Ibutamoren) is an orally active growth hormone secretagogue that mimics ghrelin to stimulate sustained GH and IGF-1 elevation over 24 hours per dose. Unlike injectable GHRPs, MK-677 requires no reconstitution or injection. This protocol covers oral dosing at 10-25mg daily before bed, the critical importance of blood glucose monitoring, appetite and water retention management, expected timelines, and cycling recommendations.

**Protocol Overview:**
- **Compound:** MK-677 (Ibutamoren Mesylate)
- **Category:** Oral GH Secretagogue (Ghrelin Mimetic)
- **Mechanism:** Orally active ghrelin mimetic that binds GHS receptors for sustained 24-hour GH release and IGF-1 elevation
- **Molecular Weight:** 624.77 Da
- **Half-Life:** ~24 hours
- **Form:** 25mg capsules or liquid (oral)
- **Route:** Oral
- **Frequency:** Once daily
- **Cycle Length:** 8-16 weeks

**Dosing (sample):**
```
Standard | 1-12+ | 25 mg | Before bed | Oral
Conservative | 1-8 | 10-15 mg | Before bed | Oral
Low-dose Long-term | 1-24 | 10 mg | Before bed | Oral
```

**FAQs:**
- **Q: Does MK-677 cause insulin resistance?**
  - A: Yes, MK-677 can elevate fasting blood glucose and reduce insulin sensitivity, especially at 25mg with extended use. Regular glucose monitoring is essential. Berberine or chromium may help mitigate this.
- **Q: How long can you run MK-677?**
  - A: Standard cycles are 8-16 weeks. Some use 10mg long-term (up to 6 months) with metabolic monitoring. Cycling 8 on / 4 off is conservative.
- **Q: Why take MK-677 before bed?**
  - A: Taking MK-677 before bed aligns with the natural nocturnal GH surge, maximizing the GH pulse. It also helps avoid the significant appetite increase during waking hours, as the ghrelin-mimetic effect peaks 1-2 hours post-dose.

---

## MK-677 + Sermorelin Stack Protocol Guide — Dosing, Synergy & Research Protocol
**URL:** https://www.pathtopeptides.com/mk-677-sermorelin-stack-protocol
**Last reviewed:** 2026-04-08

**Summary:** The MK-677 + Sermorelin stack combines an oral GH secretagogue (MK-677/Ibutamoren) with an injectable GHRH analog (Sermorelin) for comprehensive GH optimization. MK-677 is a non-peptide ghrelin receptor agonist that sustains elevated GH levels over 24 hours, increases appetite, and improves sleep. Sermorelin is a GHRH(1-29) analog that stimulates natural pulsatile GH release. Together, MK-677 provides a sustained GH baseline while sermorelin amplifies natural GH pulses, creating a more physiologic GH profile than either alone.

**Protocol Overview:**
- **Compounds:** MK-677 (Ibutamoren) + Sermorelin
- **Category:** GH Secretagogue Stack
- **Mechanism:** MK-677: ghrelin receptor agonism, sustained GH/IGF-1 elevation. Sermorelin: GHRH(1-29) analog, pulsatile GH release
- **Half-Life:** MK-677: ~24 hrs (oral) | Sermorelin: ~10-20 min
- **Route:** MK-677: Oral | Sermorelin: SubQ
- **Frequency:** MK-677: 1x daily | Sermorelin: 1x daily (PM)
- **Cycle Length:** 12-16 weeks (cycling recommended)

**Dosing (sample):**
```
Standard | MK-677 12.5mg oral at bedtime | Sermorelin 200mcg SubQ at bedtime | Both PM | 12 weeks
Enhanced | MK-677 25mg oral at bedtime | Sermorelin 300mcg SubQ at bedtime | Both PM | 12-16 weeks
Maintenance | MK-677 12.5mg oral EOD | Sermorelin 200mcg 3x/week | PM | 8 weeks
```

**FAQs:**
- **Q: Why combine MK-677 with Sermorelin instead of MK-677 alone?**
  - A: MK-677 alone provides sustained but flat GH elevation. Adding sermorelin introduces pulsatile GHRH signaling that creates natural GH peaks and troughs, which is more physiologic and may be more effective for fat loss and tissue repair.
- **Q: What time should you take the MK-677 + Sermorelin stack?**
  - A: Both at bedtime. Sermorelin SubQ 30-60 min before sleep fasted, MK-677 oral at bedtime. This synergizes with the natural nocturnal GH surge and maximizes deep sleep enhancement.
- **Q: Does MK-677 cause insulin resistance in this stack?**
  - A: MK-677 can modestly impair insulin sensitivity, particularly at 25mg. Monitor fasting glucose and HbA1c regularly. If glucose rises, reduce to 12.5mg or switch to every-other-day dosing.

---

## MK-677 (Ibutamoren): Research Guide | PtP Wiki
**URL:** https://www.pathtopeptides.com/mk-677
**Last reviewed:** 2026-04-07

**Summary:** MK-677 (Ibutamoren) is a non-peptide, orally active growth hormone secretagogue that acts as a potent agonist of the ghrelin receptor (GHSR1a). Unlike injectable GH secretagogue peptides such as GHRP-6, GHRP-2, or ipamorelin, MK-677 is a small-molecule compound that can be taken orally, providing sustained elevation of growth hormone (GH) and insulin-like growth factor 1 (IGF-1) levels for up to 24 hours from a single daily dose.

**FAQs:**
- **Q: Is MK-677 a steroid or a SARM?**
  - A: MK-677 is neither a steroid nor a SARM (selective androgen receptor modulator). It is a non-peptide ghrelin receptor agonist (growth hormone secretagogue) that stimulates the pituitary gland to release growth hormone. It does not interact with androgen receptors, does not suppress testosterone production, and does not have anabolic-androgenic steroid activity. It is frequently miscategorized as a SARM because it is often sold alongside SARMs by research chemical suppliers.
- **Q: Does MK-677 increase testosterone?**
  - A: MK-677 does not directly increase testosterone. It acts on the ghrelin/GHSR pathway to increase growth hormone and IGF-1 levels. While elevated GH/IGF-1 can have indirect anabolic effects, MK-677 does not interact with the hypothalamic-pituitary-gonadal (HPG) axis or androgen receptors. Some users report improved body composition and recovery, but these effects are GH/IGF-1-mediated, not testosterone-mediated.
- **Q: How long can MK-677 be taken?**
  - A: Clinical trials have studied MK-677 administration for up to 2 years continuously (the Nass et al. 2008 study in elderly subjects). GH and IGF-1 elevation is sustained throughout long-term use without evidence of tachyphylaxis. However, insulin resistance and blood glucose elevation may worsen with prolonged use, and regular metabolic monitoring is recommended during extended research protocols.

---

## MOTS-C Protocol Guide — Dosing, Reconstitution & Administration
**URL:** https://www.pathtopeptides.com/mots-c-protocol
**Last reviewed:** 2026-04-10

**Summary:** MOTS-C is a mitochondrial-derived peptide studied for metabolic regulation and energy homeostasis. This larger vial supports extended research protocols.

**Protocol Overview:**
- **Compound:** MOTS-C (Mitochondrial Open Reading Frame of the 12S rRNA Type-C)
- **Category:** Mitochondrial Research Peptide
- **Vial Size:** 20mg (20,000mcg)
- **Reconstitution:** 2mL bacteriostatic water (10mg/mL)
- **Route:** Subcutaneous injection
- **Frequency:** 1–3 days/week (5–10mg total per week)

**Dosing (sample):**
```
Standard | Once weekly | 5mg (50 units) | 5mg
Split dose | Mon / Thu | 2.5mg (25 units) each | 5mg
Higher dose | Mon / Wed / Fri | 3.3mg (~33 units) each | ~10mg
```

**FAQs:**
- **Q: What is the standard MOTS-C dosing protocol?**
  - A: The standard MOTS-C research protocol is 5-10mg per week administered subcutaneously, either as a single weekly injection of 5mg or split across 2-3 doses. A 20mg vial lasts approximately 4 weeks at 5mg/week.
- **Q: How do you reconstitute MOTS-C?**
  - A: Add 2mL of bacteriostatic water to a 20mg vial for a concentration of 10mg/mL. Always use sterile techniques.
- **Q: What are the storage requirements for MOTS-C?**
  - A: Lyophilized (powder): Room temperature or refrigerated, protect from light. Reconstituted: Refrigerated 36-46F (2-8C), use within 28 days.

---

## MOTS-c: Protocol, Dosage & Research Guide
**URL:** https://www.pathtopeptides.com/mots-c
**Last reviewed:** 2026-04-07

**Summary:** MOTS-c is a 16-amino-acid peptide encoded within the mitochondrial 12S ribosomal RNA gene — one of a small class of peptides originating from the mitochondrial genome rather than the nuclear genome. It functions as a metabolic regulator that activates AMPK signaling, improves insulin sensitivity, enhances mitochondrial efficiency, and mimics some cellular effects of exercise. Evidence Grade: B, primarily from animal studies with limited human data emerging.

**FAQs:**
- **Q: What is MOTS-c and where does it come from?**
  - A: MOTS-c is a 16-amino-acid peptide encoded in the mitochondrial genome (12S rRNA gene) — one of the few known peptides of mitochondrial origin. It functions as a metabolic regulator, primarily activating AMPK to improve glucose uptake, enhance mitochondrial function, and mimic some effects of exercise at the cellular level.
- **Q: What are the research applications of MOTS-c?**
  - A: MOTS-c is studied for insulin sensitization (type 2 diabetes models), exercise performance enhancement (AMPK activation), obesity/metabolic syndrome, and longevity research. Animal studies show improved glucose tolerance, reduced adiposity, and extended lifespan with MOTS-c treatment.
- **Q: What is the MOTS-c dosage?**
  - A: Research doses in animal studies translate to approximately 5–10 mg/week subcutaneous in humans (5–10 mcg/kg/day). Human clinical research is limited; some research groups use 0.5–1 mg/day or 5 mg twice weekly.

---

## NA Semax Amidate Protocol Guide — Dosing, Reconstitution & Administration
**URL:** https://www.pathtopeptides.com/na-semax-amidate-protocol
**Last reviewed:** 2026-04-10

**Summary:** NA Semax Amidate (N-Acetyl Semax Amidate) is an enhanced analog of Semax with improved bioavailability and longer duration of action. It is studied for cognitive enhancement, neuroprotection, and BDNF upregulation. The N-acetyl and amidate modifications increase stability and CNS penetration.

**Protocol Overview:**
- **Compound:** NA Semax Amidate (N-Acetyl Semax Amidate (Modified ACTH 4-10 Analog))
- **Category:** Enhanced Nootropic Research Peptide
- **Vial Size:** 10mg (10,000mcg)
- **Reconstitution:** 2mL bacteriostatic water (5mg/mL)
- **Route:** Subcutaneous injection
- **Frequency:** 5 days/week

**Dosing (sample):**
```
Monday | 8 | 400mcg | Morning
Tuesday | 8 | 400mcg | Morning
Wednesday | 8 | 400mcg | Morning
Thursday | 8 | 400mcg | Morning
Friday | 8 | 400mcg | Morning
```

**FAQs:**
- **Q: What is the standard NA Semax Amidate dosing protocol?**
  - A: The standard NA Semax Amidate research protocol uses 400mcg administered morning on protocol days. Weekly Total: 40 units (2,000mcg) • Vial Duration: ~25 days
- **Q: How do you reconstitute NA Semax Amidate?**
  - A: Using 2mL of bacteriostatic water results in a concentration of 5mg/mL (5000mcg/mL). Always use sterile techniques.
- **Q: What are the storage requirements for NA Semax Amidate?**
  - A: Lyophilized (powder): Room temperature or refrigerated, protect from light. Reconstituted: Refrigerated 36-46F (2-8C), use within 28 days.

---

## NAD+ Protocol Guide — Dosing, Reconstitution & Administration
**URL:** https://www.pathtopeptides.com/nad-protocol
**Last reviewed:** 2026-04-10

**Summary:** NAD+ is a coenzyme found in all living cells, critical for cellular energy metabolism, DNA repair, and cell signaling. Research focuses on aging, mitochondrial function, and neuroprotection.

**Protocol Overview:**
- **Compound:** NAD+ (Nicotinamide Adenine Dinucleotide)
- **Category:** Research Compound
- **Vial Size:** 1000mg (1,000,000mcg)
- **Reconstitution:** 10mL bacteriostatic water (100mg/mL)
- **Route:** Subcutaneous injection (or IV for clinical)
- **Frequency:** Daily or 3-5x/week

**Dosing (sample):**
```
SubQ Standard | 100-250mg | Daily or 3-5x/week | Subcutaneous
SubQ Loading | 500mg daily x 5 days, then 250mg 3x/week | See description | Subcutaneous
IV Clinical | 250-750mg per infusion | 1-2x/week | Intravenous (clinical only)
```

**FAQs:**
- **Q: What is the standard NAD+ dosing protocol?**
  - A: The standard NAD+ SubQ protocol uses 100-250mg administered daily or 3-5 times per week. A loading protocol uses 500mg daily for 5 days, then 250mg 3x/week maintenance. IV clinical protocols use 250-750mg per infusion 1-2x/week.
- **Q: How do you reconstitute NAD+?**
  - A: Using 10mL of bacteriostatic water results in a concentration of 100mg/mL. NAD+ dissolves readily. Always use sterile techniques.
- **Q: What are the storage requirements for NAD+?**
  - A: Lyophilized (powder): Room temperature or refrigerated, protect from light. Reconstituted: Refrigerated 36-46F (2-8C), use within 28 days.

---

## NAD+ + SS-31 Stack Protocol Guide — Dosing, Synergy & Research Protocol
**URL:** https://www.pathtopeptides.com/nad-ss-31-stack-protocol
**Last reviewed:** 2026-04-08

**Summary:** The NAD+ + SS-31 (Elamipretide) stack targets mitochondrial function from two complementary angles. NAD+ is an essential coenzyme that declines with age, fueling sirtuins, PARP DNA repair enzymes, and mitochondrial electron transport. SS-31 is a mitochondria-targeted peptide that concentrates 5000-fold within the inner mitochondrial membrane, stabilizing cardiolipin and optimizing electron transport chain efficiency while reducing reactive oxygen species. Together, NAD+ provides the fuel for mitochondrial enzymes while SS-31 repairs the machinery itself.

**Protocol Overview:**
- **Compounds:** NAD+ + SS-31 (Elamipretide)
- **Category:** Cellular Energy / Mitochondrial Repair
- **Mechanism:** NAD+: sirtuin activation, PARP DNA repair, electron transport cofactor. SS-31: cardiolipin stabilization, ETC optimization, ROS reduction
- **Half-Life:** NAD+ (IV): ~30-45 min | SS-31: ~4 hrs
- **Route:** NAD+: IV infusion or SubQ | SS-31: SubQ
- **Frequency:** NAD+: 1-3x/week | SS-31: 1x daily
- **Cycle Length:** 8-12 weeks

**Dosing (sample):**
```
Standard | NAD+ 250mg IV 1x/week | SS-31 5mg SubQ daily | Weekly IV + daily SubQ | 8 weeks
Enhanced | NAD+ 500mg IV 2x/week | SS-31 10mg SubQ daily | 2x/week IV + daily SubQ | 8-12 weeks
SubQ Only | NAD+ 100mg SubQ daily | SS-31 5mg SubQ daily | Both AM SubQ | 8-12 weeks
```

**FAQs:**
- **Q: How do NAD+ and SS-31 work together for mitochondrial health?**
  - A: NAD+ fuels mitochondrial enzymes and sirtuins but is limited if the machinery is damaged. SS-31 repairs the inner mitochondrial membrane by stabilizing cardiolipin and optimizing electron transport. NAD+ provides the fuel while SS-31 ensures the engine runs properly.
- **Q: Is subcutaneous NAD+ as effective as IV?**
  - A: SubQ has lower bioavailability but avoids clinic visits and IV side effects. SubQ 100-200mg daily can achieve similar steady-state levels as weekly IV, though it takes longer. Many prefer SubQ convenience.
- **Q: How long do effects last after stopping?**
  - A: SS-31 creates structural mitochondrial improvements lasting weeks to months. NAD+ levels decline within days of stopping. Most run periodic cycles (8-12 weeks on, 4 off).

---

## NAD+ (Nicotinamide Adenine Dinucleotide): Complete Research Guide | PtP Wiki
**URL:** https://www.pathtopeptides.com/nad
**Last reviewed:** 2026-04-08

**Summary:** NAD+ (nicotinamide adenine dinucleotide) is an essential coenzyme found in every living cell, serving as a critical cofactor for over 500 enzymatic reactions and as a substrate for signaling enzymes including sirtuins and PARPs. It is indispensable for cellular energy metabolism (glycolysis, TCA cycle, oxidative phosphorylation), DNA repair, gene expression regulation, calcium signaling, and maintenance of cellular redox balance.

**FAQs:**
- **Q: What is the difference between NAD+, NMN, and NR?**
  - A: NAD+ (nicotinamide adenine dinucleotide) is the active coenzyme itself. NMN (nicotinamide mononucleotide) and NR (nicotinamide riboside) are biosynthetic precursors that cells convert into NAD+. NMN is one enzymatic step away from NAD+ (converted by NMNAT enzymes), while NR is two steps away (first phosphorylated to NMN by NRK, then converted to NAD+). All three aim to raise intracellular NAD+ levels, but they differ in route of administration, bioavailability, and cell entry mechanisms.
- **Q: Why do NAD+ levels decline with age?**
  - A: NAD+ levels decline 40-50% between ages 40-60 due to multiple mechanisms: increased consumption by PARP enzymes responding to accumulating DNA damage; increased activity of CD38 (a NAD+-consuming enzyme that rises with chronic inflammation); decreased biosynthesis through reduced NAMPT (the rate-limiting salvage pathway enzyme) expression; and increased oxidative stress that depletes NAD+ pools. This decline contributes to mitochondrial dysfunction, impaired DNA repair, and other hallmarks of aging.
- **Q: Is NAD+ IV therapy supported by clinical evidence?**
  - A: NAD+ IV therapy is widely offered clinically but has limited controlled clinical trial data as of 2026. The rationale is based on strong preclinical evidence showing that restoring NAD+ levels reverses age-related metabolic decline. Observational and pilot studies report improved energy, cognitive clarity, and metabolic markers. However, large-scale randomized controlled trials comparing IV NAD+ to oral precursors (NMN, NR) or placebo are still needed to establish optimal delivery route and dose.

---

## Orforglipron Protocol Guide — Dosing, Reconstitution & Administration
**URL:** https://www.pathtopeptides.com/orforglipron-protocol
**Last reviewed:** 2026-04-10

**Summary:** Orforglipron is the first oral non-peptide GLP-1 receptor agonist, representing a breakthrough in weight loss research. Unlike injectable GLP-1 drugs, it is a small molecule that can be taken as a daily pill. It is studied for obesity and type 2 diabetes management.

**Protocol Overview:**
- **Compound:** Orforglipron (First Oral Small-Molecule GLP-1 Receptor Agonist)
- **Category:** Oral Non-Peptide GLP-1 Agonist
- **Vial Size:** 10mg (10mg tablet)
- **Reconstitution:** N/A (oral tablet)
- **Route:** Oral
- **Frequency:** 7 days/week

**Dosing (sample):**
```
Monday | 1 tab | 3mg | Morning
Tuesday | 1 tab | 3mg | Morning
Wednesday | 1 tab | 3mg | Morning
Thursday | 1 tab | 3mg | Morning
Friday | 1 tab | 3mg | Morning
Saturday | 1 tab | 3mg | Morning
Sunday | 1 tab | 3mg | Morning
```

**FAQs:**
- **Q: What is the standard Orforglipron dosing protocol?**
  - A: The standard Orforglipron research protocol uses 3mg administered morning on protocol days. Weekly Total: 7 tablets (21mg at starting dose) • Vial Duration: Per label
- **Q: How do you reconstitute Orforglipron?**
  - A: Orforglipron is an oral tablet requiring no reconstitution. Take with water on an empty stomach at least 30 minutes before the first meal of the day.
- **Q: What are the storage requirements for Orforglipron?**
  - A: Lyophilized (powder): Room temperature, cool dry place, protect from moisture. Reconstituted: Room temperature, keep sealed, use within 90 days.

---

## Ostarine (MK-2866) Protocol Guide — Dosing, Cycle & Administration
**URL:** https://www.pathtopeptides.com/ostarine-mk-2866-protocol
**Last reviewed:** 2026-04-10

**Summary:** Ostarine (MK-2866) is the most extensively studied SARM, known for its mild yet effective profile. Research focuses on lean mass preservation during caloric deficit, body recomposition, and joint/tendon health. It demonstrates favorable selectivity and is often the first SARM used in research protocols due to its well-characterized safety profile. Capsule Content 10mg per capsule (10,000mcg per capsule) Route of Administration Oral (capsule)

**Protocol Overview:**
- **Compound:** Ostarine (MK-2866) (Oral Research Compound - Lean Mass / Body Recomposition)
- **Category:** Selective Androgen Receptor Modulator
- **Vial Size:** 10mg capsules
- **Reconstitution:** N/A — oral compound
- **Route:** Oral (capsule or liquid)
- **Frequency:** 7 days/week

**Dosing (sample):**
```
Monday | 1 cap | 10mg | Morning
Tuesday | 1 cap | 10mg | Morning
Wednesday | 1 cap | 10mg | Morning
Thursday | 1 cap | 10mg | Morning
Friday | 1 cap | 10mg | Morning
Saturday | 1 cap | 10mg | Morning
Sunday | 1 cap | 10mg | Morning
```

**FAQs:**
- **Q: What is the standard Ostarine (MK-2866) dosing protocol?**
  - A: The standard Ostarine (MK-2866) research protocol uses 10mg administered morning on protocol days. Weekly Total: 7 capsules (70mg) • Cycle Duration: 8 weeks on, 4 weeks off
- **Q: How do you take Ostarine (MK-2866)?**
  - A: Ostarine (MK-2866) is an oral compound supplied as capsules. No reconstitution is required. Swallow the capsule with water at the same time each day.
- **Q: What are the storage requirements for Ostarine (MK-2866)?**
  - A: Store capsules at room temperature in a cool, dry place. Keep tightly sealed, away from moisture and direct light.

---

## Oxytocin 100IU Protocol Guide — Dosing, Reconstitution & Administration
**URL:** https://www.pathtopeptides.com/oxytocin-100iu-protocol
**Last reviewed:** 2026-04-10

**Summary:** Oxytocin is a naturally occurring cyclic nonapeptide hormone produced in the hypothalamus. It is researched for social bonding, anxiety reduction, trust and empathy modulation, and potential applications in autism spectrum and mood disorder studies.

**Protocol Overview:**
- **Compound:** Oxytocin 100IU (Oxytocin (Cyclic Nonapeptide))
- **Category:** Social Bonding / Anxiety Research Peptide
- **Vial Size:** 100IU (100 IU)
- **Reconstitution:** Intranasal spray bacteriostatic water
- **Route:** Subcutaneous injection
- **Frequency:** 3 days/week

**Dosing (sample):**
```
Monday | 1 spray | 10-20IU | Morning
Wednesday | 1 spray | 10-20IU | Morning
Friday | 1 spray | 10-20IU | Morning
```

**FAQs:**
- **Q: What is the standard Oxytocin 100IU dosing protocol?**
  - A: The standard Oxytocin 100IU research protocol uses 10-20IU administered morning on protocol days. Weekly Total: 3 doses (30-60IU) • Vial Duration: ~5-10 doses per 100IU device
- **Q: How do you reconstitute Oxytocin 100IU?**
  - A: Oxytocin is typically supplied as an intranasal spray. No reconstitution is required for pre-filled spray devices. If supplied as lyophilized powder, reconstitute per vial instructions with sterile water.
- **Q: What are the storage requirements for Oxytocin 100IU?**
  - A: Lyophilized (powder): Room temperature or refrigerated, protect from light. Reconstituted: Refrigerated 36-46F (2-8C), use within 28 days.

---

## Oxytocin Protocol — Dosing & Social Bonding
**URL:** https://www.pathtopeptides.com/oxytocin-protocol
**Last reviewed:** 2026-04-07

**Summary:** Oxytocin is a naturally occurring neuropeptide hormone produced in the hypothalamus and released by the posterior pituitary gland. FDA-approved for labor induction (Pitocin), oxytocin plays critical roles in social bonding, trust, empathy, maternal behavior, stress reduction, anxiolysis, and wound healing. Intranasal administration at 20-40 IU bypasses the blood-brain barrier to enhance prosocial behavior and reduce social anxiety. This protocol covers intranasal dosing, timing optimization, cycling to prevent receptor desensitization, and stacking with complementary neuropeptides.

**Protocol Overview:**
- **Compound:** Oxytocin (OT)
- **Category:** Social Bonding / Recovery Neuropeptide
- **Mechanism:** Oxytocin receptor agonist; modulates social cognition, reduces amygdala activation, promotes trust and empathy, anxiolytic and anti-stress effects
- **Molecular Weight:** 1,007.19 g/mol
- **Half-Life:** ~3-5 minutes (IV); ~2 hours (intranasal CNS effects)
- **Form:** Intranasal spray (4 IU per spray)
- **Route:** Intranasal
- **Frequency:** 1x daily or as needed (30-45 min before target context)
- **Cycle Length:** 5 days on / 2 days off, 4-8 weeks

**Dosing (sample):**
```
Low / Introductory | 20 IU | 1x daily | Intranasal | 1 week
Standard | 24 IU | 1x daily | Intranasal | 4-8 weeks
High | 40 IU | 1x daily | Intranasal | 4-8 weeks
As-Needed | 24 IU | Pre-social context | Intranasal | Intermittent
```

**FAQs:**
- **Q: What is Oxytocin and what does it do?**
  - A: Oxytocin is a neuropeptide hormone produced in the hypothalamus and released by the posterior pituitary. It plays essential roles in social bonding, trust, empathy, maternal behavior, stress reduction, and wound healing. It is FDA-approved for labor induction (Pitocin) and has extensive research for intranasal use in social cognition and anxiety.
- **Q: How is intranasal Oxytocin dosed?**
  - A: Intranasal Oxytocin is typically administered at 20-40 IU per session using a metered-dose nasal spray. Most research protocols use 24 IU (3 sprays per nostril at 4 IU per spray) administered 30-45 minutes before the desired social or therapeutic context.
- **Q: Is Oxytocin safe for regular use?**
  - A: Oxytocin has an extensive safety profile from clinical research. Intranasal administration at standard doses (20-40 IU) is generally well-tolerated with minimal side effects. However, chronic high-dose use may lead to receptor desensitization, so cycling is recommended in research protocols.

---

## P21 Protocol Guide — Dosing, Reconstitution & Administration
**URL:** https://www.pathtopeptides.com/p21-protocol
**Last reviewed:** 2026-04-10

**Summary:** P21 is a CNTF-derived tetrapeptide studied for its ability to promote neurogenesis and increase BDNF (Brain-Derived Neurotrophic Factor) levels. Research applications include Alzheimer disease modeling, cognitive decline, and neuroplasticity studies. It may enhance dentate gyrus neurogenesis.

**Protocol Overview:**
- **Compound:** P21 (CNTF-Derived Tetrapeptide (Alzheimer Research))
- **Category:** BDNF/Neurogenesis Research Compound
- **Vial Size:** 10mg (10,000mcg)
- **Reconstitution:** 2mL bacteriostatic water (5mg/mL)
- **Route:** Subcutaneous injection
- **Frequency:** 5 days/week

**Dosing (sample):**
```
Monday | 10 | 500mcg | Morning
Tuesday | 10 | 500mcg | Morning
Wednesday | 10 | 500mcg | Morning
Thursday | 10 | 500mcg | Morning
Friday | 10 | 500mcg | Morning
```

**FAQs:**
- **Q: What is the standard P21 dosing protocol?**
  - A: The standard P21 research protocol uses 500mcg administered morning on protocol days. Weekly Total: 50 units (2,500mcg) • Vial Duration: ~20 days
- **Q: How do you reconstitute P21?**
  - A: Using 2mL of bacteriostatic water results in a concentration of 5mg/mL (5000mcg/mL). Always use sterile techniques.
- **Q: What are the storage requirements for P21?**
  - A: Lyophilized (powder): Room temperature or refrigerated, protect from light. Reconstituted: Refrigerated 36-46F (2-8C), use within 28 days.

---

## Palmitoyl Tetrapeptide-7 Protocol Guide — Dosing, Reconstitution & Administration
**URL:** https://www.pathtopeptides.com/palmitoyl-tetrapeptide-7-protocol
**Last reviewed:** 2026-04-10

**Summary:** Palmitoyl Tetrapeptide-7 is a peptide fragment that modulates inflammatory processes in skin tissue. It reduces the secretion of interleukin-6 (IL-6) following UV exposure, reducing chronic low-grade inflammation (inflammaging) that contributes to skin aging. Often studied in combination with Palmitoyl Oligopeptide (Matrixyl 3000).

**Protocol Overview:**
- **Compound:** Palmitoyl Tetrapeptide-7 (Palmitoyl Tetrapeptide-7 (Skin Repair))
- **Category:** Anti-Inflammatory Skin Peptide
- **Vial Size:** 5mg (5,000mcg)
- **Reconstitution:** N/A (topical solution)
- **Route:** Topical (serum/cream)
- **Frequency:** 7 days/week

**Dosing (sample):**
```
Monday | Topical | Apply 2x/day | AM and PM
Tuesday | Topical | Apply 2x/day | AM and PM
Wednesday | Topical | Apply 2x/day | AM and PM
Thursday | Topical | Apply 2x/day | AM and PM
Friday | Topical | Apply 2x/day | AM and PM
Saturday | Topical | Apply 2x/day | AM and PM
Sunday | Topical | Apply 2x/day | AM and PM
```

**FAQs:**
- **Q: What is the standard Palmitoyl Tetrapeptide-7 dosing protocol?**
  - A: The standard Palmitoyl Tetrapeptide-7 research protocol uses Apply 2x/day administered am and pm on protocol days. Weekly Total: 14 applications/week • Vial Duration: Varies by application area
- **Q: How do you reconstitute Palmitoyl Tetrapeptide-7?**
  - A: Palmitoyl Tetrapeptide-7 is supplied for topical application. Apply directly to clean, dry skin. No reconstitution with bacteriostatic water is required for topical use.
- **Q: What are the storage requirements for Palmitoyl Tetrapeptide-7?**
  - A: Lyophilized (powder): Room temperature or refrigerated, protect from light. Reconstituted: Refrigerated 36-46F (2-8C), use within 28 days.

---

## Palmitoyl Tetrapeptide-7 Protocol Guide — Dosing & Administration
**URL:** https://www.pathtopeptides.com/palmitoyl-tetrapeptide-protocol
**Last reviewed:** 2026-04-08

**Summary:** Palmitoyl Tetrapeptide-7 (Pal-GQPR) is an anti-inflammatory cosmetic peptide that reduces IL-6 and other inflammatory cytokines in skin tissue. It is a key component of Matrixyl 3000. When used alone, it addresses inflammation-driven aging, redness, and skin sensitivity.

**Protocol Overview:**
- **Compound:** Palmitoyl Tetrapeptide-7 (Pal-GQPR / Rigin)
- **Category:** Anti-Inflammatory Cosmetic Peptide
- **Mechanism:** Suppresses interleukin-6 (IL-6) production and reduces inflammatory cytokine cascades in dermal tissue. Decreases chronic micro-inflammation (inflammaging) that accelerates collagen breakdown. Palmitoyl group enhances dermal penetration
- **Half-Life:** Local activity in skin layers
- **Form:** Topical serum or cream
- **Route:** Topical
- **Frequency:** 2x daily
- **Cycle Length:** Ongoing

**Dosing (sample):**
```
Standard Serum | 50-100 ppm | 2x daily | Topical | Ongoing
Enhanced (Matrixyl 3000) | Combined with Pal-Tripeptide-1 | 2x daily | Topical | Ongoing
Sensitive Skin | 25-50 ppm | 1-2x daily | Topical | Ongoing
```

**FAQs:**
- **Q: What is the difference between Palmitoyl Tetrapeptide-7 and Matrixyl 3000?**
  - A: Palmitoyl Tetrapeptide-7 is one half of Matrixyl 3000. The other half is Palmitoyl Tripeptide-1 (collagen stimulator). Together they provide anti-inflammatory and collagen-building effects.
- **Q: Can this help with rosacea?**
  - A: By suppressing IL-6, it may reduce redness and inflammation. It is not a treatment for rosacea but may complement prescription therapies.
- **Q: How does this differ from anti-inflammatory drugs?**
  - A: It works topically at the skin level, specifically targeting IL-6 in dermal tissue. It is gentler than topical steroids and suitable for long-term daily use.

---

## PE-22-28 Protocol Guide — Dosing, Reconstitution & Nootropic Research
**URL:** https://www.pathtopeptides.com/pe-22-28-protocol
**Last reviewed:** 2026-04-07

**Summary:** PE-22-28 (also written PE22-28) is a synthetic peptide analogue of BDNF (Brain-Derived Neurotrophic Factor) that acts as a TrkB receptor agonist. It is researched for depression, anxiety, and neuroplasticity — promoting neurogenesis and serotonergic neurotransmission via the TrkB signaling pathway. PE-22-28 is a CNS/nootropic compound and is not related to hair loss or cosmetic applications. This protocol covers intranasal and subcutaneous dosing, reconstitution from a 5mg vial, and stacking recommendations for depression and cognitive enhancement research.

**Protocol Overview:**
- **Compound:** PE-22-28 (PE22-28; BDNF TrkB receptor agonist analogue)
- **Category:** Nootropic / Antidepressant Research Peptide
- **Mechanism:** TrkB (BDNF receptor) agonist; promotes neuroplasticity, neurogenesis, and serotonergic neurotransmission. Researched for depression, anxiety, and cognitive enhancement.
- **Vial Size:** 5mg lyophilized powder (typical)
- **Route:** Intranasal OR subcutaneous injection
- **Frequency:** 1–2x daily
- **Cycle Length:** 4–8 weeks

**Dosing (sample):**
```
Intranasal Standard | 500 mcg–1 mg per nostril (1–2 mg total) | 1–2x daily | Intranasal | 4–8 weeks
SubQ Conservative Start | 250 mcg | 1x daily (AM) | Subcutaneous | 1–2 weeks, then reassess
SubQ Standard | 500 mcg | 1x daily (AM) | Subcutaneous | 4–8 weeks
```

**FAQs:**
- **Q: What is the standard PE-22-28 dosing protocol?**
  - A: PE-22-28 is extremely potent and requires ultra-low dosing. The standard research protocol uses 50mcg administered subcutaneously once daily in the morning, 5 days per week (Monday-Friday). Due to its extreme potency, accurate dosing with properly calibrated syringes is critical.
- **Q: How potent is PE-22-28 compared to other nootropics?**
  - A: PE-22-28 is approximately 10 million times more potent than BDNF at promoting synaptogenesis in research models. It works at picomolar concentrations through the HGF/c-Met receptor pathway, making it one of the most potent cognitive-enhancing compounds ever identified in preclinical research.
- **Q: How do you reconstitute a 10mg vial of PE-22-28?**
  - A: Add 2mL of bacteriostatic water to a 10mg vial for a concentration of 5mg/mL (5000mcg/mL). At 50mcg per dose, draw only 1 unit on an insulin syringe. Due to the extremely low volume, some researchers use a more dilute reconstitution for accuracy.

---

## PEG-MGF Protocol Guide — Dosing, Reconstitution & Administration
**URL:** https://www.pathtopeptides.com/peg-mgf-protocol
**Last reviewed:** 2026-04-10

**Summary:** PEG-MGF is a PEGylated form of Mechano Growth Factor, a splice variant of IGF-1. The PEG modification extends its half-life significantly. It is studied for satellite cell activation and muscle repair post-exercise. Administered subcutaneously 3 times per week after exercise.

**Protocol Overview:**
- **Compound:** PEG-MGF (PEG-MGF (PEGylated Mechano Growth Factor))
- **Category:** PEGylated Mechano Growth Factor
- **Vial Size:** 2mg (2,000mcg)
- **Reconstitution:** 2mL bacteriostatic water (1mg/mL)
- **Route:** Subcutaneous injection
- **Frequency:** 3 days/week

**Dosing (sample):**
```
Monday | 20 | 200mcg | Post-exercise
Wednesday | 20 | 200mcg | Post-exercise
Friday | 20 | 200mcg | Post-exercise
```

**FAQs:**
- **Q: What is the standard PEG-MGF dosing protocol?**
  - A: The standard PEG-MGF research protocol uses 200mcg administered post-exercise on protocol days. Weekly Total: 60 units (600mcg) • Vial Duration: ~10 doses (~3.3 weeks)
- **Q: How do you reconstitute PEG-MGF?**
  - A: Using 2mL of bacteriostatic water results in a concentration of 1mg/mL. Always use sterile techniques.
- **Q: What are the storage requirements for PEG-MGF?**
  - A: Lyophilized (powder): Room temperature or refrigerated, protect from light. Reconstituted: Refrigerated 36-46F (2-8C), use within 28 days.

---

## Pentadecapeptide (BPC Variant) Protocol
**URL:** https://www.pathtopeptides.com/pentadecapeptide-protocol
**Last reviewed:** 2026-04-07

**Summary:** Pentadecapeptide refers to the class of 15-amino acid Body Protection Compound peptides derived from human gastric juice, primarily BPC-157 and its variant formulations. The term encompasses different salt forms (acetate for injection, arginine salt for oral stability), modified sequences, and combination approaches. These pentadecapeptides exhibit remarkable tissue-protective properties including wound healing acceleration, anti-inflammatory effects, gastrointestinal protection, neuroprotection, and pro-angiogenic activity through VEGF upregulation, NO system modulation, and FAK-paxillin pathway activation. This protocol covers both injectable (acetate) and oral (arginine salt) administration routes, comparative dosing, form selection guidance, and stacking for comprehensive tissue repair research.

**Protocol Overview:**
- **Compound:** Pentadecapeptide (BPC-157 variants)
- **Category:** Tissue Repair / Gastric Protection
- **Mechanism:** Multi-pathway tissue repair: VEGF upregulation, NO system modulation, FAK-paxillin pathway, anti-inflammatory cytokine modulation, gut-brain axis support
- **Molecular Weight:** ~1,419 g/mol (BPC-157 free base)
- **Forms:** Acetate salt (SubQ) | Arginine salt (oral, acid-stable)
- **Route:** Subcutaneous and/or Oral
- **Frequency:** 1-2x daily
- **Cycle Length:** 4-8 weeks on, 2-4 weeks off

**Dosing (sample):**
```
SubQ Standard | 250 mcg | Acetate | 1-2x daily | 4-8 weeks
Oral Standard | 250-500 mcg | Arginine salt | 2x daily (empty stomach) | 4-8 weeks
Combined Protocol | 250 mcg SubQ + 250 mcg oral | Acetate + Arginine | 1x each daily | 4-8 weeks
High-Dose Repair | 500 mcg | Acetate | 2x daily near injury | 4-6 weeks
```

**FAQs:**
- **Q: What is a pentadecapeptide and how does it relate to BPC-157?**
  - A: Pentadecapeptide literally means '15-amino acid peptide.' In the context of peptide research, it typically refers to BPC-157 (Body Protection Compound-157), a 15-amino acid peptide derived from human gastric juice protein BPC. The term 'pentadecapeptide' is often used in research literature and by suppliers as an alternative name, particularly for BPC-157 variants with different salt forms (acetate vs arginine salt) or modified sequences.
- **Q: What is the difference between BPC-157 acetate and arginine salt?**
  - A: BPC-157 acetate is the most common form, suitable for subcutaneous injection. BPC-157 arginine salt (also called stable gastric pentadecapeptide or BPC-157 stable) is formulated for acid stability, making it suitable for oral administration where it must survive stomach acid. The arginine salt form maintains biological activity through the GI tract, making it the preferred form for oral/gut-targeted protocols.
- **Q: What is the standard pentadecapeptide dosing protocol?**
  - A: The standard protocol uses 250-500mcg daily, administered either subcutaneously (acetate form) or orally (arginine salt form). SubQ administration is preferred for systemic tissue repair and localized injury treatment. Oral administration is preferred for GI conditions, gut healing, and gut-brain axis modulation. Both forms can be used simultaneously for maximal coverage.

---

## Pentosan Polysulfate Protocol Guide — Dosing, Reconstitution & Administration
**URL:** https://www.pathtopeptides.com/pentosan-polysulfate-protocol
**Last reviewed:** 2026-04-10

**Summary:** Pentosan Polysulfate Sodium (PPS) is a semi-synthetic glycosaminoglycan derived from beechwood hemicellulose. It is FDA-approved for interstitial cystitis (Elmiron) and studied for osteoarthritis, joint repair, and cartilage protection. It exhibits anti-inflammatory, fibrinolytic, and glycosaminoglycan-replenishing properties.

**Protocol Overview:**
- **Compound:** Pentosan Polysulfate (Semi-Synthetic Heparinoid (FDA-Approved for IC))
- **Category:** Glycosaminoglycan Compound
- **Vial Size:** 250mg (250,000mcg)
- **Reconstitution:** N/A - Injectable Solution bacteriostatic water
- **Route:** Subcutaneous injection
- **Frequency:** 2 days/week

**Dosing (sample):**
```
Monday | N/A | 100mg | Morning
Thursday | N/A | 100mg | Morning
```

**FAQs:**
- **Q: What is the standard Pentosan Polysulfate dosing protocol?**
  - A: The standard Pentosan Polysulfate research protocol uses 100mg administered morning on protocol days. Weekly Total: 200mg per week • Vial Duration: ~2.5 weeks per vial
- **Q: How do you reconstitute Pentosan Polysulfate?**
  - A: Pentosan Polysulfate is supplied as a ready-to-use injectable solution. No reconstitution with bacteriostatic water is required. Administer via intramuscular injection using sterile technique.
- **Q: What are the storage requirements for Pentosan Polysulfate?**
  - A: Lyophilized (powder): Room temperature or refrigerated, protect from light. Reconstituted: Refrigerated 36-46F (2-8C), use within 28 days.

---

## Pinealon Protocol Guide — Dosing, Reconstitution & Administration
**URL:** https://www.pathtopeptides.com/pinealon-protocol
**Last reviewed:** 2026-04-10

**Summary:** Pinealon is a synthetic tripeptide bioregulator studied for neuroprotective properties and pineal gland regulation. Research suggests it may support cognitive function, normalize circadian rhythms, and promote neuronal survival under oxidative stress conditions.

**Protocol Overview:**
- **Compound:** Pinealon (Tripeptide Bioregulator (Glu-Asp-Arg))
- **Category:** Neuroprotective Bioregulator
- **Vial Size:** 10mg (10,000mcg)
- **Reconstitution:** 2mL bacteriostatic water (5mg/mL)
- **Route:** Subcutaneous injection
- **Frequency:** 5 days/week

**Dosing (sample):**
```
Monday | 20 | 1mg | Morning
Tuesday | 20 | 1mg | Morning
Wednesday | 20 | 1mg | Morning
Thursday | 20 | 1mg | Morning
Friday | 20 | 1mg | Morning
```

**FAQs:**
- **Q: What is the standard Pinealon dosing protocol?**
  - A: Pinealon is administered at 1-2mg subcutaneously once daily for 10-20 day cycles, followed by 3-6 months off. Oral bioregulator capsules use 10-20mg/day. A 10mg vial lasts approximately 10 days at 1mg/day.
- **Q: How do you reconstitute Pinealon?**
  - A: Add 2mL of bacteriostatic water to a 10mg vial for a concentration of 5mg/mL. Always use sterile techniques.
- **Q: What are the storage requirements for Pinealon?**
  - A: Lyophilized (powder): Room temperature or refrigerated, protect from light. Reconstituted: Refrigerated 36-46F (2-8C), use within 28 days.

---

## PT-141 Protocol Guide — Dosing, Reconstitution & Administration
**URL:** https://www.pathtopeptides.com/pt-141-protocol
**Last reviewed:** 2026-04-10

**Summary:** PT-141 (Bremelanotide) is a synthetic melanocortin receptor agonist studied for sexual function signaling pathways via MC3R and MC4R in the central nervous system.

**Protocol Overview:**
- **Compound:** PT-141 (Bremelanotide (Melanocortin Receptor Agonist))
- **Category:** Research Peptide
- **Vial Size:** 10mg (10,000mcg)
- **Reconstitution:** 2mL bacteriostatic water (5mg/mL)
- **Route:** Subcutaneous injection
- **Frequency:** As needed (max 8x/month)

**Dosing (sample):**
```
Starting dose | 1mg | 20 units (0.2mL) | 45–60 min before activity
Standard dose | 1.75mg | 35 units (0.35mL) | 45–60 min before activity
Max single dose | 1.75 mg | 40 units (0.4mL) | 45–60 min before activity
```

**FAQs:**
- **Q: What is the standard PT-141 dosing protocol?**
  - A: PT-141 (Bremelanotide) is used as-needed at 1-2mg per dose subcutaneously, administered 45-60 minutes before desired effect. Do not exceed 1 dose per 24 hours or 8 doses per month. A 10mg vial provides approximately 5-10 uses.
- **Q: How do you reconstitute PT-141?**
  - A: Add 2mL of bacteriostatic water to a 10mg vial for a concentration of 5mg/mL. Always use sterile techniques.
- **Q: What are the storage requirements for PT-141?**
  - A: Lyophilized (powder): Room temperature or refrigerated, protect from light. Reconstituted: Refrigerated 36-46F (2-8C), use within 28 days.

---

## PT-141 (Bremelanotide): Complete Research Guide | PtP Wiki
**URL:** https://www.pathtopeptides.com/pt-141
**Last reviewed:** 2026-04-08

**Summary:** PT-141 (bremelanotide) is a cyclic heptapeptide melanocortin receptor agonist that acts centrally in the brain to modulate sexual desire and arousal. It is the only peptide-based therapeutic FDA-approved for treatment of hypoactive sexual desire disorder (HSDD), marketed as Vyleesi since June 2019. PT-141 represents the first pharmaceutical to address sexual desire through direct activation of melanocortin-4 receptors (MC4R) in the hypothalamus, rather than through peripheral vascular mechanisms.

**FAQs:**
- **Q: Is PT-141 the same as Vyleesi?**
  - A: Yes, Vyleesi is the FDA-approved brand name for bremelanotide, which is the pharmaceutical name for PT-141. The research designation PT-141 and the generic name bremelanotide refer to the same cyclic heptapeptide compound. Vyleesi was approved in June 2019 specifically for hypoactive sexual desire disorder (HSDD) in premenopausal women and is administered as a 1.75 mg subcutaneous autoinjector.
- **Q: How does PT-141 differ from PDE5 inhibitors like sildenafil?**
  - A: PT-141 works through an entirely different mechanism than PDE5 inhibitors. PDE5 inhibitors (sildenafil, tadalafil) act peripherally on blood vessel smooth muscle to increase blood flow, requiring pre-existing sexual arousal. PT-141 acts centrally in the brain on melanocortin-4 receptors (MC4R) in the hypothalamus, directly stimulating neural pathways involved in sexual desire and arousal. This central mechanism means PT-141 can enhance both desire and arousal independently of vascular function.
- **Q: What are the most common side effects of PT-141?**
  - A: The most common side effect is nausea, which occurs in approximately 40% of subjects in clinical trials at the approved 1.75 mg dose. Other common side effects include flushing (20%), headache (11%), and injection site reactions (5%). Nausea is typically transient, peaking 1-2 hours post-injection and resolving within a few hours. A transient increase in blood pressure may also occur.

---

## RAD-140 (Testolone) Protocol Guide — Dosing & Administration
**URL:** https://www.pathtopeptides.com/rad-140-protocol
**Last reviewed:** 2026-04-07

**Summary:** RAD-140 (Testolone) is a non-steroidal selective androgen receptor modulator (SARM) developed by Radius Health for potential treatment of breast cancer and muscle wasting. It selectively binds androgen receptors in muscle and bone with an anabolic-to-androgenic ratio of approximately 90:1, meaning potent anabolic effects with reduced prostate and hair follicle androgenic activity. RAD-140 also demonstrates neuroprotective properties via AR-dependent pathways. This protocol covers 10-20mg daily oral dosing for 8-12 weeks, mandatory PCT, liver and hormonal monitoring, and harm reduction strategies.

**Protocol Overview:**
- **Compound:** RAD-140 (Testolone)
- **Category:** Non-Steroidal SARM
- **Mechanism:** Selective androgen receptor agonist in muscle/bone; tissue-selective activation; AR-mediated neuroprotection; partial agonist in prostate
- **MW:** 393.8 Da
- **Half-Life:** ~60 hours
- **Form:** Oral solution or capsule
- **Route:** Oral
- **Frequency:** Once daily
- **Cycle:** 8-12 weeks + 4-week PCT

**Dosing (sample):**
```
Introduction | 1-2 | 10 mg/day | Assess tolerance; take with food AM
Standard | 3-8 | 15-20 mg/day | Once daily, same time each day
Extended (advanced) | 9-12 | 10-20 mg/day | Only if bloods remain acceptable
PCT | Post-cycle 1-4 | Enclomiphene 12.5-25mg or Nolvadex 20/10mg | Begin 3-5 days after last dose
```

---

## RAD-140 (Testolone) Protocol Guide — Dosing & Administration
**URL:** https://www.pathtopeptides.com/rad-140-testolone-protocol
**Last reviewed:** 2026-04-14

**Summary:** RAD-140 (Testolone) is a potent non-steroidal SARM studied for lean mass gain, strength enhancement, and neuroprotective properties. Research indicates it has a high anabolic-to-androgenic ratio, with studies exploring its potential for muscle wasting conditions and neurodegenerative disease models. Capsule Content 10mg per capsule (10,000mcg per capsule) Route of Administration Oral (capsule)

**Protocol Overview:**
- **Compound:** RAD-140 (Testolone) (Oral Research Compound - Lean Mass / Strength / Neuroprotection)
- **Category:** Selective Androgen Receptor Modulator
- **Form:** Capsules or Liquid
- **Route:** Oral (capsule or liquid)
- **Frequency:** 7 days/week

**Dosing (sample):**
```
Monday | 1 cap | 10mg | Morning
Tuesday | 1 cap | 10mg | Morning
Wednesday | 1 cap | 10mg | Morning
Thursday | 1 cap | 10mg | Morning
Friday | 1 cap | 10mg | Morning
Saturday | 1 cap | 10mg | Morning
Sunday | 1 cap | 10mg | Morning
```

**FAQs:**
- **Q: What is the standard RAD-140 (Testolone) dosing protocol?**
  - A: The standard RAD-140 (Testolone) research protocol uses 10-20mg taken orally once daily in the morning. Cycle Duration: 8-12 weeks on, 4 weeks off. PCT recommended after cycle.
- **Q: How do you take RAD-140 (Testolone)?**
  - A: RAD-140 is taken orally as a capsule or liquid. No reconstitution or injection is needed. Take with or without food.
- **Q: What are the storage requirements for RAD-140 (Testolone)?**
  - A: Capsules (sealed): Room temperature, cool dry place, protect from light. Capsules (opened): Keep tightly sealed, away from moisture and heat.

---

## Retatrutide Protocol Guide — Dosing, Reconstitution & Administration
**URL:** https://www.pathtopeptides.com/retatrutide-protocol
**Last reviewed:** 2026-04-10

**Summary:** Retatrutide is a triple-action receptor agonist targeting GLP-1, GIP, and glucagon receptors simultaneously, representing next-generation incretin-based research.

**Protocol Overview:**
- **Compound:** Retatrutide (GLP-1 / GIP / Glucagon Receptor Agonist)
- **Category:** Triple Hormone Receptor Agonist
- **Vial Size:** 5mg (5,000mcg)
- **Reconstitution:** 2mL bacteriostatic water (2.5mg/mL)
- **Route:** Subcutaneous injection
- **Frequency:** Once weekly

**Dosing (sample):**
```
Starting | Weeks 1-4 | 0.5mg | Once weekly
Titration 1 | Weeks 5-8 | 1mg | Once weekly
Titration 2 | Weeks 9-12 | 2mg | Once weekly
Titration 3 | Weeks 13-16 | 4mg | Once weekly
Maintenance | Weeks 17-24 | 8mg (up to 12mg) | Once weekly
```

**FAQs:**
- **Q: What is the standard Retatrutide dosing protocol?**
  - A: Retatrutide uses a titration schedule: start at 0.5mg once weekly (weeks 1-4), then 1mg (weeks 5-8), 2mg (weeks 9-12), 4mg (weeks 13-16), and 8-12mg (weeks 17-24). Administer subcutaneously on the same day each week.
- **Q: How do you reconstitute Retatrutide?**
  - A: Using 2mL of bacteriostatic water results in a concentration of 2.5mg/mL. Start low and titrate slowly. Always use sterile techniques.
- **Q: What are the storage requirements for Retatrutide?**
  - A: Lyophilized (powder): Room temperature or refrigerated, protect from light. Reconstituted: Refrigerated 36-46F (2-8C), use within 28 days.

---

## Retatrutide: Complete Research Guide | PtP Wiki
**URL:** https://www.pathtopeptides.com/retatrutide
**Last reviewed:** 2026-04-08

**Summary:** Retatrutide (LY3437943) is a novel triple agonist peptide developed by Eli Lilly that simultaneously activates three key metabolic receptors: glucose-dependent insulinotropic polypeptide (GIP) receptor, glucagon-like peptide-1 (GLP-1) receptor, and glucagon receptor. This triple agonist approach represents the next evolution beyond dual agonists like tirzepatide, adding glucagon receptor activation to enhance energy expenditure and hepatic fat reduction alongside the appetite-suppressing effects of GIP and GLP-1 signaling.

**FAQs:**
- **Q: How does Retatrutide compare to tirzepatide and semaglutide?**
  - A: Retatrutide is a triple agonist (GIP + GLP-1 + glucagon), tirzepatide is a dual agonist (GIP + GLP-1), and semaglutide is a single agonist (GLP-1 only). In Phase II trials, retatrutide produced mean weight loss of up to 24.2% at 48 weeks at the highest dose, compared to approximately 20-22% for tirzepatide and 15-17% for semaglutide at comparable timepoints. The addition of glucagon receptor agonism is hypothesized to increase energy expenditure and hepatic fat reduction beyond what dual or single agonists achieve.
- **Q: Is Retatrutide FDA-approved?**
  - A: No, retatrutide is not yet FDA-approved as of 2026. It is currently in Phase III clinical development by Eli Lilly. Phase II trial results were published in 2023 showing promising efficacy for obesity and type 2 diabetes. Phase III trials are ongoing with regulatory submissions expected upon completion.
- **Q: What is the glucagon component supposed to do?**
  - A: Glucagon receptor agonism in retatrutide is designed to increase energy expenditure through hepatic thermogenesis, enhance lipid oxidation (fat burning), reduce hepatic steatosis (fatty liver), and promote amino acid catabolism. This metabolic activation complements the appetite suppression provided by GLP-1 and GIP agonism, attacking obesity from both the energy intake and energy expenditure sides of the equation.

---

## S-23 Protocol Guide — Dosing, Cycle & Administration
**URL:** https://www.pathtopeptides.com/s-23-protocol
**Last reviewed:** 2026-04-10

**Summary:** S-23 is considered the strongest SARM available, with the highest binding affinity to the androgen receptor. Research indicates significant effects on lean mass, muscle hardening, and fat reduction. Due to its high potency, it is also the most suppressive SARM to natural testosterone production. It is studied as a potential hormonal male contraceptive in preclinical models. Capsule Content 10mg per capsule (10,000mcg per capsule) Route of Administration Oral (capsule)

**Protocol Overview:**
- **Compound:** S-23 (Oral Research Compound - High-Potency Lean Mass / Hardening)
- **Category:** Selective Androgen Receptor Modulator
- **Vial Size:** 10mg capsules
- **Reconstitution:** N/A — oral compound
- **Route:** Oral (capsule or liquid)
- **Frequency:** 7 days/week

**Dosing (sample):**
```
Monday | 1 cap | 10mg | Morning
Tuesday | 1 cap | 10mg | Morning
Wednesday | 1 cap | 10mg | Morning
Thursday | 1 cap | 10mg | Morning
Friday | 1 cap | 10mg | Morning
Saturday | 1 cap | 10mg | Morning
Sunday | 1 cap | 10mg | Morning
```

**FAQs:**
- **Q: What is the standard S-23 dosing protocol?**
  - A: The standard S-23 research protocol uses 10mg administered morning on protocol days. Weekly Total: 7 capsules (70mg) • Cycle Duration: 8 weeks on, 4 weeks off
- **Q: How do you take S-23?**
  - A: S-23 is an oral compound supplied as capsules. No reconstitution is required. Swallow the capsule with water at the same time each day.
- **Q: What are the storage requirements for S-23?**
  - A: Store capsules at room temperature in a cool, dry place. Keep tightly sealed, away from moisture and direct light.

---

## S-4 (Andarine) Protocol Guide — Dosing, Cycle & Administration
**URL:** https://www.pathtopeptides.com/s-4-andarine-protocol
**Last reviewed:** 2026-04-10

**Summary:** S-4 (Andarine) is one of the earlier SARMs developed, studied for fat loss and lean mass retention. Research shows a favorable effect on body composition with moderate anabolic activity. A notable research finding is dose-dependent visual side effects (yellow tint to vision, difficulty with night vision) believed to be related to binding to retinal receptors. These effects are temporary and resolve upon discontinuation. Capsule Content 25mg per capsule (25,000mcg per capsule) Route of Administration Oral (capsule)

**Protocol Overview:**
- **Compound:** S-4 (Andarine) (Oral Research Compound - Fat Loss / Lean Mass)
- **Category:** Selective Androgen Receptor Modulator
- **Vial Size:** 25mg capsules
- **Reconstitution:** N/A — oral compound
- **Route:** Oral (capsule or liquid)
- **Frequency:** 7 days/week

**Dosing (sample):**
```
Monday | 1 cap | 25mg | Morning
Tuesday | 1 cap | 25mg | Morning
Wednesday | 1 cap | 25mg | Morning
Thursday | 1 cap | 25mg | Morning
Friday | 1 cap | 25mg | Morning
Saturday | 1 cap | 25mg | Morning
Sunday | 1 cap | 25mg | Morning
```

**FAQs:**
- **Q: What is the standard S-4 (Andarine) dosing protocol?**
  - A: The standard S-4 (Andarine) research protocol uses 25mg administered morning on protocol days. Weekly Total: 7 capsules (175mg) • Cycle Duration: 8 weeks on, 4 weeks off
- **Q: How do you take S-4 (Andarine)?**
  - A: S-4 (Andarine) is an oral compound supplied as capsules. No reconstitution is required. Swallow the capsule with water at the same time each day.
- **Q: What are the storage requirements for S-4 (Andarine)?**
  - A: Store capsules at room temperature in a cool, dry place. Keep tightly sealed, away from moisture and direct light.

---

## Selank Protocol Guide — Dosing, Reconstitution & Administration
**URL:** https://www.pathtopeptides.com/selank-protocol
**Last reviewed:** 2026-04-10

**Summary:** Selank is a synthetic analog of the immunomodulatory peptide tuftsin, studied for nootropic and anxiolytic properties.

**Protocol Overview:**
- **Compound:** Selank (Synthetic Tuftsin Analog)
- **Category:** Nootropic Research Peptide
- **Vial Size:** 5mg (5,000mcg)
- **Reconstitution:** 2mL bacteriostatic water (2.5mg/mL)
- **Route:** Subcutaneous injection
- **Frequency:** 5 days/week

**Dosing (sample):**
```
Standard | 250mcg | 10 units | 2x daily (AM & PM) | 500mcg
Moderate | 250mcg | 10 units | 1x daily (AM) | 250mcg
Higher | 500mcg | 20 units | 1x daily (AM) | 500mcg
```

**FAQs:**
- **Q: What is the standard Selank dosing protocol?**
  - A: The standard Selank protocol is 250-500mcg per dose, administered 1-2 times daily via subcutaneous injection or intranasal spray. A 5mg vial lasts approximately 10-20 days depending on dosing frequency.
- **Q: How do you reconstitute Selank?**
  - A: Add 2mL of bacteriostatic water to a 5mg vial for a concentration of 2.5mg/mL (2,500mcg/mL). Always use sterile techniques.
- **Q: What are the storage requirements for Selank?**
  - A: Lyophilized (powder): Room temperature or refrigerated, protect from light. Reconstituted: Refrigerated 36-46F (2-8C), use within 28 days.

---

## Selank: Complete Research Guide | PtP Wiki
**URL:** https://www.pathtopeptides.com/selank
**Last reviewed:** 2026-04-08

**Summary:** Selank is a synthetic heptapeptide (Thr-Lys-Pro-Arg-Pro-Gly-Pro) derived from the endogenous immunopeptide tuftsin with a stabilizing Pro-Gly-Pro C-terminal extension. Developed at the Institute of Molecular Genetics of the Russian Academy of Sciences alongside Semax, Selank is approved in Russia as a prescription anxiolytic and nootropic agent. It produces anti-anxiety effects comparable to benzodiazepines without sedation, cognitive impairment, or addiction potential.

**FAQs:**
- **Q: How does Selank compare to benzodiazepines for anxiety?**
  - A: Selank modulates GABA-A receptor sensitivity and serotonergic neurotransmission to produce anxiolytic effects comparable to benzodiazepines in clinical studies, but without sedation, cognitive impairment, muscle relaxation, or addiction/dependence. Unlike benzodiazepines, Selank does not produce tolerance, physical dependence, or withdrawal symptoms upon discontinuation. It also has nootropic (cognitive-enhancing) properties, whereas benzodiazepines typically impair cognition.
- **Q: What is tuftsin and why is Selank based on it?**
  - A: Tuftsin is a naturally occurring tetrapeptide (Thr-Lys-Pro-Arg) derived from the Fc region of immunoglobulin G (IgG). It functions as an endogenous immunostimulant, activating phagocytosis and natural killer cell activity. Selank was designed by adding a Pro-Gly-Pro extension to tuftsin, which stabilized the molecule against enzymatic degradation and unexpectedly produced potent anxiolytic and nootropic effects beyond the immune modulation of the parent peptide.
- **Q: Is Selank addictive?**
  - A: No. Selank has shown no addictive potential in any clinical or preclinical study. Unlike benzodiazepines and other GABAergic anxiolytics, Selank does not produce euphoria, tolerance, physical dependence, or withdrawal symptoms. It can be discontinued abruptly without rebound anxiety. This non-addictive profile is one of its primary advantages over conventional anxiolytics.

---

## Semaglutide + AOD-9604 Stack Protocol Guide — Dosing, Synergy & Research Protocol
**URL:** https://www.pathtopeptides.com/semaglutide-aod-9604-stack-protocol
**Last reviewed:** 2026-04-08

**Summary:** The Semaglutide + AOD-9604 stack combines the most powerful GLP-1 receptor agonist with a targeted fat-loss peptide for enhanced body composition results. Semaglutide suppresses appetite via central GLP-1 signaling, slows gastric emptying, and improves insulin sensitivity, while AOD-9604 (a modified fragment of human growth hormone amino acids 177-191) directly stimulates lipolysis without growth-promoting or diabetogenic effects. Together, these compounds address fat loss through complementary mechanisms: reduced caloric intake via appetite suppression and direct fat mobilization from adipose tissue.

**Protocol Overview:**
- **Compounds:** Semaglutide + AOD-9604
- **Category:** Weight Loss / Fat Loss Stack
- **Mechanism:** Semaglutide: GLP-1 receptor agonism, appetite suppression, gastric slowing. AOD-9604: lipolysis stimulation via beta-3 adrenergic pathway, lipogenesis inhibition
- **Half-Life:** Semaglutide: ~7 days | AOD-9604: ~4-6 hrs
- **Route:** Semaglutide: SubQ (weekly) | AOD-9604: SubQ (daily)
- **Frequency:** Semaglutide: 1x/week | AOD-9604: 1x daily (AM fasted)
- **Cycle Length:** 12-16 weeks

**Dosing (sample):**
```
Standard | Sema 0.25mg/wk (wk1-4), 0.5mg (wk5-8), 1mg (wk9+) | AOD 300mcg/day | AM fasted | 12-16 weeks
Aggressive | Sema titrate to 2.4mg/wk | AOD 500mcg/day | AM fasted | 16 weeks
Maintenance | Sema 0.5mg/wk | AOD 300mcg EOD | AM fasted | 8 weeks
```

**FAQs:**
- **Q: What is the recommended starting dose for the Semaglutide + AOD-9604 stack?**
  - A: Start semaglutide at 0.25mg weekly for the first 4 weeks to minimize GI side effects, then titrate to 0.5mg and eventually 1-2.4mg. AOD-9604 can be started at 300mcg daily from day one, injected subcutaneously in the morning on an empty stomach.
- **Q: Can Semaglutide and AOD-9604 be injected at the same time?**
  - A: They should be administered as separate injections but can be given on the same day. AOD-9604 is best taken daily in the fasted AM window, while semaglutide is injected once weekly. Do not mix them in the same syringe.
- **Q: How much weight can you lose on the Semaglutide + AOD-9604 stack?**
  - A: With proper caloric deficit and exercise, subjects typically report 15-25 lbs over a 16-week protocol. Semaglutide alone showed 15-20% body weight reduction in trials. AOD-9604 may enhance fat mobilization from stubborn adipose depots.

---

## Semaglutide Protocol Guide — Dosing, Reconstitution & Administration
**URL:** https://www.pathtopeptides.com/semaglutide-protocol
**Last reviewed:** 2026-04-10

**Summary:** Semaglutide is a GLP-1 receptor agonist studied for metabolic research. It mimics incretin hormone GLP-1 released after eating, influencing glucose regulation and appetite signaling.

**Protocol Overview:**
- **Compound:** Semaglutide (Research Peptide for Metabolic Studies)
- **Category:** GLP-1 Receptor Agonist
- **Vial Size:** 5mg (5,000mcg)
- **Reconstitution:** 2mL bacteriostatic water (2.5mg/mL)
- **Route:** Subcutaneous injection
- **Frequency:** Once weekly

**Dosing (sample):**
```
Weeks 1–4 | 0.25mg (250mcg) | 10 units (0.1mL) | Once weekly
Weeks 5–8 | 0.5mg (500mcg) | 20 units (0.2mL) | Once weekly
Weeks 9–12 | 1mg (1,000mcg) | 40 units (0.4mL) | Once weekly
Weeks 13–16 | 1.7mg (1,700mcg) | 68 units (0.68mL) | Once weekly
Weeks 17+ | 2.4mg (2,400mcg) max | 96 units (0.96mL) | Once weekly
```

**FAQs:**
- **Q: What is the standard Semaglutide dosing protocol?**
  - A: Semaglutide follows a dose-escalation protocol: start at 0.25mg once weekly for 4 weeks, then increase every 4 weeks through 0.5mg, 1mg, 1.7mg, up to a maximum of 2.4mg weekly. A 5mg vial lasts approximately 5 weeks at the starting dose.
- **Q: How do you reconstitute Semaglutide?**
  - A: Add 2mL of bacteriostatic water to a 5mg vial for a concentration of 2.5mg/mL. Start at the lowest dose and titrate up every 4 weeks.
- **Q: What are the storage requirements for Semaglutide?**
  - A: Lyophilized (powder): Room temperature or refrigerated, protect from light. Reconstituted: Refrigerated 36-46F (2-8C), use within 28 days.

---

## Semaglutide: Complete Research Guide | PtP Wiki
**URL:** https://www.pathtopeptides.com/semaglutide
**Last reviewed:** 2026-04-07

**Summary:** Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist that has become one of the most widely studied and prescribed peptide-based medications in clinical medicine. Originally developed for type 2 diabetes management, semaglutide gained global attention for its substantial efficacy in chronic weight management, with the STEP clinical trial program demonstrating average body weight reductions of 15-17% at the 2.4 mg weekly dose.

**FAQs:**
- **Q: How does semaglutide cause weight loss?**
  - A: Semaglutide causes weight loss through multiple mechanisms: it activates GLP-1 receptors in the hypothalamus to reduce appetite and increase satiety signals; it slows gastric emptying, leading to prolonged feelings of fullness; and it may reduce food reward signaling in the brain. Clinical trials (STEP program) have demonstrated 15-17% average body weight loss at the 2.4 mg weekly dose over 68 weeks.
- **Q: What is the difference between Ozempic and Wegovy?**
  - A: Ozempic and Wegovy both contain semaglutide as the active ingredient. Ozempic is approved for type 2 diabetes management at doses up to 2.0 mg weekly, while Wegovy is approved specifically for chronic weight management at a higher dose of 2.4 mg weekly. The formulations are identical in terms of the molecule, but differ in approved indication, maximum dose, and dose escalation schedule.
- **Q: What are the most common side effects of semaglutide?**
  - A: The most common side effects are gastrointestinal: nausea (affecting 20-44% of users), vomiting, diarrhea, constipation, and abdominal pain. These effects are typically dose-dependent and most pronounced during dose escalation. They tend to diminish over time as the body adjusts. Gradual dose titration is used to minimize GI side effects.

---

## Semax Protocol Guide — Dosing, Reconstitution & Administration
**URL:** https://www.pathtopeptides.com/semax-protocol
**Last reviewed:** 2026-04-10

**Summary:** Semax is a synthetic peptide derived from ACTH fragment 4-10, studied for cognitive enhancement and neuroprotection.

**Protocol Overview:**
- **Compound:** Semax (Synthetic ACTH(4-10) Analog)
- **Category:** Nootropic Research Peptide
- **Vial Size:** 5mg (5,000mcg)
- **Reconstitution:** 2mL bacteriostatic water (2.5mg/mL)
- **Route:** Subcutaneous injection
- **Frequency:** 5 days/week

**Dosing (sample):**
```
Monday | 12 | 300mcg | Morning
Tuesday | 12 | 300mcg | Morning
Wednesday | 12 | 300mcg | Morning
Thursday | 12 | 300mcg | Morning
Friday | 12 | 300mcg | Morning
```

**FAQs:**
- **Q: What is the standard Semax dosing protocol?**
  - A: The standard Semax research protocol uses 300mcg (12 units) administered morning on protocol days, 5 days/week. Standard dosing range is 200-600mcg. Weekly Total: 60 units (1,500mcg) • Vial Duration: ~23 days (~3.3 weeks)
- **Q: How do you reconstitute Semax?**
  - A: Using 2mL results in a concentration of 2.5mg/mL. Always use sterile techniques.
- **Q: What are the storage requirements for Semax?**
  - A: Lyophilized (powder): Room temperature or refrigerated, protect from light. Reconstituted: Refrigerated 36-46F (2-8C), use within 28 days.

---

## Semax + Selank Stack Protocol Guide — Dosing, Synergy & Research Protocol
**URL:** https://www.pathtopeptides.com/semax-selank-stack-protocol
**Last reviewed:** 2026-04-08

**Summary:** The Semax + Selank stack is the premier cognitive peptide combination, pairing a BDNF-boosting nootropic with an anxiolytic immune-modulating peptide. Semax is a synthetic ACTH(4-10) analog that upregulates BDNF, enhances NGF, and improves dopaminergic and serotonergic transmission for focus, memory, and cognitive performance. Selank is a tuftsin analog that provides anxiolytic effects comparable to benzodiazepines without sedation or dependence, while modulating GABA and enkephalin systems. Together, Semax sharpens cognition while Selank removes anxiety, creating a calm yet focused cognitive state.

**Protocol Overview:**
- **Compounds:** Semax + Selank
- **Category:** Cognitive Enhancement / Anxiolytic
- **Mechanism:** Semax: BDNF/NGF upregulation, dopamine/serotonin modulation. Selank: GABA modulation, enkephalin stabilization, anxiolytic
- **Half-Life:** Both: ~30 min (effects last 4-8 hrs)
- **Route:** Both intranasal (preferred) or subcutaneous
- **Frequency:** Both: 1-3x daily
- **Cycle Length:** 4-12 weeks

**Dosing (sample):**
```
Standard | Semax 0.1% 2 drops/nostril 2x/day | Selank 0.15% 2 drops/nostril 2x/day | AM + midday | 4-8 weeks
Enhanced | Semax N-Acetyl 0.1% 2 drops 3x/day | Selank N-Acetyl 0.15% 2 drops 3x/day | AM/midday/PM | 8-12 weeks
SubQ | Semax 200mcg SubQ AM | Selank 250mcg SubQ AM | AM together | 6-8 weeks
```

**FAQs:**
- **Q: How do Semax and Selank work together for cognition?**
  - A: Semax enhances performance by upregulating BDNF/NGF and improving dopaminergic transmission. Selank removes anxiety by modulating GABA and enkephalin systems. Together they create a focused yet relaxed state ideal for complex work, learning, and creative thinking.
- **Q: Is the Semax + Selank stack habit-forming?**
  - A: No. Neither causes dependence or withdrawal. Selank provides anxiolytic effects through enkephalin stabilization rather than direct GABA agonism, avoiding tolerance and dependence issues of benzodiazepines.
- **Q: Should you use intranasal or injectable Semax and Selank?**
  - A: Intranasal is the standard and preferred route, providing rapid brain penetration via the olfactory pathway. SubQ is an alternative with higher systemic bioavailability but slower brain uptake. Most clinical research uses intranasal.

---

## Semax: Complete Research Guide | PtP Wiki
**URL:** https://www.pathtopeptides.com/semax
**Last reviewed:** 2026-04-08

**Summary:** Semax is a synthetic heptapeptide consisting of the ACTH(4-10) fragment (Met-Glu-His-Phe-Pro-Gly-Pro) with a stabilizing Pro-Gly-Pro C-terminal tripeptide extension. It was developed at the Institute of Molecular Genetics of the Russian Academy of Sciences as a nootropic and neuroprotective agent. Semax is approved for clinical use in Russia for cognitive disorders, stroke recovery, and optic nerve diseases.

**FAQs:**
- **Q: Is Semax approved for medical use anywhere?**
  - A: Yes, Semax is approved in Russia and several other CIS countries as a prescription nootropic and neuroprotective agent. It is available as a 0.1% and 1% nasal spray solution. Indications include cognitive disorders, stroke recovery, optic nerve disease, and ADHD. It is not approved by the FDA or EMA.
- **Q: Does Semax have hormonal side effects like ACTH?**
  - A: No. Despite being derived from the ACTH(4-10) sequence, Semax does not stimulate adrenal cortisol production. The steroidogenic activity of ACTH resides in the 1-3 amino acid segment, which is absent in Semax. The 4-10 sequence retains the neurotrophic and cognitive effects of ACTH without any hormonal (adrenocortical) activity.
- **Q: How is Semax administered?**
  - A: Semax is primarily administered intranasally as a nasal spray solution. This route provides direct access to the CNS via the olfactory and trigeminal nerve pathways, bypassing the blood-brain barrier. In Russia, it is available as 0.1% (for cognitive enhancement) and 1% (for acute neurological conditions) nasal solutions. Subcutaneous injection is also used in research settings.

---

## Sermorelin Protocol Guide — Dosing, Reconstitution & Administration
**URL:** https://www.pathtopeptides.com/sermorelin-protocol
**Last reviewed:** 2026-04-10

**Summary:** Sermorelin is a synthetic analog of the first 29 amino acids of naturally occurring GHRH. It stimulates the pituitary gland to produce and release growth hormone in a natural pulsatile pattern.

**Protocol Overview:**
- **Compound:** Sermorelin (Growth Hormone-Releasing Hormone (1-29))
- **Category:** GHRH Analog
- **Vial Size:** 10mg (10,000mcg)
- **Reconstitution:** 2mL bacteriostatic water (5mg/mL)
- **Route:** Subcutaneous injection
- **Frequency:** 5 days/week

**Dosing (sample):**
```
Monday | 6 | 300mcg | Before bed
Tuesday | 6 | 300mcg | Before bed
Wednesday | 6 | 300mcg | Before bed
Thursday | 6 | 300mcg | Before bed
Friday | 6 | 300mcg | Before bed
```

**FAQs:**
- **Q: What is the standard Sermorelin dosing protocol?**
  - A: The standard Sermorelin protocol is 200-300mcg administered subcutaneously before bed, 5 days per week. A 10mg vial lasts approximately 47 days at 300mcg/day.
- **Q: How do you reconstitute Sermorelin?**
  - A: Add 2mL of bacteriostatic water to a 10mg vial for a concentration of 5mg/mL. Always use sterile techniques.
- **Q: What are the storage requirements for Sermorelin?**
  - A: Lyophilized (powder): Room temperature or refrigerated, protect from light. Reconstituted: Refrigerated 36-46F (2-8C), use within 28 days.

---

## Sermorelin: Complete Research Guide | PtP Wiki
**URL:** https://www.pathtopeptides.com/sermorelin
**Last reviewed:** 2026-04-08

**Summary:** Sermorelin acetate is a synthetic 29-amino-acid peptide analog of human growth hormone releasing hormone (GHRH). It represents the shortest fully functional fragment of the 44-amino-acid native GHRH molecule, retaining full biological activity at the GHRH receptor. Sermorelin was the first GHRH analog to receive FDA approval, initially for diagnostic testing of pituitary GH reserve and subsequently for treatment of idiopathic growth hormone deficiency in children.

**FAQs:**
- **Q: Was Sermorelin ever FDA-approved?**
  - A: Yes, Sermorelin acetate was FDA-approved in 1997 under the brand name Geref for diagnostic evaluation of pituitary GH secretory capacity and for treatment of idiopathic growth hormone deficiency in children. The branded product was voluntarily discontinued in 2008 for commercial reasons, not safety concerns. Sermorelin remains available through compounding pharmacies.
- **Q: How does Sermorelin differ from exogenous GH?**
  - A: Sermorelin stimulates the pituitary to produce and release its own GH in a pulsatile, physiological pattern, while exogenous GH (somatropin) delivers a flat bolus of hormone that bypasses normal regulatory feedback. Sermorelin preserves the hypothalamic-pituitary feedback loop, meaning somatostatin can still modulate GH output. This makes Sermorelin less likely to cause supraphysiological GH levels or suppress endogenous production.
- **Q: Can Sermorelin be combined with Ipamorelin?**
  - A: Yes, the combination of Sermorelin (GHRH analog) with Ipamorelin (GHS-R1a agonist) is a well-studied synergistic pairing. They activate complementary signaling pathways on pituitary somatotrophs: Sermorelin via cAMP and Ipamorelin via IP3/calcium. The result is a substantially larger GH pulse than either compound alone, with preserved pulsatility and feedback regulation.

---

## SLU-PP-332 Protocol Guide — Dosing, Reconstitution & Administration
**URL:** https://www.pathtopeptides.com/slu-pp-332-protocol
**Last reviewed:** 2026-04-10

**Summary:** SLU-PP-332 is a small molecule agonist of estrogen-related receptors (ERRs) studied as an exercise mimetic that may activate metabolic pathways triggered by physical exercise.

**Protocol Overview:**
- **Compound:** SLU-PP-332 (ERR Agonist (Exercise Mimetic))
- **Category:** Research Compound
- **Vial Size:** Tablet form (varies)
- **Reconstitution:** N/A (oral tablet)
- **Route:** Oral
- **Frequency:** 7 days/week

**Dosing (sample):**
```
Monday | 1 tab | Per tab | Morning
Tuesday | 1 tab | Per tab | Morning
Wednesday | 1 tab | Per tab | Morning
Thursday | 1 tab | Per tab | Morning
Friday | 1 tab | Per tab | Morning
Saturday | 1 tab | Per tab | Morning
Sunday | 1 tab | Per tab | Morning
```

**FAQs:**
- **Q: What is the standard SLU-PP-332 dosing protocol?**
  - A: The standard SLU-PP-332 research protocol uses Per tab administered morning on protocol days. Weekly Total: 7 tablets • Vial Duration: Depends on tablet count
- **Q: How do you reconstitute SLU-PP-332?**
  - A: SLU-PP-332 is supplied as oral tablets. No reconstitution required. Take with water.
- **Q: What are the storage requirements for SLU-PP-332?**
  - A: Lyophilized (powder): Room temperature or refrigerated, protect from light. Reconstituted: Room temperature, keep sealed, use within 90 days.

---

## SNAP-8 Protocol Guide — Dosing, Reconstitution & Administration
**URL:** https://www.pathtopeptides.com/snap-8-protocol
**Last reviewed:** 2026-04-10

**Summary:** SNAP-8 (Acetyl Octapeptide-3) is an anti-aging peptide that modulates SNARE complex formation, reducing the intensity of facial muscle contractions. It is studied for its ability to reduce the appearance of expression lines and wrinkles, particularly around the eyes and forehead.

**Protocol Overview:**
- **Compound:** SNAP-8 (Acetyl Octapeptide-3; Acetyl-Glu-Glu-Met-Gln-Arg-Arg-Ala-Asp-NH2)
- **Category:** Cosmetic Peptide / Anti-Wrinkle Topical
- **Mechanism:** Analogue of SNAP-25; inhibits neuromuscular junction SNARE complex, relaxing facial muscles to reduce expression lines
- **Formulation:** Topical serum or cream, typically 2–10 mg/mL
- **Route:** TOPICAL ONLY — never injected
- **Frequency:** 1–2x daily (AM and PM)
- **Cycle Length:** Ongoing cosmetic use

**Dosing (sample):**
```
Standard Cosmetic Use | 1–2% solution (10–20 mg/mL) | 2x daily (AM and PM) | Forehead, periorbital, expression lines
Sensitive Skin / First Use | 0.5–1% solution | 1x daily (PM) | Small test area first
Intensive Anti-Wrinkle | 2–4% solution | 2x daily | Deep expression lines, forehead
```

**FAQs:**
- **Q: What is the standard SNAP-8 dosing protocol?**
  - A: The standard SNAP-8 research protocol uses Apply 2x/day administered am and pm on protocol days. Weekly Total: 14 applications/week • Vial Duration: Varies by application area
- **Q: How do you reconstitute SNAP-8?**
  - A: SNAP-8 is supplied as a ready-to-use topical solution. No reconstitution with bacteriostatic water is required. Apply directly to clean, dry skin.
- **Q: What are the storage requirements for SNAP-8?**
  - A: Lyophilized (powder): Room temperature or refrigerated, protect from light. Reconstituted: Refrigerated 36-46F (2-8C), use within 28 days.

---

## SR-9009 (Stenabolic) Protocol Guide — Dosing & Administration
**URL:** https://www.pathtopeptides.com/sr-9009-protocol
**Last reviewed:** 2026-04-08

**Summary:** SR-9009 (Stenabolic) is a Rev-ErbA agonist developed at Scripps Research Institute. It is not a SARM but is often grouped with them. It modulates circadian rhythm genes, enhancing mitochondrial function, fat oxidation, and endurance. Despite impressive animal data, it has extremely poor oral bioavailability (~2%). This protocol covers various administration routes.

**Protocol Overview:**
- **Compound:** SR-9009 (Stenabolic)
- **Category:** Rev-ErbA Agonist (Metabolic Modulator)
- **Mechanism:** Activates Rev-ErbA alpha and beta nuclear receptors, modulating circadian rhythm gene expression. Increases mitochondrial count, enhances oxidative metabolism, reduces fat storage, and improves exercise endurance
- **Half-Life:** 4 hours
- **Form:** Oral liquid, sublingual, or injectable
- **Route:** Sublingual preferred (oral bioavailability ~2%)
- **Frequency:** 3-4x daily (split due to short half-life)
- **Cycle Length:** 8-12 weeks

**Dosing (sample):**
```
Oral (Low Bioavail.) | 20-30 mg | 3-4x daily (split) | Oral | 8-12 weeks
Sublingual | 10-20 mg | 3x daily (split) | Sublingual (hold 60s) | 8-12 weeks
Injectable | 10 mg | 2x daily | Subcutaneous | 8-12 weeks
```

**FAQs:**
- **Q: Why is SR-9009 oral bioavailability so low?**
  - A: SR-9009 undergoes extensive first-pass metabolism in the liver, resulting in only ~2% reaching systemic circulation orally. This is why sublingual administration (holding under the tongue for 60+ seconds) or subcutaneous injection are preferred routes for meaningful blood levels.
- **Q: Does SR-9009 suppress testosterone?**
  - A: No. SR-9009 is not a SARM and does not interact with androgen receptors. It modulates Rev-ErbA circadian rhythm receptors. No PCT is needed, and it can be safely stacked with SARMs without adding suppression.
- **Q: How does SR-9009 compare to Cardarine (GW-501516)?**
  - A: Both enhance endurance and fat loss but through different mechanisms. SR-9009 modulates circadian genes and mitochondrial function, while GW-501516 activates PPARdelta. GW-501516 has much better oral bioavailability. They can be stacked for synergistic effects.

---

## SR-9009 (Stenabolic) Protocol Guide — Dosing & Administration
**URL:** https://www.pathtopeptides.com/sr-9009-stenabolic-protocol
**Last reviewed:** 2026-04-14

**Summary:** SR-9009 (Stenabolic) is a synthetic Rev-ErbA agonist studied for metabolic enhancement and endurance. It is not a SARM but is commonly grouped with SARMs. Research suggests it may influence circadian rhythm biology, mitochondrial activity, and fat storage. Its short half-life necessitates split dosing throughout the day. Capsule Content 10mg per capsule (10,000mcg per capsule) Route of Administration Oral (capsule)

**Protocol Overview:**
- **Compound:** SR-9009 (Stenabolic) (Oral Research Compound - Metabolic / Endurance Enhancement)
- **Category:** Rev-ErbA Agonist
- **Form:** Capsules or Liquid
- **Route:** Oral (capsule or liquid)
- **Frequency:** 7 days/week

**Dosing (sample):**
```
Monday | 1 cap x3 | 30mg | AM / Noon / PM
Tuesday | 1 cap x3 | 30mg | AM / Noon / PM
Wednesday | 1 cap x3 | 30mg | AM / Noon / PM
Thursday | 1 cap x3 | 30mg | AM / Noon / PM
Friday | 1 cap x3 | 30mg | AM / Noon / PM
Saturday | 1 cap x3 | 30mg | AM / Noon / PM
Sunday | 1 cap x3 | 30mg | AM / Noon / PM
```

**FAQs:**
- **Q: What is the standard SR-9009 (Stenabolic) dosing protocol?**
  - A: The standard SR-9009 (Stenabolic) research protocol uses 20-30mg taken orally, split into 2-3 doses per day due to short half-life. Cycle Duration: 8-12 weeks on, 4 weeks off. No PCT needed.
- **Q: How do you take SR-9009 (Stenabolic)?**
  - A: SR-9009 is taken orally as a capsule or liquid. No reconstitution or injection is needed. Split into 2-3 doses per day due to short half-life.
- **Q: What are the storage requirements for SR-9009 (Stenabolic)?**
  - A: Capsules (sealed): Room temperature, cool dry place, protect from light. Capsules (opened): Keep tightly sealed, away from moisture and heat.

---

## SS-31 (Elamipretide) Protocol Guide — Dosing, Reconstitution & Administration
**URL:** https://www.pathtopeptides.com/ss-31-elamipretide-protocol
**Last reviewed:** 2026-04-10

**Summary:** SS-31 (Elamipretide) is a cell-permeable tetrapeptide that selectively targets mitochondrial cardiolipin. It is studied for mitochondrial dysfunction, age-related cellular decline, and cardioprotection. Clinical trials have explored doses up to 40mg/day; research protocols use scaled doses for investigation.

**Protocol Overview:**
- **Compound:** SS-31 (Elamipretide) (D-Arg-Dmt-Lys-Phe-NH2 (Cardiolipin-Binding Peptide))
- **Category:** Mitochondrial Targeting Peptide
- **Vial Size:** 5mg (5,000mcg)
- **Reconstitution:** 2mL bacteriostatic water (2.5mg/mL)
- **Route:** Subcutaneous injection
- **Frequency:** 5 days/week

**Dosing (sample):**
```
Monday | 20 | 500mcg | Morning
Tuesday | 20 | 500mcg | Morning
Wednesday | 20 | 500mcg | Morning
Thursday | 20 | 500mcg | Morning
Friday | 20 | 500mcg | Morning
```

**FAQs:**
- **Q: What is the standard SS-31 (Elamipretide) dosing protocol?**
  - A: The standard SS-31 (Elamipretide) research protocol uses 500mcg administered morning on protocol days. Weekly Total: 100 units (2,500mcg) • Vial Duration: ~10 days
- **Q: How do you reconstitute SS-31 (Elamipretide)?**
  - A: Using 2mL of bacteriostatic water results in a concentration of 2.5mg/mL (2500mcg/mL). Always use sterile techniques.
- **Q: What are the storage requirements for SS-31 (Elamipretide)?**
  - A: Lyophilized (powder): Room temperature or refrigerated, protect from light. Reconstituted: Refrigerated 36-46F (2-8C), use within 28 days.

---

## SS-31 (Elamipretide) Protocol Guide
**URL:** https://www.pathtopeptides.com/ss-31-protocol
**Last reviewed:** 2026-04-07

**Summary:** SS-31 (Elamipretide, also known as Bendavia and MTP-131) is a mitochondria-targeted tetrapeptide with the sequence D-Arg-Dmt-Lys-Phe-NH2. It selectively concentrates in the inner mitochondrial membrane by binding to cardiolipin, stabilizing cristae architecture, optimizing electron transport chain efficiency, reducing reactive oxygen species, and restoring ATP production. SS-31 has advanced through multiple clinical trials for Barth syndrome, primary mitochondrial myopathy, heart failure, and age-related macular degeneration, receiving FDA Fast Track and Orphan Drug designations.

**Protocol Overview:**
- **Compound:** SS-31 (Elamipretide / Bendavia / MTP-131)
- **Category:** Mitochondria-Targeted Peptide
- **Mechanism:** Binds cardiolipin on inner mitochondrial membrane, stabilizes cristae, optimizes ETC complex interactions, reduces ROS, restores ATP synthesis
- **Sequence:** D-Arg-Dmt-Lys-Phe-NH2 (4 amino acids, cell-permeable)
- **Half-Life:** ~4 hours (subcutaneous)
- **Vial Size:** 40mg lyophilized powder (typical)
- **Route:** Subcutaneous injection
- **Frequency:** Once daily
- **Cycle Length:** 4-12 weeks

**Dosing (sample):**
```
Conservative | 20 mg | Once daily | Subcutaneous | 4-8 weeks
Standard (Clinical) | 40 mg | Once daily | Subcutaneous | 8-12 weeks
Weight-Based | 0.25 mg/kg | Once daily | Subcutaneous | 4-12 weeks
Acute (IV Research) | 0.05 mg/kg/hr | Continuous infusion | Intravenous | Single session
```

**FAQs:**
- **Q: What is SS-31 and how does it work?**
  - A: SS-31 (Elamipretide) is a mitochondria-targeted tetrapeptide that selectively binds cardiolipin on the inner mitochondrial membrane. It stabilizes cristae structure, optimizes electron transport chain efficiency, reduces ROS production, and restores ATP synthesis in dysfunctional mitochondria.
- **Q: What is the standard SS-31 dosing protocol?**
  - A: The standard SS-31 research protocol uses 0.25-1.0 mg/kg administered subcutaneously once daily. Most clinical trials have used 40mg/day subcutaneous for adults. Protocol duration is typically 4-12 weeks depending on the research objective.
- **Q: What conditions has SS-31 been studied for?**
  - A: SS-31 has been studied in clinical trials for Barth syndrome, primary mitochondrial myopathy, age-related macular degeneration, heart failure, and renal ischemia-reperfusion injury. It has received FDA Fast Track and Orphan Drug designations for Barth syndrome.

---

## Survodutide Protocol Guide — Dosing, Reconstitution & Administration
**URL:** https://www.pathtopeptides.com/survodutide-protocol
**Last reviewed:** 2026-04-10

**Summary:** Survodutide is a dual GLP-1 and glucagon receptor agonist studied for obesity and metabolic dysfunction-associated steatohepatitis (MASH). The dual mechanism targets appetite suppression via GLP-1 while glucagon receptor activation increases energy expenditure and hepatic lipid oxidation.

**Protocol Overview:**
- **Compound:** Survodutide (Research Peptide for Obesity and MASH)
- **Category:** Dual GLP-1/Glucagon Receptor Agonist
- **Vial Size:** 10mg (10,000mcg)
- **Reconstitution:** 2mL bacteriostatic water (5mg/mL)
- **Route:** Subcutaneous injection
- **Frequency:** Once weekly

**Dosing (sample):**
```
Monday | 5 | 0.25mg | Morning
```

**FAQs:**
- **Q: What is the standard Survodutide dosing protocol?**
  - A: The standard Survodutide research protocol uses 0.25mg administered morning on protocol days. Weekly Total: 5 units (0.25mg) • Vial Duration: ~40 weeks at starting dose
- **Q: How do you reconstitute Survodutide?**
  - A: Using 2mL of bacteriostatic water results in a concentration of 5mg/mL. Start low and titrate gradually. Always use sterile techniques.
- **Q: What are the storage requirements for Survodutide?**
  - A: Lyophilized (powder): Room temperature or refrigerated, protect from light. Reconstituted: Refrigerated 36-46F (2-8C), use within 28 days.

---

## Thymosin Alpha-1 + BPC-157 Stack Protocol
**URL:** https://www.pathtopeptides.com/ta1-thymosin-alpha-stack-protocol
**Last reviewed:** 2026-04-07

**Summary:** The Thymosin Alpha-1 (TA1) + BPC-157 stack combines two well-characterized peptides that address immune function and tissue repair synergistically. TA1 (marketed as Zadaxin in 35+ countries) is a 28-amino acid thymic peptide that enhances T-cell maturation, NK cell cytotoxicity, dendritic cell function, and antibody responses. BPC-157 is a 15-amino acid gastric pentadecapeptide that accelerates tissue healing, reduces inflammation, and repairs the gut-immune barrier through VEGF upregulation and NO system modulation. Together, this stack supports comprehensive immune recovery alongside physical tissue repair, making it particularly valuable for post-illness recovery, immune rehabilitation, and chronic inflammatory conditions.

**Protocol Overview:**
- **Compounds:** Thymosin Alpha-1 (TA1) + BPC-157
- **Category:** Immune Modulation / Tissue Repair Stack
- **Mechanism:** TA1: T-cell maturation, NK activation, TLR agonism | BPC-157: VEGF, NO modulation, anti-inflammatory tissue repair
- **Route:** Subcutaneous
- **Frequency:** TA1: 2-3x/week | BPC-157: 1x daily
- **Cycle Length:** 8-12 weeks on, 4-8 weeks off

**Dosing (sample):**
```
Standard | 1.6 mg | 250 mcg | TA1 3x/wk + BPC daily | 8-12 weeks
Acute Immune | 1.6 mg | 250 mcg 2x | TA1 daily (7d) then 3x/wk + BPC 2x daily | 8-12 weeks
Maintenance | 1.6 mg | 250 mcg | TA1 2x/wk + BPC daily | 8-12 weeks
```

**FAQs:**
- **Q: Why stack Thymosin Alpha-1 with BPC-157?**
  - A: Thymosin Alpha-1 and BPC-157 address two critical recovery axes: immune function and tissue repair. TA1 enhances adaptive immunity by promoting T-cell maturation, NK cell activation, and dendritic cell function, while BPC-157 accelerates tissue healing, reduces inflammation, and repairs the gut-immune barrier. This combination is particularly relevant for recovery from chronic illness, post-surgical healing, or immune system rehabilitation.
- **Q: What is the standard TA1 + BPC-157 stack dosing?**
  - A: The standard protocol uses Thymosin Alpha-1 at 1.6mg subcutaneously 2-3 times per week, combined with BPC-157 at 250mcg subcutaneously once daily. TA1 has a longer duration of action and does not require daily dosing. BPC-157 benefits from consistent daily administration for sustained tissue repair signaling.
- **Q: How long should the TA1 + BPC-157 stack be run?**
  - A: A standard cycle runs 8-12 weeks. TA1 immune effects build progressively over weeks, with meaningful immune reconstitution typically measured at 8+ weeks. BPC-157 tissue repair effects begin within the first 1-2 weeks. After the cycle, take 4-8 weeks off before repeating.

---

## TB-500 Protocol Guide — Dosing, Reconstitution & Administration
**URL:** https://www.pathtopeptides.com/tb-500-protocol
**Last reviewed:** 2026-04-10

**Summary:** TB-500 is a synthetic version of Thymosin Beta-4, a naturally occurring peptide in virtually all human and animal cells. It is studied for tissue repair, cell migration, and inflammation modulation.

**Protocol Overview:**
- **Compound:** TB-500 (Thymosin Beta-4 Fragment)
- **Category:** Research Peptide
- **Vial Size:** 10mg (10,000mcg)
- **Reconstitution:** 2mL bacteriostatic water (5mg/mL)
- **Route:** Subcutaneous injection
- **Frequency:** 2x/week (loading) then 1x/week (maintenance)

**Dosing (sample):**
```
Loading (Weeks 1–6) | 2x/week (Mon & Thu) | 2.5mg (50 units) | 5mg
Maintenance (Weeks 7+) | 1x/week | 2.5mg (50 units) | 2.5mg
```

**FAQs:**
- **Q: What is the standard TB-500 dosing protocol?**
  - A: TB-500 uses a two-phase protocol: Loading phase (weeks 1-6) at 2.5mg twice weekly (5mg/week total), then maintenance at 2.5mg once weekly. A 10mg vial lasts 1 week during loading or 2 weeks during maintenance.
- **Q: How do you reconstitute TB-500?**
  - A: Add 2mL of bacteriostatic water to a 10mg vial for a concentration of 5mg/mL. Always use sterile techniques.
- **Q: What are the storage requirements for TB-500?**
  - A: Lyophilized (powder): Room temperature or refrigerated, protect from light. Reconstituted: Refrigerated 36-46F (2-8C), use within 28 days.

---

## TB-500 + Thymosin Alpha-1 Stack Protocol Guide — Dosing, Synergy & Research Protocol
**URL:** https://www.pathtopeptides.com/tb-500-thymosin-alpha-1-stack-protocol
**Last reviewed:** 2026-04-08

**Summary:** The TB-500 + Thymosin Alpha-1 stack combines systemic tissue healing with powerful immune modulation. TB-500 (Thymosin Beta-4 fragment) promotes cellular migration, reduces inflammation, and facilitates tissue repair throughout the body. Thymosin Alpha-1 (TA1) is an FDA-approved (outside US) immune peptide that enhances T-cell maturation, NK cell activity, and dendritic cell function. Together, these thymic peptides create a comprehensive protocol: TB-500 repairs damaged tissue while TA1 ensures the immune system supports recovery and prevents infection during the healing process.

**Protocol Overview:**
- **Compounds:** TB-500 + Thymosin Alpha-1
- **Category:** Systemic Healing / Immune Support
- **Mechanism:** TB-500: actin regulation, cellular migration, anti-inflammatory. TA1: T-cell maturation, NK cell activation, dendritic cell function, TLR modulation
- **Half-Life:** TB-500: ~6-8 hrs | TA1: ~2 hrs
- **Route:** Both subcutaneous injection
- **Frequency:** TB-500: daily or 3x/week | TA1: 2-3x/week
- **Cycle Length:** 8-12 weeks

**Dosing (sample):**
```
Standard | TB-500 750mcg 3x/week | TA1 1.6mg 2x/week | TB: M/W/F, TA1: Tu/Th | 8-12 weeks
Loading | TB-500 2mg 2x/week (wk1-4) then 750mcg | TA1 1.6mg 3x/week | Alternating days | 12 weeks
Maintenance | TB-500 750mcg 2x/week | TA1 1.6mg 1x/week | M/Th | Ongoing
```

**FAQs:**
- **Q: Why combine TB-500 with Thymosin Alpha-1?**
  - A: TB-500 and TA1 are both thymus-derived but serve different functions. TB-500 focuses on tissue repair through cellular migration and anti-inflammatory mechanisms, while TA1 optimizes immune function. Together they ensure the body can heal tissue and mount proper immune responses during recovery.
- **Q: Can TB-500 and Thymosin Alpha-1 be taken on the same day?**
  - A: Yes, as separate injections. However, many protocols alternate days (TB-500 M/W/F, TA1 Tu/Th) to spread injections and allow each peptide to work independently.
- **Q: How long should you run the TB-500 + TA1 stack?**
  - A: Standard cycle is 8-12 weeks. TB-500 loading phase (first 4 weeks) transitions to maintenance. TA1 can continue longer for sustained immune support, even indefinitely at 1x/week.

---

## TB-500 (Thymosin Beta-4): Research Guide | PtP Wiki
**URL:** https://www.pathtopeptides.com/tb-500
**Last reviewed:** 2026-04-07

**Summary:** TB-500 is a synthetic peptide based on the active region of thymosin beta-4 (Tb4), a 43-amino-acid protein that is one of the most abundant and highly conserved polypeptides in the human body. Thymosin beta-4 is found in virtually all human cells and tissues, where it serves as the primary intracellular G-actin sequestering protein — a critical regulator of the actin cytoskeleton that controls cell shape, motility, and migration.

**FAQs:**
- **Q: What is the difference between TB-500 and Thymosin Beta-4?**
  - A: TB-500 is a synthetic peptide fragment that contains the active region of thymosin beta-4 (Tb4), specifically the 17-amino-acid actin-binding domain (amino acids 17-23 of the full Tb4 sequence: LKKTETQ). Full-length thymosin beta-4 is a 43-amino-acid naturally occurring protein found in virtually all human cells. TB-500 is designed to replicate the key biological activity of Tb4 — promoting cell migration, angiogenesis, and tissue repair — in a more practical and stable form for research applications. In practice, the terms are often used interchangeably in research contexts.
- **Q: How does TB-500 promote tissue repair?**
  - A: TB-500 promotes tissue repair through its central actin-binding domain. By sequestering G-actin monomers and promoting actin polymerization, it drives cytoskeletal reorganization that is essential for cell migration into wound sites. Additionally, TB-500 upregulates vascular endothelial growth factor (VEGF) for angiogenesis, reduces inflammation through NF-kB modulation, and promotes stem/progenitor cell recruitment. These combined effects accelerate healing of skin wounds, tendons, ligaments, muscles, and cardiac tissue in preclinical models.
- **Q: What is the typical TB-500 research dosing protocol?**
  - A: The most common research protocol uses a loading phase of 2.0-2.5 mg administered subcutaneously twice weekly for 4-6 weeks, followed by a maintenance phase of 2.0-2.5 mg once weekly or biweekly for an additional 4-8 weeks. Total cycle length is typically 8-12 weeks. Some protocols use higher loading doses (5 mg twice weekly) for the first 2 weeks before reducing to standard maintenance dosing.

---

## TB-4 FRAG / Ac-SDKP Protocol — Cardiac Repair
**URL:** https://www.pathtopeptides.com/tb4-frag-protocol
**Last reviewed:** 2026-04-07

**Summary:** TB-4 FRAG, also known as Ac-SDKP (N-acetyl-seryl-aspartyl-lysyl-proline), is the bioactive anti-fibrotic tetrapeptide fragment derived from the N-terminal region of Thymosin Beta-4. This endogenous peptide is naturally produced by enzymatic cleavage and degraded by ACE (angiotensin-converting enzyme). Ac-SDKP potently inhibits collagen synthesis, reduces cardiac and organ fibrosis, promotes angiogenesis, protects cardiomyocytes from ischemic damage, and modulates inflammatory macrophage polarization. This protocol covers subcutaneous dosing at 200-750mcg daily, cycling strategies, cardiac biomarker monitoring, and stacking for comprehensive tissue repair research.

**Protocol Overview:**
- **Compound:** Ac-SDKP (TB-4 FRAG / N-acetyl-Ser-Asp-Lys-Pro)
- **Category:** Cardiac Repair / Anti-Fibrotic
- **Mechanism:** Inhibits collagen I/III synthesis, reduces TGF-beta/Smad signaling, promotes angiogenesis, anti-inflammatory macrophage polarization (M1 to M2 shift)
- **Molecular Weight:** 487.51 g/mol
- **Half-Life:** ~4.5 minutes (rapidly degraded by ACE)
- **Form:** Lyophilized powder (5mg vials)
- **Route:** Subcutaneous
- **Frequency:** 1-2x daily
- **Cycle Length:** 4-8 weeks on, 2-4 weeks off

**Dosing (sample):**
```
Introductory | 200 mcg | 1x daily | SubQ | 1 week
Standard | 500 mcg | 1x daily | SubQ | 4-8 weeks
Advanced | 750 mcg | 1x daily | SubQ | 4-8 weeks
Split Dose | 250 mcg | 2x daily (AM + PM) | SubQ | 4-8 weeks
```

**FAQs:**
- **Q: What is TB-4 FRAG (Ac-SDKP) and how does it relate to TB-500?**
  - A: TB-4 FRAG, also known as Ac-SDKP (N-acetyl-seryl-aspartyl-lysyl-proline), is the active anti-fibrotic fragment derived from the N-terminal region of Thymosin Beta-4 (TB-500). While TB-500 is the full 43-amino acid peptide, Ac-SDKP is a 4-amino acid fragment specifically responsible for anti-fibrotic, anti-inflammatory, and cardioprotective effects.
- **Q: What is the standard Ac-SDKP dosing protocol?**
  - A: The standard research protocol uses 100-750mcg administered subcutaneously once daily. Most protocols start at 100-200mcg daily for the first week, then increase to 500-750mcg daily for 4-8 weeks. The peptide has a short half-life, so consistent daily dosing is important for sustained anti-fibrotic activity.
- **Q: What are the primary research applications of Ac-SDKP?**
  - A: Ac-SDKP is primarily researched for cardiac fibrosis reduction, post-myocardial infarction repair, anti-inflammatory effects, angiogenesis promotion, and organ fibrosis prevention (cardiac, renal, pulmonary). It inhibits collagen I and III deposition and reduces TGF-beta signaling in fibroblasts.

---

## Tesamorelin / Ipamorelin Protocol Guide — Dosing, Reconstitution & Administration
**URL:** https://www.pathtopeptides.com/tesamorelin-ipamorelin-protocol
**Last reviewed:** 2026-04-10

**Summary:** Tesamorelin (GHRH analog) combined with Ipamorelin (GH secretagogue) provides synergistic growth hormone stimulation through GHRH and ghrelin-mimetic pathways.

**Protocol Overview:**
- **Compound:** Tesamorelin / Ipamorelin (Tesamorelin 5mg + Ipamorelin 5mg)
- **Category:** Growth Hormone Blend
- **Vial Size:** 10mg total (10,000mcg)
- **Reconstitution:** 2mL bacteriostatic water (5mg/mL)
- **Route:** Subcutaneous injection
- **Frequency:** 5 days/week

**Dosing (sample):**
```
Monday | 4 | 200mcg | Before bed
Tuesday | 4 | 200mcg | Before bed
Wednesday | 4 | 200mcg | Before bed
Thursday | 4 | 200mcg | Before bed
Friday | 4 | 200mcg | Before bed
```

**FAQs:**
- **Q: What is the standard Tesamorelin / Ipamorelin dosing protocol?**
  - A: The standard Tesamorelin / Ipamorelin research protocol uses 200mcg administered before bed on protocol days. Weekly Total: 20 units (1,000mcg) • Vial Duration: ~50 days
- **Q: How do you reconstitute Tesamorelin / Ipamorelin?**
  - A: Using 2mL of bacteriostatic water results in a concentration of 5mg/mL total blend. Always use sterile techniques.
- **Q: What are the storage requirements for Tesamorelin / Ipamorelin?**
  - A: Lyophilized (powder): Room temperature or refrigerated, protect from light. Reconstituted: Refrigerated 36-46F (2-8C), use within 28 days.

---

## Tesamorelin Protocol Guide — Dosing, Reconstitution & Administration
**URL:** https://www.pathtopeptides.com/tesamorelin-protocol
**Last reviewed:** 2026-04-10

**Summary:** Tesamorelin is a synthetic analog of growth hormone-releasing hormone (GHRH) that stimulates the pituitary gland to produce and release growth hormone naturally.

**Protocol Overview:**
- **Compound:** Tesamorelin (Growth Hormone-Releasing Hormone Analog)
- **Category:** GHRH Analog
- **Vial Size:** 5mg (5,000mcg)
- **Reconstitution:** 2mL bacteriostatic water (2.5mg/mL)
- **Route:** Subcutaneous injection
- **Frequency:** Once daily (or 5 days/week)

**Dosing (sample):**
```
Daily | 80 | 2mg (2,000mcg) | Morning, before breakfast
```

**FAQs:**
- **Q: What is the standard Tesamorelin dosing protocol?**
  - A: The standard Tesamorelin (Egrifta) dose is 2mg (2,000mcg) administered subcutaneously once daily before breakfast. A 5mg vial provides approximately 2.5 doses.
- **Q: How do you reconstitute Tesamorelin?**
  - A: Add 2mL of bacteriostatic water to a 5mg vial for a concentration of 2.5mg/mL. Always use sterile techniques.
- **Q: What are the storage requirements for Tesamorelin?**
  - A: Lyophilized (powder): Room temperature or refrigerated, protect from light. Reconstituted: Refrigerated 36-46F (2-8C), use within 28 days.

---

## Tesamorelin: Protocol, Dosage & Research Guide
**URL:** https://www.pathtopeptides.com/tesamorelin
**Last reviewed:** 2026-04-07

**Summary:** Tesamorelin (Egrifta) is a synthetic trans-3-hexenoic acid-modified analog of full-length GHRH(1-44), FDA-approved for reducing visceral abdominal fat in HIV-infected patients with lipodystrophy. Unlike truncated GHRH analogs (Sermorelin), it retains all 44 amino acids of native GHRH for maximal pituitary receptor engagement. Also studied for cognitive enhancement in older adults and NAFLD. Evidence Grade: A.

**FAQs:**
- **Q: What is tesamorelin used for?**
  - A: Tesamorelin (Egrifta) is FDA-approved for reduction of excess visceral abdominal fat in HIV-infected patients with lipodystrophy. It is also studied off-label for visceral fat reduction in non-HIV populations, cognitive enhancement in older adults with mild cognitive impairment, and non-alcoholic fatty liver disease (NAFLD).
- **Q: How does tesamorelin differ from other GHRH analogs?**
  - A: Tesamorelin is a trans-3-hexenoic acid conjugate of full-length GHRH(1-44) — it retains all 44 amino acids of native GHRH (unlike Sermorelin which is truncated) with a fatty acid modification for extended stability. Its half-life is 26 minutes vs ~7 minutes for native GHRH, allowing once-daily dosing.
- **Q: What is the tesamorelin dosage?**
  - A: The FDA-approved dose is 2 mg/day subcutaneous injection. This is the dose used in all Phase III trials and is standard for research applications as well.

---

## Tesofensine Protocol Guide — Dosing, Reconstitution & Administration
**URL:** https://www.pathtopeptides.com/tesofensine-protocol
**Last reviewed:** 2026-04-10

**Summary:** Tesofensine is a triple monoamine reuptake inhibitor blocking reuptake of norepinephrine, dopamine, and serotonin, studied for appetite suppression and metabolic rate effects.

**Protocol Overview:**
- **Compound:** Tesofensine (Triple Monoamine Reuptake Inhibitor)
- **Category:** Research Compound
- **Vial Size:** 500mcg capsule (500mcg)
- **Reconstitution:** N/A (oral capsule)
- **Route:** Oral
- **Frequency:** 7 days/week

**Dosing (sample):**
```
Monday | 1 cap | 500mcg | Morning
Tuesday | 1 cap | 500mcg | Morning
Wednesday | 1 cap | 500mcg | Morning
Thursday | 1 cap | 500mcg | Morning
Friday | 1 cap | 500mcg | Morning
Saturday | 1 cap | 500mcg | Morning
Sunday | 1 cap | 500mcg | Morning
```

**FAQs:**
- **Q: What is the standard Tesofensine dosing protocol?**
  - A: The standard Tesofensine research protocol uses 500mcg administered morning on protocol days. Weekly Total: 7 capsules (3,500mcg) • Vial Duration: Depends on capsule count
- **Q: How do you reconstitute Tesofensine?**
  - A: Tesofensine is supplied as an oral capsule. No reconstitution required. Take with water.
- **Q: What are the storage requirements for Tesofensine?**
  - A: Lyophilized (powder): Room temperature or refrigerated, protect from light. Reconstituted: Room temperature, keep sealed, use within 90 days.

---

## Tesofensine + Semaglutide Stack Protocol Guide — Dosing, Synergy & Research Protocol
**URL:** https://www.pathtopeptides.com/tesofensine-semaglutide-stack-protocol
**Last reviewed:** 2026-04-08

**Summary:** The Tesofensine + Semaglutide stack combines two of the most potent appetite-suppressing compounds available. Tesofensine is a triple monoamine reuptake inhibitor (serotonin, norepinephrine, dopamine) originally developed for neurodegenerative diseases that demonstrated remarkable weight loss in clinical trials. Semaglutide, a GLP-1 receptor agonist, suppresses appetite through central and peripheral mechanisms. Together they attack appetite through completely different neurotransmitter systems: tesofensine via monoaminergic pathways and semaglutide via incretin signaling. This dual approach may overcome appetite adaptation that occurs with single-agent therapy.

**Protocol Overview:**
- **Compounds:** Tesofensine + Semaglutide
- **Category:** Weight Loss / Appetite Suppression
- **Mechanism:** Tesofensine: triple monoamine (5-HT, NE, DA) reuptake inhibition, thermogenesis. Semaglutide: GLP-1 receptor agonism, gastric slowing
- **Half-Life:** Tesofensine: ~220 hrs | Semaglutide: ~7 days
- **Route:** Tesofensine: Oral (daily) | Semaglutide: SubQ (weekly)
- **Frequency:** Tesofensine: 1x daily | Semaglutide: 1x/week
- **Cycle Length:** 12-16 weeks

**Dosing (sample):**
```
Conservative | Teso 0.25mg/day oral | Sema 0.25-0.5mg/wk | AM + weekly | 12 weeks
Standard | Teso 0.5mg/day oral | Sema 1mg/wk | AM + weekly | 12-16 weeks
Advanced | Teso 0.5mg/day oral | Sema 2.4mg/wk | AM + weekly | 16 weeks
```

**FAQs:**
- **Q: Is it safe to combine Tesofensine with Semaglutide?**
  - A: While no direct drug interaction is documented, this is an advanced stack requiring careful monitoring. Tesofensine affects monoamine neurotransmitters and can elevate heart rate and blood pressure, while semaglutide has GI side effects. Regular cardiovascular monitoring is essential. Consult a healthcare provider before combining.
- **Q: What makes Tesofensine + Semaglutide effective for weight loss?**
  - A: These compounds suppress appetite through entirely different mechanisms. Tesofensine inhibits reuptake of serotonin, norepinephrine, and dopamine, while semaglutide activates GLP-1 receptors. The dual-pathway approach may overcome appetite adaptation that single agents face over time.
- **Q: What are the main risks of the Tesofensine + Semaglutide stack?**
  - A: The primary concern is cardiovascular: tesofensine can increase heart rate and blood pressure, and rapid weight loss from dual appetite suppression can increase gallstone risk. Regular vital sign monitoring and metabolic blood work are mandatory.

---

## Thymalin Protocol Guide — Dosing, Reconstitution & Administration
**URL:** https://www.pathtopeptides.com/thymalin-protocol
**Last reviewed:** 2026-04-10

**Summary:** Thymalin is a polypeptide complex extracted from the thymus gland. It is researched as a bioregulator for immune system restoration, thymic function support, and anti-aging protocols. Typically administered in short cycles of 5-10 days with rest periods between cycles.

**Protocol Overview:**
- **Compound:** Thymalin (Thymalin (Thymic Extract Peptide Complex))
- **Category:** Thymic Bioregulator
- **Vial Size:** 10mg (10,000mcg)
- **Reconstitution:** 2mL bacteriostatic water (5mg/mL)
- **Route:** Subcutaneous injection
- **Frequency:** 5 days/week

**Dosing (sample):**
```
Monday | 10 | 5mg | Morning
Tuesday | 10 | 5mg | Morning
Wednesday | 10 | 5mg | Morning
Thursday | 10 | 5mg | Morning
Friday | 10 | 5mg | Morning
```

**FAQs:**
- **Q: What is the standard Thymalin dosing protocol?**
  - A: The standard Thymalin research protocol uses 5mg administered morning on protocol days. Weekly Total: 50 units (25mg) - cycle-based • Vial Duration: ~2 days per vial at 5mg/day
- **Q: How do you reconstitute Thymalin?**
  - A: Using 2mL of bacteriostatic water results in a concentration of 5mg/mL. Always use sterile techniques.
- **Q: What are the storage requirements for Thymalin?**
  - A: Lyophilized (powder): Room temperature or refrigerated, protect from light. Reconstituted: Refrigerated 36-46F (2-8C), use within 28 days.

---

## Thymosin Alpha-1 + LL-37 Stack Protocol Guide — Dosing, Synergy & Research Protocol
**URL:** https://www.pathtopeptides.com/thymosin-alpha-1-ll-37-stack-protocol
**Last reviewed:** 2026-04-08

**Summary:** The Thymosin Alpha-1 + LL-37 stack is the most comprehensive immune support peptide protocol, combining adaptive immune modulation with innate antimicrobial defense. TA1 enhances T-cell maturation, NK cell activity, and dendritic cell function. LL-37 (Cathelicidin) is a human antimicrobial peptide that directly kills bacteria, viruses, and fungi while modulating innate immune responses and promoting wound healing. Together, TA1 optimizes adaptive immunity for pathogen recognition while LL-37 provides immediate broad-spectrum antimicrobial activity.

**Protocol Overview:**
- **Compounds:** Thymosin Alpha-1 + LL-37 (Cathelicidin)
- **Category:** Immune Modulation / Antimicrobial
- **Mechanism:** TA1: T-cell maturation, NK cell activation, dendritic cell function, TLR modulation. LL-37: direct antimicrobial, membrane disruption, LPS neutralization, innate immune activation
- **Half-Life:** TA1: ~2 hrs | LL-37: ~4-6 hrs
- **Route:** Both subcutaneous injection
- **Frequency:** TA1: 2-3x/week | LL-37: 3-5x/week
- **Cycle Length:** 8-12 weeks

**Dosing (sample):**
```
Standard | TA1 1.6mg 2x/week | LL-37 100mcg daily 5x/week | TA1: Tu/Th, LL-37: M-F | 8-12 weeks
Acute | TA1 1.6mg 3x/week | LL-37 200mcg daily | TA1: M/W/F, LL-37: daily | 4-6 weeks
Maintenance | TA1 1.6mg 1x/week | LL-37 100mcg 3x/week | TA1: Mon, LL-37: M/W/F | Ongoing
```

**FAQs:**
- **Q: Why combine Thymosin Alpha-1 with LL-37?**
  - A: TA1 optimizes adaptive immunity (T-cells, NK cells, dendritic cells) while LL-37 provides immediate innate antimicrobial defense. Together they cover both first-line defense and coordinated elimination.
- **Q: Is this stack appropriate for autoimmune conditions?**
  - A: TA1 is an immune modulator, not just stimulant, and can help balance overactive responses. However, initial therapy may temporarily flare symptoms. Start low and monitor. LL-37 should be used cautiously as it can activate mast cells.
- **Q: How long should the TA1 + LL-37 stack be continued?**
  - A: Standard course is 8-12 weeks. Then transition to maintenance (TA1 1x/week, LL-37 3x/week). TA1 can be used long-term safely, as evidenced by chronic hepatitis treatment spanning months to years.

---

## Thymosin Alpha-1 Protocol Guide — Dosing, Reconstitution & Administration
**URL:** https://www.pathtopeptides.com/thymosin-alpha-1-protocol
**Last reviewed:** 2026-04-10

**Summary:** Thymosin Alpha-1 is a naturally occurring thymic peptide that modulates immune function. It enhances T-cell maturation, dendritic cell function, and antibody responses. It is researched for immune enhancement in chronic infections, immune deficiency, and as a vaccine adjuvant.

**Protocol Overview:**
- **Compound:** Thymosin Alpha-1 (Tα1; Zadaxin / Thymalfasin)
- **Category:** Immune Modulation / Antiviral Research Peptide
- **Vial Size:** 1.6mg (Zadaxin standard) or 10mg research vials
- **Reconstitution:** 1.6mg vial + 1mL sterile water = 1.6 mg/mL
- **Route:** Subcutaneous injection
- **Frequency:** 2x per week (twice weekly)
- **Cycle Length:** 8–16 weeks (immune support); ongoing for chronic conditions

**Dosing (sample):**
```
Conservative Start | 0.8 mg | 2x per week | Subcutaneous | 2–4 weeks, then assess
Standard (Zadaxin dose) | 1.6 mg | 2x per week (e.g. Mon & Thu) | Subcutaneous | 8–16 weeks
Higher Immune Support | 1.6 mg | 3x per week | Subcutaneous | 8–12 weeks
```

**FAQs:**
- **Q: What is the standard Thymosin Alpha-1 dosing protocol?**
  - A: The standard Thymosin Alpha-1 research protocol uses 1.6mg administered morning on protocol days. Weekly Total: 106 units (3.2mg) • Vial Duration: ~1 week per vial at standard dose
- **Q: How do you reconstitute Thymosin Alpha-1?**
  - A: For a 1.6mg Zadaxin-standard vial, add 1mL of bacteriostatic water for a concentration of 1.6mg/mL (1,600mcg/mL). For a 10mg research vial, add 6.25mL to achieve the same 1.6mg/mL concentration. Always use sterile techniques.
- **Q: What are the storage requirements for Thymosin Alpha-1?**
  - A: Lyophilized (powder): Room temperature or refrigerated, protect from light. Reconstituted: Refrigerated 36-46F (2-8C), use within 28 days.

---

## Thymosin Alpha-1: Complete Research Guide | PtP Wiki
**URL:** https://www.pathtopeptides.com/thymosin-alpha-1
**Last reviewed:** 2026-04-08

**Summary:** Thymosin Alpha-1 (Ta1) is a 28-amino-acid peptide originally isolated from thymic tissue (thymosin fraction 5) by Allan Goldstein at George Washington University in the 1970s. It is an endogenous immune modulator produced by thymic epithelial cells that plays a critical role in T-cell maturation, differentiation, and activation. The synthetic version, thymalfasin, is marketed as Zadaxin and approved in over 35 countries for treatment of chronic hepatitis B and as an immune adjuvant.

**FAQs:**
- **Q: Is Thymosin Alpha-1 approved for medical use?**
  - A: Yes, Thymosin Alpha-1 (marketed as Zadaxin) is approved in over 35 countries, primarily in Asia, South America, and parts of Europe, for the treatment of chronic hepatitis B and as an immune adjuvant. It is not FDA-approved in the United States, though it has received FDA Orphan Drug designation for hepatitis B and hepatocellular carcinoma.
- **Q: How does Thymosin Alpha-1 differ from Thymosin Beta-4 (TB-500)?**
  - A: Despite sharing the thymosin name, they are entirely different peptides with different mechanisms. Thymosin Alpha-1 is a 28-amino-acid immune modulator that activates T-cells and dendritic cells, primarily used for immune support. Thymosin Beta-4 (TB-500) is a 43-amino-acid peptide involved in cell migration, actin polymerization, and wound healing. They have no structural similarity and target completely different biological pathways.
- **Q: Can Thymosin Alpha-1 be used alongside vaccines?**
  - A: Yes, Thymosin Alpha-1 has been studied as a vaccine adjuvant in multiple clinical trials. It enhances vaccine-induced immune responses by activating dendritic cells and T-helper cells, improving both antibody production and cellular immunity. It has been studied as an adjuvant for influenza, hepatitis B, and other vaccines, particularly in immunocompromised populations who respond poorly to standard vaccination.

---

## Thymosin Beta-4 Protocol Guide — Dosing, Reconstitution & Administration
**URL:** https://www.pathtopeptides.com/thymosin-beta-4-protocol
**Last reviewed:** 2026-04-10

**Summary:** Thymosin Beta-4 (TB-4) is the full-length 43-amino acid peptide studied for tissue repair, wound healing, and anti-inflammatory properties. Unlike the truncated fragment TB-500, full-length TB-4 retains all biological activity domains including actin sequestration, anti-inflammatory signaling, and stem cell migration promotion.

**Protocol Overview:**
- **Compound:** Thymosin Beta-4 (Full-Length Thymosin Beta-4 (43 Amino Acids))
- **Category:** Tissue Repair / Recovery Peptide
- **Vial Size:** 5mg (5,000mcg)
- **Reconstitution:** 2mL bacteriostatic water (2.5mg/mL)
- **Route:** Subcutaneous injection
- **Frequency:** 2 days/week

**Dosing (sample):**
```
Monday | 30 | 750mcg | Morning
Thursday | 30 | 750mcg | Morning
```

**FAQs:**
- **Q: What is the standard Thymosin Beta-4 dosing protocol?**
  - A: The standard Thymosin Beta-4 research protocol uses 750mcg administered morning on protocol days. Weekly Total: 60 units (1,500mcg) • Vial Duration: ~17 days
- **Q: How do you reconstitute Thymosin Beta-4?**
  - A: Using 2mL of bacteriostatic water results in a concentration of 2.5mg/mL. Always use sterile techniques.
- **Q: What are the storage requirements for Thymosin Beta-4?**
  - A: Lyophilized (powder): Room temperature or refrigerated, protect from light. Reconstituted: Refrigerated 36-46F (2-8C), use within 28 days.

---

## Thymulin Protocol Guide — Dosing, Reconstitution & Administration
**URL:** https://www.pathtopeptides.com/thymulin-protocol
**Last reviewed:** 2026-04-10

**Summary:** Thymulin is a zinc-dependent nonapeptide secreted by thymic epithelial cells. It is essential for T-cell differentiation and maturation. Thymulin activity is zinc-dependent, and adequate zinc status is required for its biological function. It is researched for immune modulation, thymic restoration, and anti-aging protocols.

**Protocol Overview:**
- **Compound:** Thymulin (Thymulin (Facteur Thymique Serique / FTS-Zn))
- **Category:** Zinc-Dependent Immune Peptide
- **Vial Size:** 5mg (5,000mcg)
- **Reconstitution:** 2mL bacteriostatic water (2.5mg/mL)
- **Route:** Subcutaneous injection
- **Frequency:** 7 days/week

**Dosing (sample):**
```
Monday | 4 | 100mcg | Morning
Tuesday | 4 | 100mcg | Morning
Wednesday | 4 | 100mcg | Morning
Thursday | 4 | 100mcg | Morning
Friday | 4 | 100mcg | Morning
Saturday | 4 | 100mcg | Morning
Sunday | 4 | 100mcg | Morning
```

**FAQs:**
- **Q: What is the standard Thymulin dosing protocol?**
  - A: The standard Thymulin research protocol uses 100mcg administered morning on protocol days. Weekly Total: 28 units (700mcg) • Vial Duration: ~50 days at 100mcg/day
- **Q: How do you reconstitute Thymulin?**
  - A: Using 2mL of bacteriostatic water results in a concentration of 2.5mg/mL. Always use sterile techniques.
- **Q: What are the storage requirements for Thymulin?**
  - A: Lyophilized (powder): Room temperature or refrigerated, protect from light. Reconstituted: Refrigerated 36-46F (2-8C), use within 28 days.

---

## Tirzepatide + 5-Amino-1MQ Stack Protocol Guide — Dosing, Synergy & Research Protocol
**URL:** https://www.pathtopeptides.com/tirzepatide-5-amino-1mq-stack-protocol
**Last reviewed:** 2026-04-08

**Summary:** The Tirzepatide + 5-Amino-1MQ stack pairs the most effective dual incretin agonist with a novel NNMT inhibitor for a multi-pathway approach to fat loss. Tirzepatide activates both GIP and GLP-1 receptors, producing superior appetite suppression and metabolic improvement compared to single-incretin agents. 5-Amino-1MQ inhibits NNMT, an enzyme that contributes to fat cell expansion and metabolic dysfunction. By blocking NNMT, 5-Amino-1MQ increases NAD+ levels in adipose tissue, boosts cellular energy expenditure, and shrinks fat cells. Together, these compounds create powerful synergy: reduced caloric intake plus enhanced fat cell metabolism.

**Protocol Overview:**
- **Compounds:** Tirzepatide + 5-Amino-1MQ
- **Category:** Weight Loss / Metabolic Stack
- **Mechanism:** Tirzepatide: dual GIP/GLP-1 agonism, appetite suppression, insulin sensitization. 5-Amino-1MQ: NNMT inhibition, NAD+ increase, adipocyte energy expenditure
- **Half-Life:** Tirzepatide: ~5 days | 5-Amino-1MQ: ~6-8 hrs (oral)
- **Route:** Tirzepatide: SubQ (weekly) | 5-Amino-1MQ: Oral (daily)
- **Frequency:** Tirzepatide: 1x/week | 5-Amino-1MQ: 1-2x daily
- **Cycle Length:** 12-16 weeks

**Dosing (sample):**
```
Standard | Tirz 2.5mg/wk (wk1-4), 5mg (wk5-8), 7.5mg (wk9+) | 5-Amino 100mg 2x/day oral | AM/PM | 12-16 weeks
Aggressive | Tirz titrate to 15mg/wk | 5-Amino 150mg 2x/day | AM/PM | 16 weeks
Maintenance | Tirz 5mg/wk | 5-Amino 100mg 1x/day | AM | 8-12 weeks
```

**FAQs:**
- **Q: How does the Tirzepatide + 5-Amino-1MQ stack work for weight loss?**
  - A: Tirzepatide acts as a dual GIP/GLP-1 receptor agonist that powerfully suppresses appetite and improves insulin sensitivity. 5-Amino-1MQ inhibits NNMT enzyme in fat cells, increasing NAD+ levels and boosting adipocyte energy expenditure. Together they reduce caloric intake while simultaneously increasing fat cell metabolism.
- **Q: What is the proper titration schedule for Tirzepatide in this stack?**
  - A: Start tirzepatide at 2.5mg weekly for 4 weeks, then increase to 5mg for weeks 5-8, then 7.5mg for weeks 9-12. Further titration to 10-15mg is possible based on tolerance. Never skip titration steps to avoid severe GI side effects.
- **Q: Is 5-Amino-1MQ safe to take with Tirzepatide?**
  - A: Both compounds work through different pathways with no known direct interactions. 5-Amino-1MQ is an oral NNMT inhibitor while Tirzepatide is an injectable incretin mimetic. However, 5-Amino-1MQ has limited long-term human safety data, so monitoring liver and kidney function is recommended.

---

## Tirzepatide Protocol Guide — Dosing, Reconstitution & Administration
**URL:** https://www.pathtopeptides.com/tirzepatide-protocol
**Last reviewed:** 2026-04-10

**Summary:** Tirzepatide is a dual GIP and GLP-1 receptor agonist studied for metabolic research. This starting-size vial is ideal for initial dosing protocols.

**Protocol Overview:**
- **Compound:** Tirzepatide (Research Peptide for Metabolic Studies)
- **Category:** Dual GIP/GLP-1 Receptor Agonist
- **Vial Size:** 5mg (5,000mcg)
- **Reconstitution:** 1mL bacteriostatic water (5mg/mL)
- **Route:** Subcutaneous injection
- **Frequency:** Once weekly

**Dosing (sample):**
```
Weeks 1–4 | 2.5mg | 50 units (0.5mL) | Once weekly
Weeks 5–8 | 5mg | 100 units (1.0mL) | Once weekly
Weeks 9–12 | 7.5mg | Use 10mg/mL concentration | Once weekly
Weeks 13–16 | 10mg | Use 10mg/mL concentration | Once weekly
Weeks 17–20 | 12.5mg | Use 10mg/mL concentration | Once weekly
Weeks 21+ | 15mg (max) | Use 10mg/mL concentration | Once weekly
```

**FAQs:**
- **Q: What is the standard Tirzepatide dosing protocol?**
  - A: Tirzepatide follows a dose-escalation protocol: start at 2.5mg once weekly, increasing every 4 weeks through 5mg, 7.5mg, 10mg, 12.5mg, up to a maximum of 15mg weekly. A 5mg vial provides 2 doses at the starting 2.5mg dose.
- **Q: How do you reconstitute Tirzepatide?**
  - A: For a 10mg vial, add 2mL of bacteriostatic water for a 5mg/mL concentration. For a 5mg vial, add 1mL for the same concentration. Always use sterile techniques.
- **Q: What are the storage requirements for Tirzepatide?**
  - A: Lyophilized (powder): Room temperature or refrigerated, protect from light. Reconstituted: Refrigerated 36-46F (2-8C), use within 28 days.

---

## Tirzepatide: Complete Research Guide | PtP Wiki
**URL:** https://www.pathtopeptides.com/tirzepatide
**Last reviewed:** 2026-04-07

**Summary:** Tirzepatide is a first-in-class dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist developed by Eli Lilly. It represents the most significant advancement in incretin-based therapy since the development of GLP-1 receptor agonists, achieving unprecedented weight loss outcomes in clinical trials — up to 22.5% mean body weight reduction in the SURMOUNT-1 trial at the 15 mg weekly dose.

**FAQs:**
- **Q: How is tirzepatide different from semaglutide?**
  - A: Tirzepatide is a dual GIP and GLP-1 receptor agonist, whereas semaglutide activates only the GLP-1 receptor. Tirzepatide's GIP receptor agonism provides additional metabolic benefits including enhanced insulin sensitivity in adipose tissue, improved lipid metabolism, and potentially greater weight loss. In the SURMOUNT-1 trial, tirzepatide 15 mg achieved 22.5% mean weight loss versus approximately 15% with semaglutide 2.4 mg in comparable populations.
- **Q: What is the maximum weight loss seen with tirzepatide?**
  - A: In the SURMOUNT-1 trial, the highest dose of tirzepatide (15 mg weekly) produced a mean body weight reduction of 22.5% over 72 weeks. Approximately 36% of participants lost 25% or more of their body weight, and 63% lost 20% or more. These are the largest weight loss results ever achieved with a pharmacological intervention in clinical trials.
- **Q: Is tirzepatide FDA approved?**
  - A: Yes. Tirzepatide is FDA-approved under two brand names: Mounjaro (approved May 2022) for type 2 diabetes mellitus, and Zepbound (approved November 2023) for chronic weight management in adults with obesity (BMI 30+) or overweight (BMI 27+) with at least one weight-related comorbidity.

---

## VIP Protocol Guide — Dosing, Reconstitution & Administration
**URL:** https://www.pathtopeptides.com/vip-protocol
**Last reviewed:** 2026-04-10

**Summary:** Vasoactive Intestinal Peptide (VIP) is a 28-amino acid neuropeptide with potent anti-inflammatory and immunomodulatory properties. It is researched for Chronic Inflammatory Response Syndrome (CIRS), mold illness recovery, pulmonary hypertension, and neuroprotection.

**Protocol Overview:**
- **Compound:** VIP (Vasoactive Intestinal Peptide, 28 amino acids)
- **Category:** Neuropeptide / CIRS / Mold Illness Research
- **Chemical Structure:** His-Ser-Asp-Ala-Val-Phe-Thr-Asp-Asn-Tyr-Thr-Arg-Leu-Arg-Lys-Gln-Met-Ala-Val-Lys-Lys-Tyr-Leu-Asn-Ser-Ile-Leu-Asn-NH2
- **Vial Size:** 5mg (5,000mcg)
- **Reconstitution:** 2mL bacteriostatic water (2.5mg/mL)
- **Primary Route:** Intranasal (50 mcg/actuation)
- **Alternate Route:** Subcutaneous injection
- **Frequency:** 4x daily (Shoemaker CIRS protocol) or as directed
- **Cycle Length:** 3–6 months for CIRS protocol

**Dosing (sample):**
```
Shoemaker CIRS (Standard) | 50 mcg (1 puff each nostril) | 4x daily (with meals + bedtime) | Intranasal | 3–6 months
Conservative Intranasal Start | 50 mcg (1 puff 1 nostril) | 2x daily | Intranasal | 1–2 weeks, then increase
Research SubQ | 50–200 mcg | Daily | Subcutaneous | 4–12 weeks
```

**FAQs:**
- **Q: What is the standard VIP dosing protocol?**
  - A: The standard VIP research protocol uses 50mcg administered morning on protocol days. Weekly Total: 14 units (350mcg) • Vial Duration: ~100 doses at 50mcg
- **Q: How do you reconstitute VIP?**
  - A: Using 2mL of bacteriostatic water results in a concentration of 2.5mg/mL. May be administered subcutaneously or intranasally. Always use sterile techniques.
- **Q: What are the storage requirements for VIP?**
  - A: Lyophilized (powder): Room temperature or refrigerated, protect from light. Reconstituted: Refrigerated 36-46F (2-8C), use within 28 days.

---

## YK-11 Protocol Guide — Dosing, Cycle & Administration
**URL:** https://www.pathtopeptides.com/yk-11-protocol
**Last reviewed:** 2026-04-10

**Summary:** YK-11 is a unique steroidal SARM that also acts as a myostatin inhibitor. Research suggests it may increase follistatin expression, which inhibits myostatin - a protein that limits muscle growth. This dual mechanism of androgen receptor modulation and myostatin inhibition makes it of particular interest in muscle growth research. Capsule Content 5mg per capsule (5,000mcg per capsule) Route of Administration Oral (capsule)

**Protocol Overview:**
- **Compound:** YK-11 (Oral Research Compound - Myostatin Inhibition / Lean Mass)
- **Category:** Selective Androgen Receptor Modulator / Myostatin Inhibitor
- **Vial Size:** 5mg capsules
- **Reconstitution:** N/A — oral compound
- **Route:** Oral (capsule or liquid)
- **Frequency:** 7 days/week

**Dosing (sample):**
```
Monday | 1 cap | 5mg | Morning
Tuesday | 1 cap | 5mg | Morning
Wednesday | 1 cap | 5mg | Morning
Thursday | 1 cap | 5mg | Morning
Friday | 1 cap | 5mg | Morning
Saturday | 1 cap | 5mg | Morning
Sunday | 1 cap | 5mg | Morning
```

**FAQs:**
- **Q: What is the standard YK-11 dosing protocol?**
  - A: The standard YK-11 research protocol uses 5mg administered morning on protocol days. Weekly Total: 7 capsules (35mg) • Cycle Duration: 8 weeks on, 4 weeks off
- **Q: How do you take YK-11?**
  - A: YK-11 is an oral compound supplied as capsules. No reconstitution is required. Swallow the capsule with water at the same time each day.
- **Q: What are the storage requirements for YK-11?**
  - A: Store capsules at room temperature in a cool, dry place. Keep tightly sealed, away from moisture and direct light.

---